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Microbiota regulate short chain fatty acids and influence 
histone acylations in intestinal epithelial cells. 
Rachel Claire Fellows  
Summary 
The intestinal microbiota have a vital role in aiding digestion by metabolising dietary fibres. In this 
process, they produce short chain fatty acids (SCFAs) such as butyrate, an important energy source for 
intestinal epithelial cells. SCFAs are chemically related to histone acylations, a growing number of post-
translational modifications that include histone acetylation, butyrylation and crotonylation. Histone 
post-translational modifications are thought to be involved in the regulation of gene expression as 
they can specifically recruit transcription factors and chromatin remodellers. Histone acylations are 
abundant in the intestine and are associated with active chromatin. In this project, I have identified 
that butyrate can upregulate histone acylations in both colon carcinoma cells and intestinal organoids 
in a dynamic manner. In addition, I identified that class I histone deacetylases (HDACs) are efficient 
histone decrotonylases. I have achieved this through a combination of biological analysis of the effects 
of treatment with HDAC inhibitors and in vitro analysis of purified proteins, which enabled 
determination of kinetic parameters. When investigating how SCFAs could influence histone 
acylations in vivo, I identified that antibiotic induced depletion of the microbiota in mice caused 
reduction in luminal SCFA concentration and global changes in histone acetylation and crotonylation, 
particularly those at histone H4. RNA-sequencing of these mice identified changes in the expression 
of genes which were involved in many important biological processes, such as cell signalling, energy 
generation and metabolism. Further to this, I studied lysine crotonylation and H4K8 acetylation at 
dysregulated genes to understand the how the presence of these modifications at the promoter 
influences gene expression in this context. These intriguing findings suggest that histone acylations 
could act as a nutrient sensors to couple changes in microbiota composition to that of gene expression 
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1.1.1 The environment influences gene regulation 
From its first beginnings identifying euchromatin and heterochromatin by staining cells over 100 years 
ago through to next generation sequencing today, the epigenetic field has transformed our 
understanding of the cell (Allis and Jenuwein, 2016). The meaning of the term epigenetics has changed 
over time, but an up to date definition is “the study of molecules and mechanisms that can perpetuate 
alternative gene activity states in the context of the same DNA sequence” (Cavalli and Heard, 2019). 
Epigenetic regulation enables an organism to respond and adapt to its environment. This is apparent 
in studies of monozygotic twins who diverge in phenotype and epigenotype over time, providing an 
opportunity to investigate how epigenetic variation influences complex traits (Bell and Spector, 2011). 
Epigenetic regulation has been implicated in a wide range of diseases, as any gene or set of genes can 
be affected (Cavalli and Heard, 2019).  
1.1.2 Chromatin enables spatial organisation of the genome 
Chromatin describes the complex of proteins, DNA and RNA found in the nucleus. If the DNA from all 
46 human chromosomes were laid out end to end it would be approximately 2 meters long, but it 
must be packaged into the nucleus, which is typically 6 μM in diameter (Alberts et al., 2015). 
Therefore, it is essential that the genetic material is well organised so that it can be contained in the 
nuclear space. The chromatin structure provides an elegant mechanism for fine control of gene 
expression. The basic unit is the histone octamer, containing pairs of histones H2A, H2B, H3 and H4. 
The DNA is coiled around the histone octamer in 147 base pair segments, with extensive DNA-histone 
contacts, to create the nucleosome as shown in Figure 1.1 (Alberts et al., 2015). There are two types 
of chromatin. In heterochromatic regions, nucleosomes are densely packed, resulting in resistance to 





genes. This spatial organisation is a key epigenetic regulator as genes can be turned on or off simply 
by changing the packaging between histones and DNA. Additionally, the chromatin can be remodelled 
to bring together distal genetic elements, for example, an enhancer and a promoter, to activate gene 
expression (Alberts et al., 2015). Chromatin state can be influenced by many factors including DNA, 
RNA and histone modifications, non-coding RNA species, protein chaperones and chromatin 
remodelling enzymes.  
 
Figure 1.1. The nucleosome 
The nucleosome is composed of an octamer of H2A, H2B, H3 and H4 histones which wrap 147 base pairs of DNA. 
Histones have an N-terminal region which can be extensively modified, for example with acetylation (Ac), 
phosphorylation (P), Butyrylation (Bu), Crotonylation (Cr) and methylation (Me). P300 is an acetyltransferase, 
bromodomains specifically recognise acetyl-groups and histone deacetylases (HDAC) remove them. 
 
1.1.3 Histone modifications are linked to gene transcription and chromatin conformation 
Due to their close contact with DNA, histone post-translational modifications (hPTM) are involved in 
DNA packaging and regulation of gene expression. Modifications to the core region of histones 
influence nucleosome stability, whilst modifications to lateral surface and histone tails change the 
association with DNA and interact with specific binding proteins. Histone tails are extensively modified 
with a range of chemical groups leading to the suggestion that this creates its own language with 
specific sets of modifications providing a ‘code’ for reader proteins to bind. Many specific hPTM 
binding proteins include chromatin remodelling enzymes which open or compact certain regions of 
the genome, transforming chromatin from a static to a dynamic structure. These enzymes use ATP as 




to make the underlying DNA sequence more accessible (Tang et al., 2010). Chromatin remodelling 
enzymes are both diverse and abundant in the cell with approximately one remodelling complex per 
10 nucleosomes (Längst and Manelyte, 2015). Their targeting and regulation are finely tuned by 
multiple subunits that exist in complex with the catalytic subunit. These include histone and DNA 
binding modules which coordinate the nucleosome remodelling activity. A major family of ATP 
dependent chromatin remodellers are the SWI/SNF complexes which in humans includes the BAF and 
PBAF complexes (Tang et al., 2010). Whilst some modifications are associated with euchromatin and 
others with heterochromatin, it is still unclear if these modifications are the direct cause or the 
consequence of changes to gene expression (Howe et al., 2017). Despite their widely reported gene 
regulatory role and ability to act as binding platforms for factors involved in transcription or associated 
chromatin remodelling, it is still an unsolved issue whether changes to histone modifications occur 
prior or subsequently to the activation or repression of gene expression. This may limit our 
interpretation of studies on these epigenetic switches, but it does not negate their potentially 
important role in cellular processes. 
1.1.4 Histone methylation 
Histone methylation can occur as mono-, di- or tri- methylation depending on if there are one, two or 
three methyl groups added to the histone residue (Martin and Zhang, 2005). Methylation does not 
change the electronic charge of the histone but functionality is conferred by the binding of proteins 
which can distinguish between sites of methylation and number of methyl groups (Martin and Zhang, 
2005; Musselman et al., 2014). Histone methylation is associated with both active and repressive 
chromatin (Black et al., 2012). Methylation of H3 lysine 9 (H3K9), H3K27 and H4K20 are associated 
with gene repression, whilst methylation of H3K4, H3K36 and H3K79 are associated with active genes 
(Hyun et al., 2017). Different methylation states can have different distributions along the chromatin. 
H3K4me1 is present at enhancers, H3K4me2 at the 5’ end of transcribing genes and H3K4me3 at 
promoters of active and poised genes (Santos-Rosa et al., 2002; Heintzman et al., 2007; Mikkelsen et 
al., 2007; Kim and Buratowski, 2009). A single methyltransferase, Set1, is responsible for all H3K4 
methylation in yeast and it has 6 human homologs SET1A, SET1B and MLL1-4 (Shilatifard, 2012). H3K4 
methylation is correlated with transcription but it is still unclear whether the addition of methylation 
preceeds changes to gene expression and how methyltransferase complexes are recruited to the 
histone (Howe et al., 2017; Hyun et al., 2017). Interestingly, mutations in MLL/KMT2 family of H3K4 
methyltransferases increase likelihood of various types of cancer (Rao and Dou, 2015). H3K27 
methylation is a paradym repressive modification and its misregulation is also associated with 




polycomb group protein, was associated with increased progression of prostate cancer and worse 
survival rates (Varambally et al., 2002). Since this study, EZH2 has been linked to other types of cancer 
and associated with alterations in cell migration, growth and invasion, resulting in the development 
of inhibitors against this enzyme (Bracken et al., 2003; Kleer et al., 2003; Velichutina et al., 2010; 
McCabe et al., 2017). H3K27 and H3K4 methylation can occur at the same sites, creating regions that 
are poised for activation. Switching between active, poised and repressed states is important in 
embryonic stem cells for differentiation into various cell types and enrichment of H3K4 and H3K27 
methylation at the same sites was shown to be important in this process (Barski et al., 2007; Mikkelsen 
et al., 2007; Vastenhouw and Schier, 2012). Intriguinly, the H3K27 demethylase UTX/KDM6A and the 
H3K4 methyltransferase ALR/MLL2 are subunits of the same multi-subunit complex, enabling 
interaction between these two methylation marks (Issaeva et al., 2007). Methylation of H3K9 is an 
important mark of silenced transcription and heterochromatin (Barski et al., 2007). The G9a-GLP 
heterodimer can add mono- and di-methylation to H3K9 at euchromatic regions and then spread this 
mark to nearby nucleosomes to establish a repressive region. This mechanism is required for Oct3/4 
and nanog silencing in embryonic stem cells to enable differentiation, which may explain why H3K9 
methylation is often misregulated in cancer (Bittencourt et al., 2014; Casciello et al., 2015). H3K36 
methylation occurs along the gene body and is thought to prevent erroneous initiation of transcription 
(Wagner and Carpenter, 2012). This mark is also implicated in inhibiting PRC2 mediated methylation 
of H3K27 to prevent the spread of a repressive chromatin environment and is involved in multiple 
pathways that repair damage to DNA (Pfister et al., 2006; Fnu et al., 2011; Kassam et al., 2013). 
1.1.5 Histone acetylation 
1.1.5.1 The discovery of histone acetylation and its regulatory proteins 
Histone acetylation and phosphorylation were discovered within four years of each other in 1959 and 
1963 respectively (Fischer et al., 1959; Phillips, 1963). However, due to technical challenges in studying 
acetylation, phosphorylation was the main focus for many years and was found to be a central 
regulator of signal transduction pathways, metabolism and other cellular processes (Verdin and Ott, 
2015). Protein acetylation has now been identified in a diverse array of organisms from bacteria to 
humans and is linked to gene regulation (Allis and Jenuwein, 2016). It frequently occurs in structured 
domains and in highly conserved proteins such as metabolic enzymes, chaperones and ribosomes. This 
is in contrast to phosphorylation, which is often in unstructured regions of rapidly evolving proteins, 
giving insight into how the functions of these hPTMs may differ (Choudhary et al., 2014). At least 22 
histone acetyltransferases (HAT, also known as lysine acetyltransferase or KAT) have been identified 




identified which are grouped into class I (HDAC1-3 and HDAC8), class II (HDAC4-7 and HDAC9), class 
III sirtuins (SIRT1-7) and class IV (HDAC11). Classes I, II and IV HDACs share a similar structure and are 
zinc dependent whilst the class III SIRT use a distinct mechanism and rely on NAD+ as a cofactor 
(Choudhary et al., 2014). HATs or HDACs are often present in multi-domain complexes which influence 
their activities, specificities and targeting to specific sites (Shahbazian and Grunstein, 2007). CBP, p300 
and GCN5 all have bromodomains that read acetyl-groups to enable them to recognise specific sites 
on chromatin and coordinate transcription. In the human genome, 61 bromodomains are encoded, of 
which 29 have been characterised (Filippakopoulos et al., 2012). Plant homeodomain and YEATS 
domain containing proteins have also been found to be acetyl readers (Lange et al., 2008; Li et al., 
2014). Interestingly, most HATs and acetyl-binding domain-containing proteins are found 
predominantly in the nucleus (Choudhary et al., 2014).  
1.1.5.2 The diverse roles of histone acetylation 
Histone acetylation is associated with regions of active transcription and is thought to act through two 
main mechanisms (Choudhary et al., 2014). Acetylation neutralises the positively charged lysine to 
reduce attraction towards the negatively charged DNA, enabling loosening of the chromatin. 
Acetylation of histone tail residues also allows the recruitment of specific proteins, such as those 
involved in transcription or chromatin remodelling (Allis and Jenuwein, 2016). Histone acetylation is 
thought to be important for the recruitment or stabilisation of the SWI/SNF complex to enable 
chromatin remodelling, for example as part of double strand break repair (Hassan et al., 2001; Agalioti 
et al., 2002; Ogiwara et al., 2011). During this process, the general transcription factor TFIID makes 
multiple contacts with the DNA and chromatin to stabilise its interaction with the promoter and 
facilitate formation of the preinitiation complex. TFIID binding is enabled by multiple subunits, TBP 
binds the TATA box on the DNA, TAF3 binds H3K4me3 and TAF1 can bind acetylated histones (Krasnov 
et al., 2016). In fact, the mouse homolog of TAF1 Brdt, an essential factor for male genome 
programming in meiotic and haploid cells, requires hyperacetylation of H4 at both lysines 5 and 8 to 
be able to bind (Morinière et al., 2009; Gaucher et al., 2012). In addition, the presence of H3K4me3, 
TATA box and H3K14ac were found to have synergistic effects on binding, demonstrating the 
combinatorial nature of these protein binding sites (van Nuland et al., 2013). In yeast, the HAT Sas2, 
establishes an increasing gradient of H4K16ac away from the telomeres, whilst Sir2 removes H4K16ac 
to generate a compact chromatin environment at the telomere (Kimura et al., 2002). Interestingly, 
H4K16ac is associated with DNA damage repair and senescence (Dang et al., 2009; Li et al., 2010; 
Sharma et al., 2010; Krishnan et al., 2011).  
H3 and H4 acetylation have different effects on the stability of the nucleosome. H3 acetylation was 




counteracted this (Gansen et al., 2015). Broad H3/H4 acetylation renders a region permissive to the 
action of cellular machinery involved in transcription and chromatin modulation but activation of gene 
expression often requires targeted acetylation at the promoters of genes (Eberharter and Becker, 
2002). Furthermore, acetylation at different residues of the histone tail can have different functions. 
This could be because different enzymes are responsible for their addition, recognition and removal. 
For example, deletion of PCAF/GCN5 ablated H3K9ac whilst deletion of p300/CBP reduced 
H3K27ac/H3K18ac (Jin et al., 2011). H4K12ac was found to increase in macrophage determined 
dendritic cells after chronic alcohol exposure. Use of a specific inhibitor for the HAT Tip60 reduced 
H4K12ac as well as upregulating cytokines such as ICAM, IL-6 and IL-10 (Parira et al., 2017). 
Diacetylation of H4K5 and H4K12 occurs prior to nucleosome assembly and these modifications are 
therefore associated with newly assembled chromatin (Sobel et al., 1995; Chang et al., 1997). H3K27ac 
was shown to have a robust circadian rhythm along with H3K4me3, H3K9ac and recruitment of RNAPII 
(Takahashi, 2015).  
1.1.5.3 The control, distribution and function of H4K8 acetylation 
H4K8ac is relatively under-studied compared to other acetyl-marks. However, it is associated with 
active genes and various functions have been attributed to this modification. In a study which profiled 
39 different acetylation and methylation marks in CD4+ T cells, H4K8ac was found to be elevated in 
the promoter and transcribed regions of active genes along with H4K5, H4K12 and H4K16 acetylations. 
Acetylations of H3K18 and H3K27, amongst others, were mainly associated with transcription start 
sites. Interestingly, H4K8ac associated with around 12 % of enhancers, compared to 17 % for H3K27ac 
and 32 % for H3K4me1 (Wang et al., 2008). A more recent study found that H4K8ac and H4K16ac were 
associated with transcription start sites (TSS) in embryonic stem cells at active genes that also 
contained H3K27ac, but with a slightly broader distribution. H3K27ac, H4K8ac and H4K16ac were 
correlated, with the tightest association being between acetylation at H4K8 and H4K16. Contrastingly, 
H4K5 and H4K12 acetylation were depleted around the TSS (Hayashi-Takanaka et al., 2015). 
Fascinatingly, Li et al. (2019) showed that both H4K8ac and H3K27ac are found at a novel class of super 
enhancers, a genomic feature that is implicated in tumourigenesis and is also marked by H3K4me3. 
GCN5/PCAF is responsible for acetylation of H4K8 (Kuo et al., 1996; Cieniewicz et al., 2014). During 
the initiation of human IFN-β transcription, the enhanceosome recruits GCN5 resulting in acetylation 
of H4K8 and H3K9. H4K8ac is required for SWI/SNF binding, whilst H3K9ac, H3K14ac and H3S10 
phosphorylation mediate TFIID binding (Agalioti et al., 2002; Ford and Thanos, 2010). A study of Ras-
mediated transformation of normal cells into cancerous cells found that the HAT Tip60 increased in 
Ras-transformed cells along with global upregulation of H4K8ac and H4K12ac. In another 




Gene to Complement-32 knockdown, a gene associated with the progression of colon cancer (Vlaicu 
et al., 2010). Additionally, H4K8ac has been shown to be a major regulator of transcription changes 
mediated by chromatin during the life cycle of Plasmodium falciparum and was associated with both 
euchromatin and heterochromatin. H4K8ac was the most responsive to HDAC inhibitors of the H4 
acetylations tested (Gupta et al., 2017).  
1.1.5.4 The functions of non-histone acetylation 
Acetylation of non-histone proteins can also influence transcription. Tat is a HIV protein that is rate 
limiting for viral replication. The non-acetylated form binds to the HIV RNA stem loop structure of the 
transactivating response element, which results in increased RNA polymerase processivity. Acetylated 
Tat instead binds to the transcriptional co-activator PCAF, which promotes association of Tat with RNA 
polymerase II and HIV gene transcription (Dorr et al., 2002; Mujtaba et al., 2002). Acetylation can 
influence protein function by changing the subcellular location of that protein (Drazic et al., 2016). 
This is because the subcellular localisation domain of a protein often contains lysine residues 
(Choudhary et al., 2014). Lysines are actually one of the most frequently modified amino acids and 
can accommodate many different types of hPTM (Choudhary et al., 2014). For example, 
glyceraldehyde-3-phosphate dehydrogenase catalyses an intermediate step in glycolysis in the 
cytoplasm, converting glyceraldehyde-3-phosphate into 1,3-bisphosphoglycerate. It can translocate 
to the nucleus, as a result of acetylation of three lysine residues by PCAF, to regulate transcription and 
DNA repair (Ventura et al., 2010). Finally, acetylation can also change enzymatic activity as many 
residues present in the catalytic active sites are lysines. This can have opposing effects. For example, 
acetylation of acyl-CoA synthetase short chain family member 1 (ACSS1) is inactivating whilst 
phosphoglycerate mutase 1 (PGAM1) acetylation enhances its activity. SIRT HDACs counteract this 
acetylation. SIRT3 removes acetyl groups from ACSS1, whilst when glucose is restricted SIRT1 is 
upregulated to deacetylate PGAM1. As PGAM1 is an enzyme involved in glycolysis, acetylation may be 
used to modulate enzyme activity in a feedback mechanism to respond to changing conditions. A 
further interesting point is that p300/CBP can be autoacetylated, an activity which appears to be 
dependent on its dimerization and is reversed by SIRT2 (Choudhary et al., 2014).  
1.1.6 Histone modifications mark regulatory elements 
Promoters and enhancers are sequences of DNA that enable gene expression by providing binding 
sites for transcription factors and transcriptional machinery. Promoter regions are upstream of the 
TSS and are the site of binding for RNA polymerases and transcription factors (Voet and Voet, 2011). 
Unlike prokaryotes which have a distinct sequence motif of TATAAT at around -10 and TTGACA at -35 




is more complex. Enhancers are found in non-coding regions of the genome, outside genes and in 
introns, and act to facilitate or enhance gene expression. For example,  a typical β-globin gene contains 
two upstream elements, in addition to a promoter, which are bound to transcription factors and 
required to achieve normal levels of expression of β-globin (Voet and Voet, 2011). Enhancers can be 
many kilobases away upstream or downstream from the gene they regulate and also lack a consensus 
sequence. Hundreds of thousands of enhancer regions have been identified, far more than the around 
20,000 protein-encoding human genes, but not all were found to have enhancer function in transgenic 
assays. Many of these regions were identified due to their sequence conservation but these could 
have alternative functions to enhancers or play a role in a different stage of development to the time 
points that were assayed (Pennacchio et al., 2015).  
There is increasing evidence to suggest that promoters and enhancers have a defined chromatin state 
which can be used to identify them in different cell types and under different conditions. Heintzman 
et al. (2007) profiled different histone modifications by chromatin immunoprecipitation (ChIP) at 
promoters and enhancers. They identified that both contain a nucleosome depleted region and are 
enriched for histone acetylation and H3K4 methylation. In a pioneering study, H3K4me1 was found to 
be a hallmark of distal enhancer elements, whilst H3K4me3 defined promoter regions (Heintzman et 
al., 2007). Current evidence still suggests that enhancers have high H3K4me1 and promoters have 
high H3K4me3 (Sharifi-Zarchi et al., 2017), but the situation is in fact more nuanced as H3K4me1 is 
also at large 5’ portions of actively transcribed genes (Calo and Wysocka, 2013), whilst H3K4me3 was 
found to mark active enhancers in developing T and B lymphocytes (Pekowska et al., 2011). The 
distribution of H3K4me1 is broad in non-coding regions (Calo and Wysocka, 2013) and is thought to 
mark developmental enhancers in human or mouse embryonic stem cells prior to their activation 
(Creyghton et al., 2010; Rada-Iglesias et al., 2011; Zentner et al., 2011).  
It has been suggested that the presence of H3K27ac, which is typically combined with H3K4me1, 
distinguishes active from inactive enhancers (Bonn et al., 2012; Zhu et al., 2013; Andersson et al., 
2014). Interestingly, using H3K27ac containing enhancers enabled a better prediction of 
developmental state than using enhancers that contained only H3K4me1 (Creyghton et al., 2010). 
Two-thirds of H3K27ac containing enhancers showed activity in transgenic assays (Nord et al., 2013). 
Poised enhancers also exist which contain H3K27me3 and H3K4me1 but not H3K27ac (Rada-Iglesias 
et al., 2011; Zentner et al., 2011). Whilst these three modifications have been the particular focus for 
characterising these genetic elements, it is likely that other marks are also present. P300/CBP binding 
is associated with enhancers (Visel et al., 2009; Creyghton et al., 2010) and this enzyme can add acetyl-
groups to H3K27 or H3K18 (Jin et al., 2011). In addition, H3K9ac and histone crotonylation have been 




1.1.7 The histone acylation family 
Histone acetylation is now part of a growing group of hPTMs called histone acylations which are of 
interest due to their potential to bridge cellular metabolism and epigenetic regulation (Zhao et al., 
2017). The different structural properties, binding proteins and suggested functions of this family are 
shown in Table 1.1. Lysine acetylation (Kac), propionylation (Kpr) and butyrylation (Kbu), contain short 
saturated fatty acyl chains of 2, 3 and 4 carbons respectively (Zhang et al., 2009). Lysine crotonylation 
(Kcr) is more rigid due to a double bond which gives it a flat planar structure (Tan et al., 2011). They 
can be derived from the short chain fatty acids (SCFA) acetate, propionate, butyrate and crotonate. 
There are also the hydroxylated modification β-hydroxybutyrylation (Kβ-HBu); the acidic modifications 
of malonylation (Kmal), succinylation (Ksucc) and glutarylation (Kglu); the branched modification 
hydroxyisobutyrylation (Khib); and the aromatic benzoylation (Kbz) amongst others (Du et al., 2011; 
Peng et al., 2011; Z. Zhang et al., 2011; Dai et al., 2014; Tan et al., 2014; Xie et al., 2016; Huang, Zhang, 
et al., 2018). In some cases, these hPTMs are only a few atoms different, for example crotonylation 





Table 1.1. The histone acylation family 
The structures, chemical properties, acyltransferases (writers), binding proteins (readers), deacylases (erasers) 
and functions currently attributed to many members of the histone acylation family are shown. [1] (Berndsen 
and Denu, 2008), [2] (Lange et al., 2008; Filippakopoulos and Knapp, 2012; Li et al., 2014), [3] (Choudhary et al., 
2014), [4] (Haberland et al., 2009; Voss and Thomas, 2009; Allis and Jenuwein, 2016; Blasi et al., 2016), [5] (Chen 
et al., 2007; Montgomery et al., 2014; Kebede et al., 2017; Han et al., 2018), [6] (Flynn et al., 2015; Xiong et al., 
2016; Y. Li et al., 2016; Zhang et al., 2016; Zhao et al., 2016), [7] (Feldman et al., 2013), [8] (Kebede et al., 2017), 
[9] (Chen et al., 2007; Montgomery et al., 2014; Goudarzi et al., 2016; Kebede et al., 2017), [10] (Flynn et al., 
2015; Xiong et al., 2016; Y. Li et al., 2016; Zhang et al., 2016; Zhao et al., 2016), [11] (Feldman et al., 2013), [12] 
(Goudarzi et al., 2016; Kebede et al., 2017; S. Liu et al., 2017), [13] (Sabari et al., 2015; X. Liu et al., 2017), [14] 
(Flynn et al., 2015; Andrews et al., 2016; Xiong et al., 2016; Y. Li et al., 2016; Zhang et al., 2016; Zhao et al., 2016), 




Sabari et al., 2015; Ruiz-Andres et al., 2016; S. Liu et al., 2017; Fellows et al., 2018; Jiang et al., 2018; Abu-Zhayia 
et al., 2019; Wang et al., 2019; Wan et al., 2019), [17] (Kaczmarska et al., 2017), [18] (Xiong et al., 2016), [19] 
(Zhao et al., 2018; Zhang et al., 2019), [20] (Xie et al., 2016), [21] (Peng et al., 2011), [22] (Ishiguro et al., 2018), 
[23] (Wang et al., 2017), [24] (Y. Wang et al., 2018), [25] (Peng et al., 2011; Park et al., 2013; L. Li et al., 2016), 
[26] (Tan et al., 2014; L. Li et al., 2016; Smestad et al., 2018), [27-29] (Tan et al., 2014), [30] (Huang, Luo, et al., 
2018; Huang, Tang, et al., 2018), [31] (Xiong et al., 2016; Zhao et al., 2016), [32] (Dai et al., 2014; Huang, Luo, et 
al., 2018), [33] (Dai et al., 2014) and [34-35] (Huang, Zhang, et al., 2018). 
1.1.8 Histone crotonylation and its role in transcription and cellular functions 
Kcr was first identified by Tan and colleagues using unbiased mass spectrometry methods and is 
present in yeast, C. elegans, D. melanogaster, mouse and human, suggesting that it is evolutionarily 
conserved. Kcr occurs on all core histones at 28 different sites, and while some overlap with Kac sites, 
there are many sites where only Kcr occurs (Tan et al., 2011). The precursor of crotonylation, crotonyl-
CoA is around three orders of magnitude lower in concentration in the cytoplasm of HeLa S3 cells than 
acetyl-CoA, suggesting that crotonylation would be less abundant than acetylation in these cells 
(Sabari et al., 2015). In line with this, our group found that crotonylation was present at H3K18 on 
around 2% of H3 histones in small intestinal crypt and colon compared to 20% of H3 histones 
containing acetylation at H3K18. Interestingly, H3K18cr in the colon always occurred with H3K23ac, 
suggesting an interaction between these two modifications (Fellows et al., 2018). Despite its lower 
abundance than acetylation, crotonylation is therefore not a trace modification. Kcr was found to be 
mainly associated with active chromatin, including at TSS, putative enhancers, regions with higher 
H3K4me3 and is positively correlated with transcript levels (Hawkins et al., 2010; Tan et al., 2011; 
Fellows et al., 2018). Interestingly, Sabari and colleagues found that p300 catalysed crotonylation 
could directly activate transcription of p53 to a greater extent than acetylation in a cell free assay 
(Sabari et al., 2015). Together this evidence suggests that is associated with regions of active gene 
expression and could potentially be involved in their regulation. 
 
Crotonylation has been linked to a growing number of cellular processes and disease states including 
the cell cycle, kidney injury, carcinogenesis, HIV reactivation and even depression (Ruiz-Andres et al., 
2016; S. Liu et al., 2017; Fellows et al., 2018; Jiang et al., 2018; Wan, Liu and Ming, 2019). During 
spermatogenesis, spermatocytes undergo meiotic division to produce the haploid round spermatids 
which then form the highly specialised spermatozoa (Neto et al., 2016). As part of this the single X 
chromosome is inactivated but some genes have been shown to escape this process (Yan and 
McCarrey, 2009). Tan et al. (2011) identified that the majority of genes with higher Kcr at the promoter 




expressed in adult mouse testes and were preferentially associated with the X and Y chromosomes. 
They suggested that Kcr marked a subset of genes that escape meiotic sex chromosome inactivation 
after meiosis, suggesting that it could sustain gene expression in a repressive environment (Tan et al., 
2011). This accumulation of Kcr at the TSS of sex linked genes was found to be dependent on RNF8, a 
DNA damage response factor involved in epigenetic reprogramming of escapee genes in post-meiotic 
spermatids (Sin et al., 2012). Kcr was found to increase in a model of acute kidney injury at promoters 
of stress-induced genes, which also showed increased expression levels. Crotonate pre-treatment 
increased expression of these genes and was protective against acute kidney injury (Ruiz-Andres et 
al., 2016). Our group identified that histone crotonylation is linked to the cell cycle, being upregulated 
in S and G2-M phase over G1 arrested cells. HDACs were implicated in the regulation of crotonylation 
during the cell cycle as the HDAC inhibitor MS725 prevented the downregulation of histone 
crotonylation that occured on G1 arrest (Fellows et al., 2018). HDACs were also implicated in 
regulating crotonylation in hepatocellular carcinoma cell lines as upregulation of histone crotonylation 
occurred on HDAC1 or HDAC3 knock-down, reducing cell migration ability and suppressing 
proliferation. Histone crotonylation was upregulated in colon carcinoma, but reduced in 
hepatocellular carcinoma, suggesting that the levels of this modification in cancer are context 
dependent (Wan et al., 2019). A different study found that H3K9cr was downregulated on UV or 
radiation induced DNA damage. This reduction was mediated by class I, II and IV HDACs, which have 
been previously shown to localise at sites of DNA damage and regulate histone acetylation to promote 
DNA double-strand break repair (Miller et al., 2010; Abu-Zhayia et al., 2019). In plants, acetylation, 
crotonylation and butyrylation at H3K9 have been shown co-occur at the promoters of a large number 
of active genes and are affected by submergence and starvation. H3K9ac appeared more responsive 
to these environmental changes than H3K9cr or H3K9bu (Lu et al., 2018). 
 
Histone crotonylation was recently implicated in the context of HIV, where immune cells with 
transcriptionally silent HIV-1 escape detection by the immune system. Kcr was found to mark the long 
terminal repeat in the HIV gene to regulate its transcription, in a mechanism mediated by Acyl-CoA 
synthetase short chain family member 2 (ACSS2). Promoting Kcr at the long terminal repeat of HIV led 
to reactivation of latent HIV and Kcr was proposed as a novel target in strategies for HIV eradication 
(Jiang et al., 2018). Other recent evidence suggests that histone crotonylation is involved in 
Alzheimer’s disease. NEAT1 was shown to regulate the transcription of endocytosis regulated genes 
involved in the clearance of β-amyloid by neuroglial cells. The accumulation of β-amyloid plaques in 
neural cells is thought to be involved in the neurodegeneration seen in Alzheimer’s disease. NEAT1 




generation, to regulate the expression of endocytosis related genes. NEAT1 interacted with p300/CBP 
resulting in autoacetylation of p300, which enhances its activity, and with the transcription factor 
STAT3, which bound H3K27ac but not H3K27cr (Wang et al., 2019).  
1.1.9 The function of other types of histone acylation 
Chen et al. (2007) identified histone Kbu and Kpr as novel in vivo modifications. They suggested that 
as the precursors of Kbu and Kpr, butyryl-CoA and propionyl-CoA, are important metabolites and 
because these histone acylations cause distinct structural changes to the histone, that they are likely 
to have an important function in biological processes separate from that of other hPTMs (Chen et al., 
2007). Kbu and Kpr were associated with active chromatin in mouse liver and could promote gene 
expression of a chromatinized template in an in vitro transcription system (Goudarzi et al., 2016; 
Kebede et al., 2017). Butyrylation competed with acetylation at H4K5 and H4K8 to prevent binding of 
the testes specific transcriptional activator BRDT, resulting in delayed histone removal. Rapid turnover 
of acetyl and butyryl marks may result in dynamic association of BRDT with chromatin. This could 
facilitate the replacement of histone with the non-histone sperm-specific transition proteins and 
protamines, which occurs in late spermatogenesis and is dependent on BRDT (Goudarzi et al., 2016). 
H4K8hib was also implicated in spermatogenesis as it showed more intense labelling in elongating 
spermatids than spermatocytes, similar to the pattern of H4K8ac. Both H4K8hib and H4K8ac were 
enriched at TSS of genes and preferentially associated with sex chromosomes, but H4K8hib was a 
better marker of transcriptional activity in round spermatids and spermatocytes than H4K8ac. 
Interestingly, nearly all sex-linked H4K8hib genes also had Kcr but none of them had Kac (Dai et al., 
2014).  
1.1.10 Histone acyltransferases 
The identification of acyl readers and modifiers for these novel histone acylations is important, as it 
enables researchers to learn more about their cellular functions. To investigate if known HATs have 
the capacity to use larger acyl chains, Simithy et al. (2017) used mass spectrometry to analyse the 
relative transfer of different acyl-CoAs by CBP, p300, GCN5 and PCAF on recombinant H3, and by MOF, 
Tip60 and NatA on recombinant H4. They found that most could use acetyl-, propionyl- and butyryl-
CoA efficiently. The activity reduced with longer and more acidic acyl chain length with the exception 
of crotonyl-CoA which was least preferred due to its rigid and planar carbon-carbon double bond. 
PCAF and p300 had the highest crotonylation activities on H3. However, in equimolar competition 
assays, the HAT enzymes preferred to use acetyl-CoA (Simithy et al., 2017). Other studies have shown 




be the dominant site of histone crotonyltransferase and HAT activity. (Chen et al., 2007; Sabari et al., 
2015).  
 
Many HATs exist in multi-subunit complexes which enhance catalytic activity and direct the enzyme 
to specific regions of the genome (Shahbazian and Grunstein, 2007). Whilst p300 does not require a 
helper protein it may require accessory proteins to restrict its access to unintended targets (Berndsen 
and Denu, 2008). Mutants of p300 and CBP with histone crotonyltransferase but not HAT activity were 
found to enhance transcription in a luciferase reporter assay relative to wild type p300/CBP. This was 
associated with increased histone crotonylation at promoters and recruitment of histone 
crotonylation readers (X. Liu et al., 2017). The HAT enzymes GCN5 and PCAF can propionylate and 
butyrylate histones, although butyryl group transfer is less efficient than acetyl group transfer 
(Leemhuis, Packman, et al., 2008; Ringel and Wolberger, 2016). It seemed that increasing acyl chain 
length was prohibitory to these enzyme’s activity, as GCN5, PCAF, TIP60 and HBO1 showed no increase 
in histone crotonylation levels when they were transfected into cells (X. Liu et al., 2017). MOF and its 
yeast homologue Esa1 can crotonylate histones in vivo. However, whilst Esa1 was shown to be 
responsible for the majority of histone crotonylation in yeast cells, it was p300/CBP that contributed 
to the bulk of crotonylation in human HeLa cells (X. Liu et al., 2017).   
1.1.11 Non-enzymatic acylation 
The mechanism of acetylation by GCN5 involves deprotonation of a lysine residue, which enables it to 
act as a nucleophile towards the electrophilic group of the carbonyl-CoA. In fact, deprotonation of 
lysines is pH dependent and at alkaline pH, lysine acetylation can occur without GCN5 (Tanner et al., 
1999). Reproducing the high acetyl-CoA concentrations and alkaline pH found in the mitochondria was 
sufficient to cause non-enzymatic acylation of mitochondrial and non-mitochondrial proteins (Wagner 
and Payne, 2013). The high energy thioester bond in between the acyl and the CoA group is intrinsically 
reactive towards nucleophiles and thought to enable non-enzymatic acylation (Wagner and Hirschey, 
2014). Interestingly, certain sites are more susceptible to non-enzymatic acylation, as incubation of 
recombinant H3 and H4 with supraphysiological levels of acyl-CoA resulted in more acylation at the 
globular and C-terminal domains of histones. Acidic acylations, such as Kmal and Kglu were the most 
easily transferred to histones in the absence of enzymes. In contrast, HATs preferred residues in the 
N-terminal tails of histones, which could be due to their increased accessibility relative to other 
residues on the histone (Simithy et al., 2017). Therefore, cellular histone acylation may be a 




The stoichiometry, i.e. abundance relative to total available sites, of most cellular protein acetylation 
sites is low. In yeast, 86% of acetylation sites have less than 1% stoichiometry. The most abundant 
sites are on histones, HDAC and HAT complexes and transcription factors, supporting the role of action 
of regulatory enzymes at these sites (Weinert et al., 2014). In has been proposed that non-enzymatic 
protein acylation could be due to the accumulation of intrinsically reactive metabolic intermediates in 
periods of stress to alter protein function and cellular homeostasis. This ‘carbon stress’ could function 
in a similar way to oxidative stress, in which reactive oxygen species are generated as an inherent part 
of metabolism and are prevented from accumulating in the cell by various mechanisms. One example 
of carbon stress is in diabetes, where the accumulation of aldehyde containing sugars in the blood 
causes non-enzymatic glycation and formation of advanced glycation end products which interfere 
with protein function and cellular signalling to promote disease pathophysiology, including 
cardiovascular and retinal complications. The NAD+ dependent SIRT HDACs have been implicated in 
metabolic homeostasis, resistance to stress and prolonging lifespan among other favourable cellular 
processes (Wagner and Hirschey, 2014). The loss or ablation of SIRT3 was shown to increase 
mitochondrial protein acetylation and lead to the acceleration or development of disease states 
including hearing loss, metabolic syndrome and cardiac hypertrophy (Hafner et al., 2010; Someya et 
al., 2010; Hirschey et al., 2011). The effect of protein acetylation has been shown to be inhibitory, 
particularly for energy producing processes in the mitochondria (Ghanta et al., 2013). Therefore, these 
novel protein modifications could be important for modulating protein function and metabolism in 
periods of cellular stress associated with disease states. Alternatively, accumulation of protein 
modifications could simply be a consequence of increased cellular stress. 
1.1.12 Histone decrotonylases 
1.1.12.1 The SIRT histone deacetylases 
SIRT1-3 were found to catalyse the hydrolysis of lysine crotonylated peptides in vitro but only SIRT3 
was found to have activity in cells. This study suggested that the HDAC and histone decrotonylase 
(HDCR) activity of these enzymes uses the same mechanism (Bao et al., 2014). Contrastingly, another 
study in cells found that SIRT1 had both HDAC and HDCR activity, but no HDCR activity could be 
detected for SIRT2-5 and SIRT7 (Wei, Liu, et al., 2017). This difference could be due to the varying 
sensitivities of the assays used, but these results do show that some SIRT enzymes have HDCR activity 
in vivo. Investigation of the structure of SIRT3 in complex with H4K5cr showed that it is present in a 
shallow binding pocket, stabilised by hydrogen bonding and aromatic/hydrophobic interactions. Much 
of the crotonyl side chain is exposed to the solvent which may explain the relatively low affinity, as 




enzymes can use non-acetyl acylations. SIRT5 was shown using liquid chromatography/mass 
spectrometry to efficiently hydrolyse Ksucc or Kmal peptides (Du et al., 2011). Using a flurorescent 
assay, SIRT5 was also shown to remove glutaryl groups, whilst other HDACs could not (Tan et al., 2014). 
SIRT6 could efficiently remove myristoyl groups from H3K9 peptides and from tumour necrosis factor 
alpha with higher efficiency than acetyl groups, as monitored by liquid chromatography (Jiang et al., 
2013). 
1.1.12.2 Class I, II and IV histone deacetylases 
Initial comparison of the HDCR and HDAC capability of class I, II and IV HDAC enzymes in a fluorometric 
assay found that these enzymes had weak or no HDCR activity. The authors proposed that the inability 
of HDACs to decrotonylate histones could functionally distinguish acetylation from crotonylation 
which have common transferase enzymes (Tan et al., 2011). However, whilst considerably lower than 
the HDAC activity, the HDCR activity of HDAC1, 2 and 3 in this assay was above that of background 
(Tan et al., 2011). Another in vitro fluorometric assay of HDAC3 in combination with the NCoR1 
complex showed that this enzyme did have HDCR activity in vitro. Although this was considerably 
lower than its HDAC activity, the authors commented that this was in the same range of efficiency as 
the deacetylase activity of HDAC8 and HDAC11 (Madsen and Olsen, 2012). A more recent study 
showed that the class I enzymes HDAC1, HDAC2, HDAC3 and HDAC8, but none of the class II or class 
IV enzymes, had decrotonylase activity in embryonic stem cells using an immunofluorescence 
approach (Wei, Liu, et al., 2017). Knockdown of HDAC1/2/3 in combination by RNA silencing in 
cervical/uterine cancer HeLa S3 cells revealed a dramatic increase in histone crotonylation and 
acetylation whilst knockdown of SIRT1/3/5 in combination did not noticeably affect either 
modification (Wei, Liu, et al., 2017). This suggests that class I HDACs are the major histone 
decrotonylases in cell culture.   
Class I HDACs are found in multiprotein complexes, which in mammals are the Sin3, NuRD, CoREST 
and NCoR/SMRT complexes. These complexes are highly conserved and have been shown to function 
in distinct cellular processes including cell cycle regulation, maintenance of stem cell pluripotency and 
cellular differentiation (Hayakawa and Nakayama, 2011). Multi-subunit proteins have been described 
as molecular toolboxes, containing components involved in targeting, regulation of enzymatic activity 
and specificity as well as different chromatin modifying capabilities such as demethylation, 
deacetylation or chromatin remodelling. These complexes are not static, but can replace different 
domains to modulate their function in different contexts (Meier and Brehm, 2014). The complex of 
HDAC1/CoREST1/LSD1 was able to remove crotonyl-groups from fluorescein-tagged H3K18 peptides 
in addition to acetyl-groups from H3K18 and H4K16. Furthermore, genetic deletion of HDAC1/2 in 




reduction in decrotonylase activity and 54% reduction in deacetylase activity relative to control cells 
(Kelly et al., 2018). 
1.1.12.3 Cromodomain Y-like protein downregulates crotonylation 
Chromodomain Y-like protein (CDYL) is a transcription corepressor, which reads H3K9me3 and 
H3K27me3, and interacts with the polycomb repressive complex 2 to propagate repressive marks 
along the chromatin (Vermeulen et al., 2010; Y. Zhang et al., 2011). CDYL contains an N-terminal 
chromodomain and a C-terminal enoyl-CoA hydratase/isomerase domain which can recruit HDAC1 
and HDAC2 (Caron et al., 2003). CDYL knock-out increased histone crotonylation in HeLa cells in 8 out 
of 36 sites on histones, suggesting CDYL has a role in crotonyl-group removal. CDYL could not 
decrotonylate histones but it could hydrate crotonyl-CoA, converting it to β-hydroxybutyryl-CoA. 
Whilst enoyl-CoA hydratase is more efficient, this enzyme is only mitochondrial, whilst CDYL is present 
in the nucleus. Transgenic mice with increased CDYL protein levels showed sperm defects and reduced 
fertility. The CDYL transgenic mice had reduced Kcr at promoters and reduced expression in round 
spermatids, but not spermatocytes (S. Liu et al., 2017). As promoter Kcr was found previously to be 
higher in round spermatids than spermatocytes and marked genes that escaped sex chromosome 
inactivation (Tan et al., 2011), this implicates regulation of Kcr by CDYL as an important process during 
spermatogenesis. In the brain, overexpression of CDYL in the prelimbic cortex increased social 
avoidance behaviours and reduced Kcr. This study found that CDYL represses the nerve growth factor 
VGF by changing Kcr and H3K27me3 at the promoter to inhibit structural synaptic plasticity and 
promote stress induced depression. Stress upregulated CDYL but not p300 or HDAC enzymes 
suggesting it has a unique role in induction of stress induced depression like behaviours (Y. Liu et al., 
2018).  
1.1.13 Nucleosome turnover and histone acylations 
Nucleosome turnover is essential for cell division as the chromatin must be disrupted to allow DNA 
replication and newly replicated DNA re-packaged into chromatin. As histones are removed from the 
DNA, histone chaperones play a key role in mediating histone recycling or delivery of new histones, to 
enable chromatin state reassembly after passing of the replication fork. New nucleosomes are made 
by first depositing a H3-H4 tetramer on the DNA, followed by two H2A-H2B dimers (Probst et al., 
2009). In addition, nucleosomes exhibit turnover at regulatory elements and turnover rates are 
highest at promoters and chromatin boundary elements (Dion et al., 2007; Jamai et al., 2007; Deal et 
al., 2010; Radman-Livaja et al., 2011). Therefore, the maintenance of chromatin marks on the 
nucleosome represents a significant challenge. Existing hPTMs are thought to promote new 




writer enzyme to catalyse transfer of the modification (Probst et al., 2009). Histone acylations may 
facilitate nucleosome turnover as they destabilise the nucleosome by neutralising or adding a negative 
charge to the positively charged lysines (Barnes et al., 2019). Nucleosome remodelling also provides 
an additional means to regulate hPTMs. In the case of H3K79 methylation, which is transferred to 
histones by DOT1L but lacks a known demethylase, nucleosome exchange enables erasure of the 
modification and establishment of varied states of methylation (Chory et al., 2019). Additionally, the 
assembly of a new nucleosome can be a means to add modifications to a genomic region. Newly 
synthesised H3.1-H4 dimers are diacetylated at H4K5 and H4K12 which is mediated by the chromatin 
chaperone Asf1 and catalysed by the HAT RbAp46 in the cytoplasm (Jasencakova et al., 2010). H3.1 
and H3.3 are acetylated and methylated prior to assembly, which is thought to influence which final 
hPTMs are present in the nucleosome (Loyola et al., 2006). Proteome analysis of Kcr upon p300 
knockdown revealed that 11% of p300 targeted Kcr was outside the nucleus, consistent with the sub-
cellular distribution of this acyltransferase (Huang, Wang, et al., 2018). Therefore, nascent histone 
dimers or other substrates might be crotonylated or acetylated prior to nucleosome assembly, as an 
additional means of regulating these hPTMs. 
1.1.14 Histone acyl readers 
1.1.14.1 Bromodomains 
Bromodomain containing proteins, of which there are 8 families in humans, are the most well-known 
acetyl-binders. Additionally, some bromodomains may require multiple adjacent modifications to be 
able to efficiently bind histones, meaning that different modifications could jointly recruit proteins to 
coordinate specific biological processes (Filippakopoulos et al., 2012). To determine if they could also 
be crotonyl-readers, Andrews et al. (2016) conducted bromodomain pull down experiments and 
found that Kac- and Kpr-containing peptides bound specifically to bromodomains, but longer acyl 
groups did not interact or did only weakly, as in the case of TAF1 and BRD2 (Andrews et al., 2016). 
However, close inspection of their supplementary data shows that binding of Kcr by TAF1 second 
domain (TAF1(2)) and both BRD2 domains, relative to Kac, was stronger than for p300 (Sabari et al., 
2015). A different study performed a more extensive study of 49 human bromodomains, using peptide 
arrays and isothermal titration calorimetry. Most human bromodomains only recognised Kac and Kpr, 
but TAF1(2) could recognise Kcr and Kbu with high affinity. Remarkably, considering the similarity of 
these modifications, BRD9 and CECR2 bound Kbu but not Kcr (Flynn et al., 2015). The structure of 
BRD3(2) in complex with H3K18ac shows that the binding pocket is side-open and its shape blocks 
extension of the acyl chains meaning that Kbu and Kpr must protrude out of the side (Figure 1.2). Kcr, 




2016). A structure of TAF1(2) in complex with H4K5cr peptide showed that the carbonyl oxygen of Kcr 
is hydrogen bonded to a conserved asparagine residue similar to Kac recognition and interaction is 
reinforced by hydrophobic/aromatic interactions. However, much of the pocket is made up of a 
network of hydrogen bonding interactions putting the crotonyl group in a less favourable environment 
(Zhang et al., 2016). As all bromodomains strongly prefer Kac over Kcr, recognition of Kcr may not be 
the primary function of bromodomains.  
1.1.14.2 YEATS domains 
The YEATS domain family is thought to selectively bind Kcr with high affinity (Andrews et al., 2016; Y. 
Li et al., 2016; Zhang et al., 2016; Zhao et al., 2016). The YEATS family, named from the proteins Yaf9, 
ENL, AF9, Taf14 and Sas5, are an evolutionarily conserved group of proteins that in humans consist of 
ENL, AF9, GAS41 and YEATS2 and in yeast consist of Sas5, Taf14 and Yaf9. Many important chromatin 
remodelling and transcription complexes contain a YEATS domain (Schulze et al., 2009). Whilst they 
all have a preference for Kcr, their site preferences and order of affinity to other acylations differ. AF9 
prefers H3K9cr over H3K27cr and H3K18cr with affinities in the order of Kcr > Kpr > Kbu > Kac (Y. Li et 
al., 2016). YEATS2 preferred H3K27cr over H3K4, H3K23 or H3K9cr and recognised acylated H3K27 
peptides in the order of Kcr > Kbu > Khib > Kpr > Kac (Zhao et al., 2016).  YEATS domain proteins use a 
unique mode of recognition from that of SIRT HDACs, bromodomains or DPF domains (Figure 1.2a). 
The reader pocket is elongated and end open allowing full extension of the acyl-chain, as opposed to 
the side-open bromodomains and the end-dead DPF domains (Sabari et al., 2017; Zhao et al., 2017). 
Structures of human proteins AF9, TAF14 and YEATS2 showed the amide plane of the crotonyl group 
sandwiched between critical aromatic residues through π-π stacking which is stabilised by additional 
hydrophobic/aromatic interactions and hydrogen bonding (Figure 1.2b and c). Use of aromatic 
residues is common in proteins that recognise acetylation and methylation, for example, histone 
methyllysine recognition by HP1 uses a conserved cage of 3 aromatic residues. However, π-aromatic 
stacking, enabled by the crotonyl-group, has not been identified for any other groups of proteins 
(Andrews et al., 2016). This could explain the preference of YEATS domains for Kcr. Kbu and Kpr can 
contribute to hydrophobic interactions but do not have the double bond required for π-electron 
conjugation, resulting in lower affinity. The planar double bond also makes the crotonyl group flatter 
and more able to fit in the narrow binding pocket. For the AF9 YEATS structure, authors identified that 
a phenylalanine side chain (F28) flips on Kcr insertion. As this residue is highly divergent within the 
YEATS family, they hypothesised that changes to this residue have been used to fine tune specificity 
(Y. Li et al., 2016). Yeast protein Taf14 recognised H3K9cr using the same π-aromatic stacking 
mechanism and comparison with a structure of H3K9ac showed alternative conformations of a 




reduced affinity. Taf14 has been identified as core component of the transcription factor complexes 
TFIID and TFIIF (Kabani et al., 2005), suggesting a direct link between crotonylation and binding of 
polymerases (Y. Li et al., 2016).  
1.1.14.3 DPF domains  
In an expansion of the functional potential of histone crotonylation, the double plant homodomain 
finger (DPF) domain containing proteins MOZ and DPF2 were found to prefer Kcr to other histone 
acylations in the order of Kcr > Kbu > Kpr > Kac > Kβ-HBu (Xiong et al., 2016). MOZ/MORF are HAT 
paralogs known to be involved in leukemogenesis (Yang, 2015), whilst DPF1/2/3 are non-catalytic 
subunits of the BAF ATP dependent chromatin remodelling complexes, which have diverse roles in 
development and cancer (Wu, 2012). Both were previously identified to recognise H3K14 acetylation 
and influence gene expression (Xiong et al., 2016). H3K14cr was preferred by MOZ and DPF over 
H3K14ac, or nucleosomes containing Kac or Kcr at other sites, implying that DPF domains have 
particular site specificity regardless of the type of acylation. Interestingly, a dual H3K14crK23cr 
peptide, which may increase hydrophobicity, enhanced the binding affinity by 1.6-fold suggesting 
sensitivity to nearby modifications. In contrast to bromodomains and YEATS domains, DPF domains 
have an end-dead pocket which uses hydrophobic interactions and hydrogen bonding to tightly 
encapsulate the crotonyl group without using π-aromatic stacking (Figure 1.2). DPF2 has a higher 
affinity for H3K14cr than MOZ, but a double mutant of an aspartate and arginine on MOZ to make it 
more like DPF2 increased the affinity threefold. H3K14cr was identified at the promoters of the MOZ 
target genes HOXA5, HOXA7 and HOXA9. Mutation of MOZ disrupted H3K14cr binding, resulting in 
increased H3K14cr at the nuclear periphery (Xiong et al., 2016). Heterochromatin preferentially 
localises at the nuclear periphery and interactions with the nuclear envelope components such as 
lamin are thought to facilitate silencing (Arib and Akhtar, 2011). Therefore, MOZ could bind to H3K14cr 
on certain HOX genes and lead to translocation from the nuclear periphery to nuclear plasma to 





Figure 1.2. The molecular basis of histone acetylation and crotonylation recognition 
a) Crystal structures of the reader pockets of YEATS domain (left, AF9 in complex with H3K9cr, protein database 
(PDB) code 5HJB), bromodomain (middle, BRD3 second bromodomain in complex with H3K18ac, PDB code 5HJC) 
and DPF domain (right, MOZ in complex with H3K14cr, PDB code 5B76). H3K18cr is modelled in the BRD3 
structure in purple to show the steric clash. Histone peptides are shown as a yellow ribbon with the acyllysine 
side chain in stick mode and the extended hydrocarbon group of crotonyl in green. Nitrogen atoms are in blue 
and oxygen atoms in red. b) Comparison of the reader pockets of the YEATS domain containing proteins AF9 
(left, in complex with H3K9cr, PDB code 5HJB), TAF14 (middle, in complex with H3K9cr, PDB code 5IOK) and 
YEATS2 (right, in complex with H3K27cr, PDB code 5IQL). Key residues forming the aromatic pocket of the 
proteins in turquoise, pink and purple. c) The residues involved in aromatic stacking interactions by the YEATS 
domain containing proteins AF9 (purple), TAF14 (grey) and YEATS2 (pink). These diagrams are from the same 




1.1.15 Crotonylation on non-histone proteins.  
Crotonylation was initially identified on histones in human cell lines and mouse sperm (Tan et al., 
2011) but has now been identified on thousands of non-histone proteins outside of the nucleus (Wei, 
Mao, et al., 2017; Wu et al., 2017; Xu et al., 2017). One study found that crotonate treatment of HeLa 
cells enhanced Kcr on histone and non-histone proteins but did not affect Kac. In contrast, p300 
overexpression increased both modifications on histone and non-histone proteins. Crotonate is likely 
to enhance Kcr by increasing crotonyl-CoA levels, allowing p300 to catalyse transfer of more Kcr to 
many types of protein. They identified 70 crotonylated proteins which was increased to 453 on 
crotonate treatment. Gene ontology revealed that the majority of these proteins are involved in DNA 
and RNA metabolism, as well as the cell cycle (Wei, Mao, et al., 2017). Another study found that 40% 
of crotonylated proteins were in the cytoplasm, 27% in the nucleus and 13% in the mitochondria (Xu 
et al., 2017). A third study, which identified the most crotonylated proteins, found a very similar 
distribution with 37.5% cytosolic, 27.4% nuclear and 13.5% mitochondrial crotonylated proteins (Wu 
et al., 2017). They also found this was similar to the pattern of global proteome localisation suggesting 
that crotonylated proteins have broad distribution and biological functions. This study investigated 
the effects of suberoyl anilide hydroxamic acid (SAHA) treatment on Kcr in human lung carcinoma 
A549 cells, as they had previously found that SAHA treatment had upregulated Kac. On core histones, 
24 out of 35 Kcr sites were upregulated, suggesting that class I and II HDACs are involved in Kcr 
regulation on these histones. Interestingly most sites on histone H1, the nucleosome linker histone, 
were slightly downregulated.  This suggests that class I and II HDACs have no activity on this histone 
but there might be an indirect or non-specific effect of SAHA inhibition of HDACs, for example as a 
result of cellular stress. On non-histone proteins, 281 proteins were upregulated with roles identified 
in translation, transcription, gene expression and ribosome (GO and KEGG terms). The 41 
downregulated proteins were implicated in cellular components of the endolysosome, lysosome 
lumen and vacuolar lumen compartments. KEGG pathway enrichment analysis identified carbon 
metabolism, pentose phosphate pathway and biosynthesis of amino acids and lysosome. Most of the 
up- and down-regulated proteins were in the cytoplasm and nucleus (Wu et al., 2017). Whilst class I 
HDACs are mainly nuclear, class II HDACs can be nuclear or cytoplasmic (Haberland et al., 2009). As 
many cytoplasmic proteins were crotonylated and known class II HDAC targets were found to have 






1.2.1 Metabolism is essential for life 
Metabolism is essential for all living organisms as it enables breaking down food for energy, creating 
macromolecules from building blocks and breaking down waste. Despite a wide diversity of life on 
Earth, the underlying biochemical reactions are surprisingly similar. Simple building blocks such as 
amino acids and sugars are combined to create complex molecules that can store the information and 
energy required to sustain reproduction and evolution of species. For example, the eleven carboxylic 
acids of the tricarboxylic acid (TCA) cycle are common to all of life and are thought to have originated 
in a pre-enzymatic environment (Smith and Morowitz, 2004). Centred on this is carbon, which can 
serve as the backbone for complex structures as it can form multiple bonds with many other atoms 
and thus enables variety in biological macromolecules (Pace, 2001). Cellular metabolism can be 
grouped into either catabolic, breaking down, or anabolic, building up reactions. These chemical 
reactions are linked together to form multiple steps in a network of pathways, each catalysed by an 
enzyme that allows the reaction to occur at a physiological temperature and in a time frame that is 
useful to the cell. If a cell requires more energy, catabolic pathways are used to break down molecules 
into high energy intermediates such as NADH, which are used to generate ATP, the energy currency 
of the cell. When nutrients are limited this can include the breakdown of large macromolecules to 
maintain cellular homeostasis. If a cell requires certain proteins or nucleic acids to be made, for 
example during a period of proliferation, then a series of anabolic reactions will be used to generate 
the desired macromolecule from its building blocks. The metabolic requirements of each cell are 
determined by its environment and tissue type, but every cell must constantly perform multiple 
biochemical transformations to enable it to perform its functions (Metallo and Vander Heiden, 2013).  
1.2.2 Metabolic regulation enables response to the environment 
A cell’s metabolism is a complex network of interconnected steps involving thousands of metabolites. 
This means that multiple food sources can be converted into the same central metabolite, which can 
then be used in multiple cellular functions. Metabolic network activity is determined by the 
concentrations of intermediates and the activity of the enzymes performing the reactions. This activity 
or flux is influenced by the genotype, epigenotype, signalling, inhibitor action and nutrient input (Reid 
et al., 2017). Encoding multiple isoforms of enzymes, such as pyruvate kinase, allows alternative 
splicing to produce enzymes with properties that fulfil the needs of that tissue type. For example, 
pyruvate kinase isoform M1 (PKM1) has high activity and promotes use of pyruvate by the TCA cycle, 




promote glucose to lactate conversion. Mis-regulation of PKM2 is thought to contribute to the altered 
glucose metabolism in cancer (Anastasiou et al., 2012). The function and environment of a cell 
determines its metabolic requirements. For example, hepatocytes must be flexible in their choice of 
metabolic pathway in order to maintain energy intensive processes such as macromolecule synthesis 
and breaking down toxic molecules. Therefore, in a low glucose environment, the cell adapts by using 
fatty acid or amino acid catabolism to provide high energy intermediates for oxidative respiration 
(Metallo and Vander Heiden, 2013).  
External cell signalling is also an important way to direct cellular metabolism. For example, release of 
the anabolic hormone insulin stimulates cells to uptake glucose, which is turned into glycogen for 
storage, whilst suppressing gluconeogenesis (Saltiel and Kahn, 2001). Metabolites can also act as 
signalling molecules, creating a direct and fast responsive feedback mechanism. Pyruvate kinase 
converts phosphoenolpyruvate (PEP) to pyruvate in the last step of glycolysis. Fructose-1,6-
bisphosphate, an earlier stage intermediate of glycolysis, acts as an allosteric activator of pyruvate 
kinase to promote flux through the pathway (Jurica et al., 1997). The abundance of a single metabolite 
is not always informative of the metabolic state of a cell as many regulatory systems detect the 
substrate/product ratio to maintain homeostasis. For example, adenosine monophosphate-
responsive protein kinase (AMPK) senses the energy state of a cell by responding to the ATP/AMP and 
ATP/ADP ratios. It responds by phosphorylating many metabolic enzymes including glycogen synthase 
and acetyl-CoA carboxylase, to downregulate their activity (Hardie, 2011; Oakhill et al., 2011). AMPK 
has also been found to prevent activation of SREBP1, a transcription factor involved in lipid 
metabolism (Li et al., 2011). Thus, through short and long acting mechanisms, AMPK can increase 
glucose uptake and catabolic processes to generate ATP, whilst reducing anabolic processes which 
require ATP.  
1.2.3 Chromatin modifications reflect cellular metabolism 
Many of the epigenetic switches on chromatin are linked to the metabolic state of the cell because 
the enzymes that catalyse these modifications are mediated by the availability of substrates, cofactors 
and allosteric inhibitors which are important metabolic intermediates (Reid et al., 2017). As chromatin 
modifications are involved in transcription regulation, this could allow the metabolic state of the cell 
modulate gene expression in response to changes in the metabolic requirements of the cell. The 
activities of cellular enzymes are controlled by their kinetic (km) and thermodynamic (kd) properties 
relative to substrate concentration. Changes in metabolite (substrate) concentration are only relevant 
for enzyme activity when the concentration of the metabolites fluctuates close to the Km of the 




AKT which phosphorylate H3S10 and ATR and ATM which phosphorylate H2A.X (S139) in mammals 
(Banerjee and Chakravarti, 2011; Locasale and Cantley, 2011). The concentration of ATP is in the 
millimolar range and far in excess of the enzyme’s km, which is in the micromolar range, meaning that 
kinases would not be limited by substrate availability (Locasale and Cantley, 2011). Acetylation and 
methylation reactions often use substrates which fluctuate at a concentration in a similar range to the 
Km of the enzyme, meaning that these modifications can be responsive to changes in metabolism such 
as the TCA cycle or methionine metabolism (Reid et al., 2017). For example, the concentration range 
of acetyl-CoA in humans is 2 - 13 µM and yeast is 3 - 30 µM, whilst the Km of the acetyltransferase 
GCN5 (also called KAT2A) is 0.62 µM and its yeast counterpart is 2.5 µM (Langer et al., 2002; Cai et al., 
2011; Lee et al., 2014). The concentration of S-adenosyl methionine in human erythrocytes was 
measured as 3.5 µM, whilst the Km of human SUV39H1 and SET9 were 0.9 µM and 5.4 µM respectively 
with H3 (Oden and Clarke, 1983; Chin et al., 2006). Some histone modifying enzymes use key 
metabolites, including SIRT HDACs which use NAD+, HATs which use acetyl-CoA and histone 
methyltransferases that use S-adenosyl methionine. In addition, metabolites such as S-adenosyl 
homocysteine, coenzyme A (CoA), 2-hydroxyglutarate, succinate and β-hydroxybutyrate (β-HBu) can 
act as competitive inhibitors of these enzymes. In one interesting study, limiting methionine supply to 
colon carcinoma cells was found to deplete S-adenosylmethionine and S-adenosylhomocysteine as 
well as reducing H3K4me3 abundance (Mentch et al., 2015). As these metabolites are involved in 
many different pathways, the activity of these chromatin modifying enzymes integrates activity from 
across cellular metabolism and links it to histone and DNA modifications (Reid et al., 2017). In parallel, 
changes in metabolite levels may alter gene expression which then leads to changes in histone 
modifications. 
1.2.4 Multiple pathways influence histone acetylation  
Acetyl-CoA is an abundant metabolite and is central to many different pathways. It is generated by 
the pyruvate dehydrogenase (PDH) complex after glycolysis, by thiolase in the beta-oxidation pathway 
and ketone body breakdown, and in the metabolism of some amino acids such as lysine and 
tryptophan (Voet and Voet, 2011). Figure 1.3 shows how it is central to many cellular pathways. It is 
thought that acetyl-CoA is a sensor of the metabolic state of the cell due to its central position in 
anabolic and catabolic pathways. It enables coupling to chromatin as histone acetylation is thought to 
be sensitive to the availability of acetyl-CoA in many different organisms (Takahashi et al., 2006; Friis 
et al., 2009; Wellen et al., 2009; Cai et al., 2011; Donohoe et al., 2012). An interesting example of 
changes to acetyl-CoA levels influencing histone acetylation is in a model system known as the yeast 




in synchronisation of oscillating oxygen consumption (Mellor, 2016). This involves switching between 
the oxidative phase, where mitochondrial respiration is highest, the reductive and building phase, 
where cell division occurs and the oxygen consumption begins to drop, and the reductive and charging 
phase which is quiescent-like and involves induction of stress and starvation genes. Acetyl-CoA levels 
are highly cyclical during this process, with peak levels coinciding with oxidative phase and induction 
of growth genes. A fascinating study showed that increased levels of acetyl-CoA on entry into the 
oxidative growth phase resulted in increased acetylation by Gcn5p-SAGA, specifically at genes that are 
important for growth. The authors suggested that the cell uses histone acetylation to coordinate the 
induction of growth when energy levels are high (Cai et al., 2011). Further to this, the coregulation of 
histone acetylation, particularly at H3K18ac and H3K9ac, with key transcription factors Pip2 (fatty acid 
metabolism), Hfi1 (SAGA complex formation) and Xbp1 (carbohydrate and amino acid metabolism) 
was found be important for the regulation of gene expression in the yeast metabolic cycle using a 
multi-omic integrative approach (Sánchez-Gaya et al., 2018). 
 
Figure 1.3. Acetyl-CoA is a central component of cellular metabolism 
Acetyl-CoA is generated during glycolysis, ketone body breakdown, amino acid breakdown and in fatty acid beta-
oxidation. It is used to generate the reduced intermediates NADH and FADH2 in the TCA cycle which are used to 
generate ATP. It is also used to produce phospholipids, triglycerides, eicosanoids, cholesterol and longer chain 
fatty acids. The compartmentalisation of acetyl-CoA metabolism into mitochondria, cytoplasm and nucleus is 




cytoplasm and nucleus, which can be added onto chromatin by HATs. Acetyl-CoA can also be generated from 
pyruvate due to the PDH complex moonlighting into the nucleus. 
1.2.5 Acetyl-CoA generation in different cellular compartments 
Compartmentalisation is essential for proper cell function. For example, it enables highly degradative 
enzymes such as trypsin to be isolated to prevent cell damage. Whilst many inhibitors are allosteric, 
competitive inhibition is thought to predominate in metabolism, with inhibitors likely to be neighbours 
in metabolic networks and therefore are similar in structure. Additionally, central metabolites are 
more likely to be inhibitors. One of the main ways that this metabolic self-inhibition is alleviated is 
through compartmentalisation, which separates the enzymes from their inhibitors (Alam et al., 2017). 
This could be why some processes such as fatty acid oxidation and the TCA cycle occur in the 
mitochondria whilst others like glycolysis occur in the cytoplasm. Acetyl-CoA is generated in the 
cytoplasm by glycolysis, and also in the mitochondria by pyruvate decarboxylation and β-oxidation of 
fatty acids (Figure 1.3). However, it cannot pass through intracellular membranes due to its high 
energy thioester bond. At the entry point of the TCA cycle, acetyl-CoA is converted by citrate synthase 
into citrate, which can be transported out of the mitochondria. Citrate can then be converted back to 
acetyl-CoA by cytoplasmic ATP citrate lyase (ACLY) (Voet and Voet, 2011).  
ACLY also exists in the nucleus in mammalian cells enabling the generation of nuclear acetyl-CoA 
(Wellen et al., 2009). Silencing of ACLY was found to reduce histone acetylation in HCT116 colon 
carcinoma cells with reduced expression of genes involved in glucose uptake and metabolism. This 
could be rescued by supplementation of acetate at higher than physiological concentrations, an effect 
mediated by ACSS2 which converts acetate to acetyl-CoA (Wellen et al., 2009). Acetate can flow freely 
from the cytoplasm into the nucleus through the nuclear pore complex (Moore et al., 1975). Nuclear 
ACSS2 recycles acetate released by HDACs into acetyl-CoA which can be used to produce histone 
acetylation (Wellen et al., 2009). This recycling has been shown to prevent loss of histone acetylation 
during nutrient limitation and hypoxia, as ACSS2 expression and nuclear localisation increases (Bulusu 
et al., 2017). The importance of these mechanisms for cell fate was demonstrated by silencing ACLY 
in 3T3-L1 preadipocytes, which prevented the increase in histone acetylation normally seen on 
differentiation to adipocytes. This was rescued by supplementation of acetate, which could increase 
histone acetylation in the ACLY silent cells (Wellen et al., 2009). 
Fascinatingly, mitochondrial inhibition reduced cytoplasmic citrate levels but did not change histone 
acetylation (Yi et al., 2011) suggesting an alternative source of nuclear acetyl-CoA. Several metabolic 
enzymes have been identified in the nucleus and are thought to transiently relocate there in periods 




to translocate to the nucleus when human cancer cells were stimulated by epidermal growth factor 
(EGF). PKM2 phosphorylated proteins using PEP, rather than ATP, as the phosphoryl group donor, 
resulting in the generation of nuclear pyruvate (Vander Heiden et al., 2010; Gao et al., 2012; Yang et 
al., 2012). A different study found that the PDH complex, which converts pyruvate to acetyl-CoA, 
translocated to the nucleus during cell cycle progression and increased histone acetylation at H3K9 
and H3K18, which are known to be important for entry into S phase (Cai et al., 2011), as well as levels 
of other S phase progression markers. This was facilitated by the heat shock protein Hsp70 and could 
be induced by growth factors or mitochondrial inhibition (Sutendra et al., 2014). These studies suggest 
that cellular stress can induce an alternative method of acetyl-CoA generation in the nucleus to 
facilitate cellular responses.  
1.2.6 Histone acetylation and metabolism in cancer 
Changes to metabolism are a hallmark of carcinogenesis (Hanahan and Weinberg, 2011; Ward and 
Thompson, 2012) and metabolic-epigenetic interactions play an important role in cellular 
transformation. The source of acetyl-CoA and the functional effects of histone acetylation are context 
dependent. In cell culture where cells are rapidly proliferating, the majority of histone acetylation is 
derived from glucose (Evertts et al., 2013; Lee et al., 2014). Contrastingly, introduction of the medium 
chain fatty acid octanoate resulted in an increase in histone acetylation in immortalized hepatocytes 
(alpha mouse liver 12). Using isotope tracing and proteomics, the authors demonstrated that the 
majority of acetylation was lipid-derived, even in the presence of excess glucose (McDonnell et al. 
2016). Cancerous cells use glycolysis instead of the more energy efficient oxidative phosphorylation, 
even in the presence of oxygen, known as the Warburg effect (Warburg, 1956; Vander Heiden et al., 
2009). In colon carcinoma cells, low doses of butyrate inhibited growth and increased histone 
acetylation, an effect attributed to the lack of butyrate metabolism and subsequent accumulation to 
concentrations where it acted as an HDAC inhibitor. When the Warburg effect was prevented by low 
glucose concentrations, butyrate instead promoted growth, despite also increasing histone 
acetylation. This was in an ACLY dependent manner suggesting metabolism of butyrate to generate 
acetyl-CoA. High doses of butyrate inhibited growth in either context. This could be because the 
amount of butyrate exceeded the capacity of cells (without the Warburg effect) to metabolise it, 
allowing it to exist in high enough concentrations to act as an HDAC inhibitor. Interestingly, HDAC 
inhibition and butyrate metabolism/HAT activation upregulated different sets of target genes, the first 
being enriched for cell-proliferative genes and the second for anti-apoptotic genes. The authors 




mechanism acting first to upregulate gene expression and the ACLY-independent (HDAC mediated) 
mechanism acting to maintain gene expression at higher butyrate doses (Donohoe et al., 2012).  
1.2.7 Metabolism influences histone acylations by generating acyl-CoAs 
1.2.7.1 Crotonyl-CoA generation as part of beta-oxidation and lysine metabolism 
Fatty acid β-oxidation in the mitochondria breaks down long chain fatty acids by removing two carbons 
in each cycle until two molecules of acetyl-CoA are left. The last cycle is shown in Figure 1.4. Short 
chain acyl-CoA dehydrogenase (ACAD) converts butyryl-CoA to crotonyl-CoA, then enoyl-CoA 
hydratase coverts it to β-hydroxybutyryl-CoA which is then turned into two acetyl-CoA molecules by 
thiolase (Schulz, 1991). Interestingly, ACAD deficient mice had increased lysine butyrylation as a result 
of butyryl-CoA accumulation. However, the study looked generally at lysine butyrylation and did not 
examine if butyrylation increased on histones (Pougovkina et al., 2014). Another source of crotonyl-
CoA results from the breakdown of some amino acids. An intermediate step in the saccharopine 
pathway, which metabolises lysine, tryptophan and 5-hydroxylysine; involves the conversion of 
glutaryl-CoA to crotonyl-CoA by glutaryl-CoA dehydrogenase (Besrat et al., 1969). However, this 
enzyme is present in the mitochondrial matrix (Lenich and Goodman, 1986). It is unclear how non-
acetyl acyl-CoAs leave the mitochondria as the CoA group prevents their transport across cellular 
membranes. Whilst generation of acyl-CoAs by beta-oxidation and the TCA cycle, which generates 
malonyl- and succinyl-CoA, is thought to contribute to mitochondrial protein acylation; some have 
suggested that these high energy metabolites are used up in the mitochondria before they can 





Figure 1.4. The last cycle of fatty acid β-oxidation 
Fatty acid β-oxidation removes two carbons from CoA activated fatty acids in each cycle. In the last cycle, butyryl-
CoA is converted into crotonyl-CoA, to β-hydroxybutyryl-CoA, then to acetoacetyl-CoA and finally to two 
molecules of acetyl-CoA.  
 
1.2.7.2 Crotonyl-CoA generation during fatty acid synthesis 
Fatty acid synthesis occurs in the cytoplasm and uses acetyl-CoA and malonyl-CoA to generate long 
chain fatty acids. This is catalysed by fatty acid synthase, a multi-enzyme complex that uses an acyl 
carrier protein (ACP) to shuttle intermediates to different catalytic sites. Malonyl- and acetyl-groups 
are transferred from CoA to ACP and joined to form acetoacetyl-ACP. Then in the reverse of β-
oxidation, acetoacetyl-ACP is converted to β-hydroxybutyryl-ACP, then to crotonyl-ACP and finally to 
butyryl-ACP. The cycles of carboxylative reactions continue to build up the fatty acid, two carbons at 
a time (Voet and Voet, 2011). As this occurs in the cytoplasm, intermediates could be easily shuttled 
off to the nucleus or attached to newly formed nucleosomes in the cytoplasm. This is an anabolic 
process which requires energy, which could mean that it occurs in a different cellular context to beta-
oxidation or lysine breakdown, i.e. during conditions of plentiful energy rather than nutrient input and 




1.2.7.3 Crotonyl-CoA production from crotonate 
Histone crotonylation has been shown to be sensitive to the addition of crotonate to the media of 
HeLa S3 cells, which increased intracellular crotonyl-CoA and crotonylation at core histones in a dose-
dependent manner. The abundance of histone crotonylation was not influenced by acetate treatment  
(Tan et al., 2011; Sabari et al., 2015). ACSS2 can convert acetate to acetyl-CoA in mammalian cells but 
was also found to use larger acyl chains such as propionate in vitro (Frenkel and Kitchens, 1977). ACSS2 
knock-down reduced the effect of crotonate treatment on histone crotonylation. This suggests that 
ACSS2 could convert crotonate to crotonyl-CoA in vivo to contribute to the pool of nuclear crotonyl-
CoA used for histone crotonylation. In fact, ACSS2 knock-down reduced histone crotonylation even 
without addition of crotonate to the media, suggesting basal levels of crotonyl-CoA and histone 
crotonylation are maintained by an endogenous source of crotonate (Sabari et al., 2015). It is unclear 
at present what the source of this cell-generated crotonate is. Whilst histone crotonylation was 
responsive to crotonate, histone acetylation did not change on acetate treatment. The lack of change 
in histone acetylation is, at first, surprising because acetate is converted into acetyl-CoA by ACSS2 and 
histone acetylation is known to be responsive to acetyl-CoA levels (Takahashi et al., 2006; Friis et al., 
2009; Wellen et al., 2009; Cai et al., 2011; Donohoe et al., 2012). However, this could be because the 
pool of acetyl-CoA is already large and indeed in a previous study acetate only increased histone 
acetylation levels in ACLY-depleted cells (Wellen et al., 2009). The pool of crotonyl-CoA in cells is small 
compared to acetyl-CoA, and is below the Km of p300, meaning that environmental fluctuations might 
have a greater proportional effect on the crotonyl-CoA pool than the acetyl-CoA pool.  
Crotonyl-CoA can compete with acetyl-CoA for p300 as modifying the relative amounts of acetyl-CoA 
and crotonyl-CoA in an in vitro p300 catalysed reaction dictated the relative amounts of the respective 
modifications (Sabari et al., 2015). This means that changes to the relative abundance of acetyl- and 
crotonyl-CoA could influence histone acetylation and crotonylation abundance in vivo. To test if 
changing the ac-CoA/cr-CoA ratio in cells could influence their respective modifications Sabari and 
colleagues knocked-down ACLY or PDHE1α, which is a critical subunit of the PDH complex. Both ACLY 
and PDHE1α knockdown reduced histone acetylation but increased histone crotonylation. As the 
intracellular crotonyl-CoA concentration is low relative to acetyl-CoA and the relative concentration 
of crotonyl-CoA and acetyl-CoA could influence p300 activity in vitro, they suggested that lowering 
acetyl-CoA concentrations by ACLY or PDHE1α knockdown might reduce competition between acetyl-
CoA and crotonyl-CoA for p300, enabling more p300 mediated crotonyl-transfer to the histone (Sabari 




1.2.8 The relative abundance of acyl-CoAs 
Relative to acetylation, other acylations are less abundant. Kpr, Kbu, Kcr, Kβ-HBu, Kmal, Ksucc and 
Kglu, had low abundances of 1-5% relative to total acylation levels, whereas Kac was in the range of 
15-30% in HeLa and myogenic cells (Simithy et al., 2017). The abundance of different histone 
acylations was found to show a strong positive correlation with the cellular levels of their acyl-CoA 
donors. Myogenic differentiation in which myoblasts fuse to form multinucleated cells, resulted in 
significantly decreased levels of Kac, Kpr, Kbu, Kmal, Ksucc and Kglu, whilst Kcr increased. 
Correspondingly, acetyl-, propionyl-, butyryl-, malonyl-, and succinyl-CoA levels decreased but 
crotonyl- and glutaryl-CoA did not change (Simithy et al., 2017). The reduction in other acyl-CoAs may 
have freed up HAT enzymes such as p300 to transfer more crotonyl-CoA to histones, resulting in more 
crotonylation without changing crotonyl-CoA levels. Therefore, the abundance of a particular histone 
acylation may be sensitive to not just the abundance of its acyl-CoA, but also the ratio of many acyl-
CoAs in different cellular pools. In the nucleus, histone acylation abundance is a result of the balance 
of HAT and HDAC activities. Sensing metabolite ratios is a common feature of metabolism as it 
provides more information on the metabolic state than a single metabolite. For example, the acetyl-
CoA:CoASH ratio in the nucleus is glucose sensitive which can impact histone acetylation levels (Lee 
et al., 2014). Additionally, as some histone acetylation marks have very fast turnover (Zheng et al., 
2013), which could also be true for crotonylation, this could allow rapid adjustment to gene expression 
to accommodate changing metabolic state. The active mark H4K3me3 has fast turnover and was 
shown to be globally depleted in yeast when growth conditions changed (Radman-Livaja et al., 2010; 
Zheng et al., 2014). However, this could be because nucleosome turnover was found to be higher 
around the TSS of actively transcribed genes in yeast and Drosophila (Dion et al., 2007; Deal et al., 
2010). Whilst H3K4me3 is highly associated with active genes, very little transcription changes when 
H3K4me3 is removed and therefore it may not directly trigger gene expression (Clouaire et al., 2012; 
Howe et al., 2017). Therefore, the situation is likely to be more complex and requires further 
investigation. 
1.2.9 Metabolism, histone crotonylation and gene expression 
Sabari et al. (2015) studied the macrophage response to lipopolysaccharide (LPS) in which p300 
recruitment is required to facilitate histone acetylation and chromatin remodelling. LPS activated 
genes were divided into two groups; pre-activated genes had p300, H3K18ac and H3K18cr before 
stimulation, whereas de novo activated genes acquired this on LPS stimulation. Only the de novo 
activated genes were sensitive to crotonate pre-treatment, which showed increased H3K18cr but 




of inflammatory proteins. In contrast, pre-activated genes were minimally affected. The effects of 
crotonate on de novo gene activation were dependent on ACSS2 as knockdown of this gene reduced 
de novo mRNA levels (Sabari et al., 2015). A further study showed that crotonate-mediated 
enhancement of gene expression is dependent on the crotonyl-reader AF9 containing a fully functional 
YEATS domain. AF9 localisation to chromatin was higher for the LPS stimulated genes that were 
sensitive to crotonate pre-treatment (Y. Li et al., 2016). AF9 may exert its effects by reading non-
histone crotonylation in addition to histone crotonylation, as other YEATS domains are known to bind 
non-histone acetylation. For example, Yaf9 can bind acetylation on the non-histone protein Eaf1 in 
the fungal pathogen Candida albicans (X. Wang et al., 2018). 
1.2.10 Metabolism and histone β-hydroxybutyrylation 
During starvation the liver produces ketone bodies, such as β-HBu, which are released into the blood 
stream to be used as an energy source (Laffel, 1999). Treatment of cells in culture with heavy labelled 
β-HBu followed by mass spectrometry analysis found 28 sites of the previously unidentified Kβ-HBu 
on histones. Additionally, cell culture treatment with β-HBu produced a dose dependant increase in 
Kβ-HBu as a result of cell culture treatment, but no change was seen in Kac. Using ChIP-sequencing 
(ChIP-seq) they found H3K9β-HBu to be enriched at TSS and correlated with the active mark H3K4me3. 
Mice were starved or fed normally for 48 hours and ChIP-seq and RNA-sequencing (RNA-seq) 
performed on extracted livers. It was found that β-hydroxybutyrylation increased as a result of 
starvation and many of the pathways most enriched for H3K9β-HBu were also the pathways with the 
greatest up-regulation of gene expression (Xie et al., 2016). These results show that Kβ-HBu can 
respond to changes β-HBu concentrations in cell culture and to dietary changes, which could 
potentially be true for other histone acylations.  
1.3 Gut microbiota 
1.3.1 The importance of the gut microbiota 
Communities of symbiotic microorganisms exist in all multicellular organisms and are thought to have 
been important in their evolution (Ley et al., 2008). In humans, microorganisms exist on most mucosal 
surfaces, including those of the skin, eyes, mouth, lungs, gut and vagina. They are thought to regulate 
the function of the digestive, immune, neural and homeostatic systems amongst others (Brestoff and 
Artis, 2013; Sommer and Bäckhed, 2013). The gut microbiota is the most bacteria dense and diverse 
community of micro-organisms in the body (Ley et al., 2006). The latest estimates suggest that there 




body (Sender et al., 2016). Due to the diversity of bacterial species, there are thought to be 100 times 
more genes in the gut bacteria than human genes in our genome (Ley et al., 2006), a large number of 
which are involved in energy production and metabolism (Gill et al., 2006). This provides exciting 
potential for the genome of the microbiota to adapt to the needs of its constituents and the host far 
more rapidly than the host genome is able to (Musso et al., 2011). The gut microbiota exists in a 
symbiotic relationship with the host. The microbiota is in an equilibrium that allows the coexistence 
of beneficial and harmful bacteria, with the spread of pathogenic bacteria prevented by large numbers 
of commensal bacteria and the action of the immune system (Blaser and Kirschner, 2007; Flint et al., 
2012).  
1.3.2 The structure of the gut 
The gastrointestinal tract is a hollow tube stretching from the mouth to the anus. After food passes 
through the oesophagus, the stomach initially stores food and begins the digestive process. Next, the 
small intestine is the main site of digestion and absorption, followed by the colon which salvages water 
and electrolytes, and compacts the stool, which is stored in the rectum (Thompson, 2010). In humans 
the gastrointestinal tract is around 5 meters, although this varies considerably between individuals. 
The surface area is much larger with latest estimates suggesting an area of around 32 meters squared 
(Helander and Fandriks, 2014). Whilst the mouse gut surface area is much smaller, at 1.4 meters 
squared, the body surface area to intestinal surface area is very similar to humans, suggesting that the 
mouse is a good model for studying gut biology (Casteleyn et al., 2010).  
The large surface area of the gut is due to villi and microvilli which enable efficient absorption of 
nutrients from the diet. In the small intestine, the epithelial layer of cells lining the lumen are 
invaginated to form finger like projections called villi and pocket-like structures called crypts. In the 
colon there are crypts but not villi (Clevers and Batlle, 2013). The intestinal epithelium is constantly 
renewing, with stem cells in the base of the crypt generating new cells which move through the transit 
amplifying compartment, the differentiating zone and finally up to the top of the villi where they are 
lost by anoikis (apoptosis induced by loss of contact between epithelial cells) into the gut lumen. 
Various specialised cells exist in the epithelium, as shown in Figure 1.5. The small intestine contains a 
single diffuse layer of mucus which is not attached to the epithelium and contains some bacteria. The 
colon contains inner and outer mucus layers. The inner mucus layer is compact, attached to the 
epithelium and is normally free from bacteria. The outer mucus layer is diffuse with an undefined 
border and provides a habitat for intestinal bacteria. The colon microbiota is larger and more diverse 
than that of the small intestine (Hansson, 2012). The lamina propria is a thin layer of connective tissue 




exist in different sections of the intestine which vary in physiology, flow rate, substrate availability, 
host secretion, pH and oxygen tension (Flint et al., 2012).  
 
Figure 1.5 The structure of the small intestine and colon 
The small intestine contains crypts and villi whilst the colon only has crypts. Stem cells in the base of the crypt 
are supported by Paneth cells and label retaining cells. Paneth cells secrete antimicrobial proteins and support 
the stem cells; label retaining cells are paneth cell precursors; transit amplifying cells are proliferative and 
lineage committed to become enterocytes, which are the absorptive cells; goblet cells secrete mucus; 
enteroendocrine cells secrete hormones and tuft cells secrete prostanoids and opioids. Cells differentiate as 
they move up from the crypt and are lost into the lumen by anoikis. There is a higher density of microbes in the 
colon than the small intestine. 
1.3.3 Microbiota development through life 
The gut microbiota changes substantially throughout the duration of an organism’s life and is thought 
to play an important part in its development (Kundu et al., 2017). In the first few months, an infant 
receives microbes from the mother’s breast milk, resulting in large numbers of Bifidobacteria, which 
are well suited to process milk oligosaccharides. Once solid food is introduced the complexity of the 
microbiota gradually increases, something that coincides with the rapid development of the immune 




allowing for more environmental niches and is accompanied by increased microbial richness, a key 
indicator of gut microbiota health (Kundu et al., 2017). Some species are commonly detected in most 
adult faecal samples, but there seems to be a wide variability in bacteria species between adult 
individuals (Flint et al., 2012). It has been suggested that there is some redundancy between species 
and a functional core is shared between the majority of individuals. This core community is thought 
to buffer stresses and restore the original composition of the microbiota, resulting in substantial 
stability over time (Turnbaugh and Gordon, 2009; Rajilic-Stojanovic et al., 2013).  
1.3.4 The effect of diet on microbiota composition  
Particular components of the diet are known to stimulate polysaccharide utilizing bacteria to increase 
butyrate production, either directly or through cross-feeding (Louis and Flint, 2009). For example, low 
carbohydrate diets in obese human males produced a reduction in Roseburia/E. Rectale species with 
a corresponding decrease in butyrate concentration in the faeces (Duncan et al., 2007). The butyrate 
producing Roseburia/Eubacterium Rectale species and F. prausnitzii have been found to prefer lower 
pH values of around 5.5, rather than 6.5, with highest butyrate production but reduced acetate 
concentrations at pH 5.5 (Walker et al., 2005). Interestingly, the pH alters the relative abundance of 
protonated and ionized forms of SCFAs, which influences its absorption as the ionized form cannot 
diffuse into the cell (Cook and Sellin, 1998). Comparing the microbial faeces of children in Burkino 
Faso, which have a high fibre diet, and those of children in Italy on a high fat and protein diet, revealed 
that higher fibre diets produce an enrichment for Bacteriodetes and depletion of Firmicutes species. 
Children in Burkino Faso also had higher levels of SCFAs, including specific species which were involved 
in the utilisation of xylan and cellulose (De Filippo et al., 2010). An interesting study tested the stability 
of the microbial community on dietary change in human volunteers and found that consumption of 
either an animal-based or a plant-based diet over a short period could dramatically change the 
structure of the microbiota (David et al., 2014). However, another study which measured the 
microbiota on sourdough and white bread containing diets in humans, saw greater inter-individual 
variability than differences between diet (Korem et al., 2017). Studies using galacto-oligosaccharide 
or inulin supplementation saw an increase in Bifidobacteria species and F. prausnitzii relative to other 
community members, but not all subjects responded (Ramirez-Farias et al., 2009; Davis et al., 2011).  
1.3.5 The microbiota increases host energy harvest from the diet  
The microbiota plays a key role in energy harvest from food as it digests resistant macromolecules 
that would be otherwise excreted, into small molecules which can be used by host cells to produce 




metabolites and lipids (Nicholson et al., 2012). In particular, colonocytes rely on butyrate as its main 
energy source using β-oxidation, rather than glycolysis, to produce acetyl-CoA for the TCA cycle and 
mitochondrial respiration. As colonocytes occupy a large surface area and have a high turnover (2-5 
days), the intestines would be a major sink for glucose and deprive other tissues if it were not for this 
microbial derived energy source (Stappenbeck et al., 1998; Kaiko et al., 2016). Germ-free mice were 
found to consume more food than conventionalised germ-free mice or conventionally raised mice, 
but are leaner and are more protected against an insulin-resistant state (Backhed et al., 2004). Germ-
free mice were also found to have lower NADH/NAD+ and ATP levels in the colon but not in the liver, 
kidney, heart or testes compared to conventionally raised mice (Donohoe et al., 2011). Transcriptome 
and proteome analysis identified downregulation of enzymes involved in butyrate metabolism as the 
most affected pathway in colonocytes of germ-free mice, along with reduced TCA cycle functioning 
and oxidative phosphorylation. Butyrate administration rescued oxidative phosphorylation and the 
energy state of germ-free mice, along with reduced autophagy (Donohoe et al., 2011).  
1.3.6 Production of SCFAs by the gut microbiota 
The fermentation of indigestible oligo- and poly-saccharides by gut bacteria results in the production 
of SCFAs of which the most abundant are acetate, propionate and butyrate. These exist in high 
concentrations from 70-140 mM in the proximal colon to 20-70 mM in the distal colon (den Besten et 
al., 2013). The ratio of acetate to propionate to butyrate is estimated to be 20:1:4 ratio in the ileum 
and changes to a 3:1:1 ratio in the colon and faeces (Cook and Sellin, 1998; Flint et al., 2012). Other 
SCFAs including isobutyrate (C4), valerate (C5) and hexanoate (C6) also exist in concentrations 5-10% 
of total SCFAs (Cook and Sellin, 1998). Much of the acetate and propionate produced by the microbiota 
is released into the portal circulation and is made available for other tissues, including the liver which 
uses 70% of acetate and 30% of propionate (den Besten et al., 2013). Colonocytes use 70-90% of 
microbial derived butyrate in preference to acetate or propionate (Cook and Sellin, 1998). Crotonate 
may also exist in the colon, as it is an intermediate in anaerobic metabolism and certain Clostridium 
species have been shown to been able to utilize it (Bader et al., 1980; Guccione et al., 2010). 
Additionally, crotonate was identified in the faeces of miniature Dachshunds, where it was present at 
a concentration around three times less than butyrate (Igarashi et al., 2017). This suggests that 
crotonate exists in the gut lumen, but as it is usually not tested there is little evidence of its presence 
in the gut in different organisms or on different diets.  
Butyrate producing bacteria in the gut are strict anaerobes and the majority belong to distinct families 
within the Firmicutes phylum, although members of Bacteriodetes and Actinobacteria phyla have been 




producers has led them to be considered as a functional group, rather than a single phylogenetic one 
(Rivière et al., 2016). The two most abundant butyrate-producing bacteria are F. prausnitzii and E. 
rectale, which were present in 8 % of next generation sequences in obese human males and in up to 
14 % of the phylogenetic core in normal weight individuals, as determined by 16S rRNA gene 
sequencing of faecal samples (Louis and Flint, 2009; Tap et al., 2009; Walker et al., 2011, 2014). Whilst 
they use comparable pathways for butyrate synthesis, E. rectale is flagellated and can use a range of 
dietary fibres, whilst F. prausnitzii is not flagellated and has a limited capacity to use dietary 
polysaccharides, meaning that these bacteria sit in distinct ecological niches (Flint et al., 2012). These 
bacteria colonize the mucosal layer of the gut, as opposed to the luminal layer, making their metabolic 
products easily accessible to the colonocytes (Van Den Abbeele et al., 2013). Interestingly F. prausnitzii 
has been shown to be cross fed by Bifidobacterium species which supplies them with acetate and 
lactate (Ferreira-Halder et al., 2017). This indicates that treatments targeted at some groups of 
bacteria may indirectly influence others. For example, prebiotics such as inulin-type fructans can 
stimulate Bifidobacteria species but can also have beneficial effects related to butyrate producers 
(Rivière et al., 2016). Both Bifidobacteria species and F. prausnitzii are reduced in patients with 
inflammatory bowel disease and colorectal cancer suggesting that they play a key role in intestinal 
function (Rivière et al., 2016).     
1.3.7 Crosstalk between the microbiota, intestinal epithelium and immune system  
There is substantial cross-talk between different elements of the gut. Intestinal epithelial cells (IEC) 
form a physical barrier, release mucus, sense bacterial signals and secrete antimicrobial peptides, 
cytokines and chemokines to modulate the behaviour of the bacteria and immune cells (Roda et al., 
2010; Gallo and Hooper, 2012). It has been suggested that IECs can modulate the adhesion of bacteria 
to the mucus and to the IECs, to increase the competitive advantage of certain microbes (McLoughlin 
et al., 2016). In turn, immune cells release cytokines to regulate epithelial permeability, IEC 
proliferation and antimicrobial peptide secretion (Dahan et al., 2007). The microbiota plays a critical 
role in development and maturation of both innate and adaptive immunity, to maintain immune cell 
homeostasis (Kabat et al., 2014). SCFAs are involved in mediating the cross-talk between IECs, 
microbiota and the immune system. For example, SCFAs activate the G-protein coupled receptors 
GPR43 and GPR109a to induce the production of IL-18 by IECs, a pro-inflammatory cytokine that is 
involved in repair and maintenance of epithelial integrity (Singh et al., 2014; Macia et al., 2015). SCFA 
administration in humans promoted the expression of anti-microbial peptides such as LL37 by IECs 




SCFAs have been found to have both immune stimulating and anti-inflammatory effects, the reason 
for which is still unclear (Corrêa-Oliveira et al., 2016). SCFAs and gut function   
The pleiotropic effects of SCFAs in the gut, including acting as modulators of intestinal pH, cell volume, 
ion transport, proliferation, differentiation and gene expression may be because they have multiple 
modes of action (Cook and Sellin, 1998). They can be converted to acyl-CoAs which are intermediates 
in important metabolic processes, act as epigenetic regulators by inhibiting HDACs and influence 
signalling through the G-coupled protein receptors GPR43, GPR41 and GPR109A (Corrêa-Oliveira et 
al., 2016). In addition to passive diffusion of protonated SCFAs, the solute carriers Slc16a1 and Slc5a8 
actively transport SCFAs across the cellular membrane from the intestinal lumen into the IEC cytosol 
(Cook and Sellin, 1998; den Besten et al., 2013). Interestingly, butyrate is potent HDAC inhibitor and 
propionate inhibits HDAC nearly as effectively, but acetate inhibits it only weakly, therefore these 
SCFAs may induce different cellular responses in some contexts (Candido et al., 1978; Cousens et al., 
1979).  
A fascinating study demonstrated how the structure of the gut enables butyrate to influence certain 
cell types differently. Butyrate was found to inhibit proliferation of cultured primary intestinal stem 
cells via HDAC inhibition, but not via GPCR stimulation. The suppressive effect of butyrate was in part 
mediated by foxo3, a negative cell cycle regulator. Colonocytes in the upper regions of the crypt 
metabolise butyrate and use it for oxidative phosphorylation, which is ACAD dependent. The 
breakdown of butyrate by colonocytes results in titration of butyrate down the crypt with highest 
concentrations at the top down to much lower concentrations at the base, which protects the stem 
cells (Kaiko et al., 2016). In fact, butyrate concentrations in the crypt base have been estimated to be 
much lower than that of the lumen, at 50-800 μM (Donohoe et al., 2012). Acetate and propionate did 
not inhibit stem cells and passed through the epithelial barrier for use by other tissues (Kaiko et al., 
2016).  
SCFA metabolism by colonocytes may be important for establishing the oxygen gradient that exists in 
the gut, as antibiotic mediated reduction of the microbiota diminished hypoxia. The oxygen 
concentration decreases from the O2 rich lamina propria to the hypoxic colon lumen, where many 
anaerobic bacteria live, with the colonic epithelium functioning at a pO2 well below that of other 
tissues (He et al., 1999). Despite this low oxygen abundance, butyrate was found to promote its own 
metabolism in IECs by stimulating pyruvate dehydrogenase kinases which inhibit the PDH complex and 
suppress glycolysis (Blouin et al., 2011). Butyrate has also been found to activate AMPK in colonic cell 
lines and AMPK is known to inhibit the Warburg effect and suppress tumour growth (Donohoe et al., 




gut and results in stabilisation of hypoxia inducible factor (HIF), a transcription factor that mediates 
maintenance of barrier integrity amongst other things (Kelly et al., 2016). Interestingly, HIF 
stabilisation is protective against colitis (Karhausen et al., 2004), and may be one of the reasons why 
butyrate has been successful in some cases to treat colitis, which is a disease characterised by 
inflammation of the colon. Interestingly F. prausnitzii is stimulated by low oxygen conditions 
suggesting that it exists in a niche that involves exposure to some oxygen, such as in the mucin layer, 
closer to the IECs (Flint et al., 2012).   
1.3.8 SCFAs and disease 
The gut microbiota has been implicated in a wide range of diseases including cardiovascular disease, 
obesity, diabetes, malignancy, inflammatory bowel diseases and even neurodegenerative disorders 
(Musso et al., 2011; Borre et al., 2014; Shreiner et al., 2015). Dietary fibre has been shown to reduce 
the risk of colon cancer and inflammatory bowel diseases, but the mechanism involved is unclear. As 
fermentation of fibre produces SCFAs, these have been under intense study for their potential 
therapeutic benefits but the results have been variable. In one study SCFA irrigation of patients with 
diversion colitis resulted in the disappearance of symptoms, but another study saw no benefit (Harig 
et al., 1989; Guillemot et al., 1991). In a rat model of cancer, it was demonstrated that only dietary 
fibre that increased the concentration of butyrate in the distal colon was protective against colon 
cancer (McIntyre et al., 1993). Another study found that the ratio of SCFAs may be important, as 
comparing polyp/colon cancer patients with normal controls showed a higher abundance of acetate 
and a lower abundance of butyrate relative to total SCFA concentration (Weaver et al., 1988). Butyrate 
may be protective because of its differential effect on normal and malignant cells. It was found to 
induce apoptosis and inhibit proliferation in cancer cell lines, but withdrawal of butyrate induced 
apoptosis in normal pig colonocytes (Hague et al., 1993; Luciano et al., 1996). This could be due to the 
differences in metabolism between normal and malignant cells (Vander Heiden et al., 2010), as 
butyrate promotes growth (or has no effect) on non-cancerous cells but inhibits proliferation in cancer 
cells undergoing the Warburg effect (Donohoe et al., 2012). Butyrate may have a context dependent 
effect in colon cancer. In a study of mice with a tumour suppressor gene and mismatch repair gene 
mutation, butyrate feeding promoted tumourigenesis (Belcheva et al., 2014). In contrast, mice 
deficient in the butyrate receptor GRP109a were susceptible to colon cancer (Singh et al., 2014). A 
reduction in butyrate producers has been identified in patients with inflammatory bowel disease and 
colorectal cancer (Rivière et al., 2016). In addition, dietary fibre mediated increase in butyrate 
concentration in the distal colon is protective against colorectal cancer (Cook and Sellin, 1998). In 




anti-diabetic effects, but other evidence suggests that overproduction of SCFAs in the bowel can lead 
to obesity (Sanna et al., 2019). An interesting recent study suggested that a shift in microbial pathways 
towards butyrate production increased insulin production, but did not affect type 2 diabetes risk. In 
contrast, a shift towards propionate production and increased propionate in the faeces did not change 
insulin production, but reduced the risk of type 2 diabetes (Sanna et al., 2019). C. difficile infections 
often follows disruption to the normal gut microflora, for example due to antibiotics, resulting in 
damage to the epithelium and inflammation of the colon (Napolitano and Edmiston, 2017). A 
fascinating recent study found that administration of butyrate, or treatments that increase butyrate, 
protected against C. difficile by attenuating intestinal inflammation and improving barrier function in 





1.4 Objectives of this study 
My overall aim of the thesis is to shed new light onto the symbiotic microbiota-host crosstalk in the 
gut by elucidating mechanisms through which the microbiota may affect metabolism, epigenetic state 
and gene expression in the intestinal epithelium. My hypothesis is visualised in Figure 1.6. I propose 
that metabolites, generated by the microbiota from the diet may direct the use of metabolic pathways 
in the IECs to enable energy generation. Changes to cellular metabolism would in turn influence 
histone modifications, by changing substrate availability or enzyme activity, to alter chromatin state. 
I will focus on histone acetylation and crotonylation as they are known to respond to the availability 
of acetyl-CoA and crotonyl-CoA, which are derived from multiple sources including microbial 
generated SCFAs. Whilst many histone crotonylation sites and interacting proteins have been 
identified, much less is understood about how it is influenced by cell metabolism and the microbiota. 
As these hPTMs are implicated in regulation of gene expression, I suggest that microbiota induced 
changes to histone acetylation and crotonylation would in turn influence gene expression and enable 
the microbiota to effect IEC function in a reversible and dynamic manner.  
I will therefore examine how histone crotonylation and acetylation are influenced by changes to the 
microbiota and the mechanism by which this occurs. I aim to: 
- Test if SCFAs can influence histone crotonylation or acetylation in colon carcinoma cells and 
organoids. 
- Determine whether SCFAs can influence histone acylations through inhibition of HDACs 
- Find out if HDACs have the capacity to use longer crotonyl- or butyryl-modifications.  
- Test if high fibre diets can increase SCFA concentrations in the gut and find out how this 
influences histone acylations in IECs. 
- Investigate the effects of antibiotics treatment on SCFA concentrations and histone acylations 
in IECs. 
- Find out whether ACAD deficient mice have an altered response to high fibre diet or antibiotics 
treatment. 
- Characterise certain histone crotonylation and acetylation marks that are linked to the 




- Determine how antibiotics treatment changes gene expression in the colon and how this is 
linked to histone modifications. 
 
Figure 1.6. Hypothesis: SCFA induced changes to chromatin mediate the interaction between the 
microbiota and intestinal epithelial cells 
The microbiota digests dietary fibre containing foods such as apples, broccoli, rye bread, potatoes and beans 
to produce SCFAs. These microbial metabolites are an important energy source for intestinal epithelial cells 
that influence their metabolism and chromatin state. Changes to modifications on the nucleosome enables 
transition from a more closed and inactive state (blue) to an open active state (red), which enables 





2 Materials and Methods 
2.1 Antibodies 
Anti-crotonyl-histone H3 lys18 (anti-H3K18cr, PTM-517), anti-butyryl-histone H3 lys18 (anti-H3K18bu, 
PTM-306), anti-hydroxybutyryl-histone H3 lys18 (anti-H3K18β-HBu, PTM-1292), anti-crotonyl-histone 
H4 lys8 (anti-H4K8cr, PTM-522) anti-butyryl-histone H4 lys8 (anti-H4K8bu, PTM-311), anti-lysine 
crotonyl (anti-Kcr, PTM-501) and anti-lysine acetyl (anti-Kac, PTM-101) were from PTM biolabs. Anti-
acetyl-histone H3 lys18 (anti-H3K18ac, ab1191), anti-acetyl-histone H4 lys8 (anti-H4K8ac, ab15823), 
anti-crotonyl-histone H4 lys8 (anti-H4K8cr, ab201075) and anti-histone H3 (anti-H3, ab1791) were 
from abcam. Anti-HDAC1 (05-100, Clone 2E10) was from millipore, anti-HDAC2 (sc9959, C-8) was from 
SantaCruz and anti-HDAC3 (BD61124) was from BD Biosciences. Anti-rabbit IgG horseradish 
peroxidase (HRP) linked whole antibody (anti-rabbit, NA934-1ml) was from GE healthcare. Anti-mouse 
IgG HRP linked whole antibody (anti-mouse, 401215) was from Calbiochem.  
2.2 In vitro experiments 
2.2.1 Peptide assay 
95% pure and lyophilized H3K18-crotonyl or -acetyl peptides were obtained from BioGenes. 
Sequences were TGGKAPR-Lys(Crotonyl)-QLATKAA-EDA-Biotin (Peptide 60556.1) and TGGKAPR-
Lys(Acetyl)-QLATKAA-EDA-Biotin (Peptide 60555.1). EDA is a spacer amino acid sequence. H3K18cr 
and H3K18ac peptides were diluted in HDAC assay buffer (25 mM Tris-HCl pH 7.5, 50 mM KCl, 1 mM 
MgCl2 and 1 µM ZnSO4) and incubated with 0.12 μM HDAC1 or buffer alone for 2 hours at 30 °C, 
followed by stopping at 95 °C for 1 minute. In the following experiment 0.12, 0.06, 0.03 or 0.015 μM 






2.2.2 HDAC assay with recombinant acylated histone H3 
The activity of recombinant HDAC1, HDAC2 and HDAC3/NcoR1 were assayed using acetylated, 
crotonylated or butyrylated recombinant histone H3 as described in full in the appendix (section 8.1). 
The full protocol was published in Bio-protocols (Fellows and Varga-Weisz, 2018). In brief, 5.65 µM 
recombinant histone H3 was combined with 87 µM acyl-CoA and 0.66 µM recombinant p300 catalytic 
domain, in a buffer containing 50 mM Tris-HCl, 50 mM KCl, 0.1 mM EDTA, 0.01% Tween 20, 10% 
glycerol and 1 mM DTT. It was then incubated for 2 hours at 30 °C followed by stopping at 65 °C for 5 
minutes. A 1:3 dilution of the reaction mix was made in a buffer containing 25 mM Tris-HCl pH 7.5, 50 
mM KCl, 1 mM MgCl2 and 1 µM ZnSO4. A series of reactions were set up with the reaction mix and a 
1:2 serial dilution of recombinant HDAC enzyme starting with 0.25 µM HDAC1, 0.18 µM HDAC2 or 0.45 
µM HDAC3/NCoR1 for 2 hours at 30 °C, followed by stopping the reaction at 95 °C for 1 minute. After 
mixing 1:1 with 2x laemmli buffer and 2-mercaptoethanol, reactions were analysed by western 
blotting using anti-Kcr or anti-H3K18ac antibodies as described in section 2.6.2. For inhibitor tests, 
crotonylated H3 or acetylated H3 were incubated with constant 0.12 µM HDAC1 and a 1:2 serial 
dilution of inhibitor, starting at 200 nM trichostatin A (TSA), 50 mM crotonate or 10 mM butyrate. 
Reactions were analysed by dot blotting. For enzymatic assays, 0.03 µM HDAC1 was incubated with 
1.41, 0.94, 0.71, 0.57 and 0.47 µM acetylated or crotonylated H3 for 0, 0.5, 1, 2, 4 and 10 minutes in 
triplicate. Reactions were analysed by dot blotting by spotting in quadruplicate on nitrocellulose 
membrane followed by blotting with anti-Kcr and anti-H3K18ac as described in section 2.6.2. Spots 
were quantified using image J and the raw intensity value divided by zero time point for each 
substrate concentration to give relative values. Multiplying by the starting substrate concentration 
converted the image intensity to substrate concentration, which was plotted against time and a 
linear regression fitted for the first 30 sec or first 1 min of the reaction, as appropriate. The initial 
rate was plotted against substrate concentration in GraphPad Prism Version 7 software and the 
analysis tools used to calculate Km, Vmax, and Kcat. For assays testing HDAC1 histone acylation, 
recombinant H3.1 and a 1:2-fold serial dilution of crotonate, acetate or butyrate starting at 50 mM 
was incubated with 0.11 µM HDAC1 or without HDAC for 2 hours at 30 °C. Reactions were analysed 
by western blotting using anti-H3K18ac/bt/cr, as described in section 2.6.2. 
2.3 Colon carcinoma cell experiments 
2.3.1 Defrosting cells 
Human colon carcinoma (HCT116) cells were a gift from Simon Cook’s lab (Babraham Institute) who 




a list of frequently misidentified cell lines, as listed by the International Cell Line Authentication 
Committee (ICLAC). A frozen ampule of HCT116 cells was rapidly thawed in a 37 °C water bath and 
added dropwise to a sterile 15 ml tube containing 5 ml prewarmed media (DMEM with pyruvate, 4.5 
g/L glucose, 10% foetal bovine serum (FBS, heat inactivated), 100 units/ml penicillin and 100 µg/ml 
streptomycin). After spinning at 1000 xg for 5 minutes, media was removed and cells resuspended 
with 10 ml fresh media. Cells were counted with a haemocytometer and a phase contrast microscope, 
seeded to 0.75-1 million cells per ml in a T75 flask and incubated at 37 °C with 5% CO2. Media was 
changed after 24 hours and cells were passaged after 48 hours.  
2.3.2 Passaging HCT116 cells 
Media was removed from a T75 flask containing HCT116 cells at 60-80% confluency and put in a 50 ml 
tube. Cells were washed with 5 ml of phosphate buffered saline (PBS). 2 ml of prewarmed trypsin-
EDTA 0.05 % solution with phenol red was added and incubated at 37 °C for 2 minutes. The flask was 
tapped firmly and dissociation confirmed under the microscope. Trypsinised cells and a 5 ml wash of 
the flask with fresh media were transferred to the 50 ml tube and spun 1000xg for 5 minutes. Cells 
were resuspended in 10 ml fresh media and the appropriate volume added to a prewarmed T75 flask 
with 12 ml media. For three days of culture, a 1:15 dilution was used and for four days of culture, a 
1:20 dilution was used. 
2.3.3 HCT116 cell treatment 
A homogeneous solution of HCT116 cells was prepared in prewarmed media and seeded in 6 well 
plates at a density of 200,000 cells per well (3 ml per well). After around 24 hours, when the cells were 
around 20-40% confluent, the desired amount of compound was added and plate was swirled to mix. 
24 hours after treatment the cells were harvested as quickly as possible to prevent loss of histone 
modifications. Each well was washed with 1 ml PBS, followed by incubation with 300 µl trypsin-EDTA 
solution at 37 °C for 2 minutes. The solution was transferred to a 1.5 ml tube with 900 µl fresh media 
and the mix was used to wash the well. Cells were spun at 4 °C, 425xg for 5 minutes. After removing 
the media, cells were resuspended in cold 500 µl PBS and spun again. Cells were then resuspended in 
30 µl RT PBS and 30 µl of 1x laemmli buffer without β-mercaptoethanol and immediately put at 95 °C 
for 5 minutes. After cooling samples were frozen at -20 °C or prepared for western blot immediately 




2.3.4 HCT116 cell chromatin preparation 
Two or three T75 flasks containing HCT116 cells at 60-80% confluency and typically 15-20 million cells 
were used per ChIP. Treatment was with 5 mM crotonate for 24 hours prior to harvest. Cells were 
trypsinised, collected in 50 ml tubes and resuspended in 10 ml RT PBS, as described for passaging. 
Cells were fixed in 10 ml of PBS with 1% methanol free formaldehyde for 10 minutes at room 
temperature (RT) with gentle agitation. After quenching with 0.125 M glycine for 5 minutes, cells 
were spun at 480xg and 4 °C for 5 min. 100x stock of protease inhibitor cocktail was made by 
dissolving one tablet of EDTA-free protease inhibitor cocktail (PIC, Sigma) in 500 μl H2O. The cell 
pellet was resuspended in HCT116 ChIP lysis buffer (150 mM NaCl, 25 mM Tris-HCl pH8, 5 mM 
EDTA, 0.1% triton, 1% SDS) supplemented with protease inhibitors (10 mM sodium butyrate, 1 mM 
PMSF and 1x PIC) at a ratio (v/v) of 75-100 µl buffer to 10 µl approximate pellet volume. After 
incubation for 10 minutes on ice, sonication was performed in a water-cooled Biorupter (Diagenode) 
at high power, 30 seconds on and 30 seconds off for 12-15 cycles, to obtain fragment sizes of 200-500 
base pairs (bp). The sonicated material was transferred to a 1.5 ml tube, incubated for at least 30 
minutes on ice and then spun at 28,000xg and 4 °C for 10 minutes. After putting the supernatant in a 
fresh tube, sonication test tubes were prepared with 5 µl sonicated chromatin, 74 µl elution buffer 
(0.1 M NaHCO3 and 1% SDS) and 20 mg/ml 1 µl proteinase K. These tubes were incubated in a 
thermomixer for 2 hours at 65 °C and 300 rpm followed by purification with the Qiagen polymerase 
chain reaction (PCR) purification kit, eluting in 30 µl. 500 ng was run on a 1.5% agarose gel at 120V 
and 250 mA for 40 minutes to verify fragment size distribution. ChIP was performed as described 
in section 2.7.3. 
2.4 Organoid experiments 
2.4.1 Small intestinal organoid establishment 
Before starting, 24 well tissue culture plates were prewarmed and phenol-free matrigel was thawed 
on ice. After killing mice with CO2 and cervical dislocation, the small intestine was dissected and fat 
removed. The intestine was flushed with cold PBS using a 1000 µl pipette and opened longitudinally. 
The villi were scraped off gently using a coverslip and the intestine cut into 2 to 4 mm pieces with 
scissors. Five times, the pieces were shaken vigorously for 1 minute in a 50 ml tube with cold PBS and 
supernatant discarded until the supernatant was only a bit cloudy. The pieces were incubated on ice 
whilst shaking with 2 mM EDTA in PBS for 30 minutes. The remaining villi were removed by shaking 
vigorously for 10 seconds and incubating with 5 mM EDTA in PBS for a further 30 minutes. After 




spun at 425xg for 5 minutes. The pellet was resuspended in 2 ml of cold PBS, transferred to a 1.5 ml 
tube and spun again. The crypts were then resuspended in 100% red-phenol free matrigel (BD 
Biosciences, 50 µl per 100-200 crypts) and seeded in 50 µl drops in the prewarmed 24 well plate. After 
30 minutes incubating at 37 °C to polymerise the matrigel, 500 µl complete small intestine growth 
media was added to each well containing advanced DMEM/F12 (Sigma), 2 mM Glutamax (Invitrogen), 
10 mM HEPES (Gibco), 100 U/ml penicillin/streptomycin (Invitrogen), 1 mM N-acetyl-cysteine 
(Sigma), 1× B27 supplement (Invitrogen), 1× N2  supplement (Invitrogen), 50 ng/ml mouse EGF 
(Peprotech), 100 ng/ml mouse Noggin (Peprotech), and 10% human R-spondin-1-conditioned 
medium from R-spondin-1-transfected HEK293T cells (Cultrex). RT PBS was added to unused wells 
to reduce evaporation. Medium was changed after 24 hours and then every two to three days. 
Organoids were passaged after six to eight days. 
2.4.2 Colon organoid establishment 
After killing mice with CO2 and cervical dislocation, the colon was dissected, opened longitudinally and 
rinsed three to four times in a petri dish with cold Hank’s balanced salt solution (HBSS) without Ca2+ 
or Mg2+. The colon was cut into 2-5 mm pieces, transferred to a 15 ml tube containing cold Dulbecco’s 
PBS and pieces washed three times by pipetting them up and down with a 0.1% bovine serum albumin 
(BSA) coated 10 ml pipette, letting the pieces sink and replacing the solution. Colon pieces were 
incubated on ice with shaking and 5 mM EDTA in HBSS for 35 minutes. Pieces were washed three 
times, by pouring off the solution and adding fresh HBSS. 3ml fresh HBSS was added and the pieces 
pipetted up and down three times with a coated 5 ml pipette, then the solution was transferred to a 
fresh, BSA coated 15 ml tube. This was repeated twice to get as many crypts as possible. The tube was 
spun at 600xg and 4 °C for 5 minutes, then pellet resuspended in 500 µl cold PBS and transferred to a 
1.5 ml tube. After another spin, the pellet was resuspended in 100% thawed matrigel and 50 µl drops 
prepared in a 24 well plate, which was incubated at 37 °C for 30 minutes. 500 µl prewarmed complete 
colon growth medium was added to each well containing advanced DMEM/F12 (Sigma), 2 mM 
Glutamax (Invitrogen), 10 mM HEPES (Gibco), 100 U/ml penicillin/streptomycin (Invitrogen), 1 mM 
N-acetyl-cysteine (Sigma), 1× B27 supplement (Invitrogen), 1× N2  supplement (Invitrogen), 
50 ng/ml mouse EGF (Peprotech), 100 ng/ml mouse Noggin (Peprotech), 10% human R-spondin-1-
conditioned medium from R-spondin-1-transfected HEK293T cells (Cultrex), 50% wnt3a 
conditioned medium from L Wnt-3A cells (ATCC CRL-2647), 10 µM Y-27632 (Rock-inhibitor) and 
500 µg/ml primocin. Media was changed after 24 hours to growth media without primocin and then 
every two to three days with growth media without Y-27632 or primocin. Organoids were passaged 




2.4.3 Organoid passage 
When there were 4-16 wells of organoids, media was removed from a three-quarters of the wells with 
an aspirator leaving just the matrigel drop. A 1000 µl pipette was used to disrupt the Matrigel in all of 
the wells. Then, the remaining quarter media was used to collect all of the cells and matrigel in a 15 
ml tube on ice. 1 ml cold PBS was used to wash four wells and was also transferred to the 15 ml tube 
which was made up to 12 ml with cold PBS. With one or two wells the same procedure was applied, 
but all media and matrigel were transferred to a 1.5 ml tube and 500 µl cold PBS used to wash the 
wells. The tube was submerged in ice and incubated for 30 minutes to let the matrigel thaw.  After 
spinning at 4 °C and 600xg for 5 minutes, media and as much matrigel as possible was removed. If 
organoids were still spread through the matrigel, fresh PBS was added and the tube spun at 800xg for 
5 minutes. Organoids were disrupted in 300 µl cold basal medium with a 200 µl pipette for about 5 
minutes until the organoid specks were only just visible. After spinning again at 600xg and 4 °C for 5 
minutes, media was removed and cells resuspended in 25 µl media and 25 µl 100% Matrigel per well 
required. Typically, two or three times more wells were made than the number collected for 
passaging, so that there was a 1:2 or 1:3 dilution of the organoids. After incubating at 37 °C for 30 
minutes, 500 µl complete colon or small intestine growth media was added with rock inhibitor (colon 
only). PBS was added to unused wells. 
2.4.4 Organoid treatment  
48 hours after seeding organoids, media was changed to complete growth media containing the 
desired concentration of the treatment. Four wells were used per condition to ensure that enough 
material was obtained. After 48 hours with the treatment, the organoids were harvested. Media was 
removed and each well washed with 500 µl cold PBS. 250 µl cell recovery solution was added to each 
well and left on ice for 3 minutes. Drops were disrupted with a 1000 µl pipette and transferred to a 15 
ml tube for each condition. 250 µl cell recovery solution was used to wash four wells, which was also 
transferred to the 15 ml tube. Tubes were incubated on ice for 30 minutes, made up with cold PBS 
and spun at 600xg and 4 °C for 5 minutes. After washing with 5 ml cold PBS, the cell pellet was 
resuspended in 500 µl PBS, transferred to a 1.5 ml tube and spun again. The pellet was resuspended 
in 30 µl PBS and 30 µl 1x laemmli sample buffer then boiled at 95 °C for 5 minutes. After cooling, 
organoid extracts were either frozen at -20 °C or processed immediately for western blot as described 




2.5 Mouse experiments 
2.5.1 Mouse experiments at the Babraham Institute  
Untreated mice for the ChIP-seq experiments, for establishing organoids and for crotonate 
treatment were housed at the Babraham Institute Biological Service Unit. All experimental 
protocols at Babraham Institute were approved by the Babraham Research Campus local ethical 
review committee and the Home Office (PPL 80/2488 and 70/8994). All mice were C57BL/6 adult 
males, were kept in specific pathogen-free conditions and fed ad libitum. Crotonate was added at 
0, 10 or 50 mM to the drinking water for two weeks for the crotonate treatment experiment.  
2.5.2 High fibre diet and antibiotic treatment of mice 
The antibiotics treatment and high fibre diet experiments were performed at the University of 
Campinas. Male C57BL/6, Balb/c or Balb/c ByJ mice at age 8–12 weeks were provided by the 
Multidisciplinary Centre for Biological Investigation and all the experimental procedures were 
approved by the Ethics Committee on Animal Use of the Institute of Biology, University of Campinas 
(protocol number 3742-1). The Balb/c and Balb/c ByJ strains (JAX stock #001026) were obtained 
from the Jackson Laboraroty, USA in 2013. Mice received 200 µl of a mixture of antibiotics (5 mg/ml 
of neomicin, 5 mg/ml of gentamicin, 5 mg/ml of ampicillin, 5 mg/ml of metronidazole, and 
2.5 mg/ml of vancomycin, Sigma Aldrich) daily for 3 days by gavage. The weight of the animals was 
monitored throughout the experiment. The high fibre diets were given for one month with the 
control diet based on the AIN93M diet (Reeves et al., 1993), with 5% of cellulose and with inulin 
and pectin diets containing 5% of cellulose and 10% of inulin or pectin. At the end of treatment 
period, faeces were collected and snap-frozen in liquid nitrogen. After that, the animals were 
anesthetized using a mix of ketamine and xylazine (300 and 30 mg/kg, respectively)  and the blood 
was collected by cardiac puncture. The blood was maintained at RT for 30 min and then centrifuged 
(3000×g, 8 min). The serum was collected and frozen at −80 °C. After euthanizing the animals by 
cervical dislocation, the entire intestine was harvested and the small intestine, colon, colon 
contents and cecum were isolated. Mice of the same age and breed were randomly put in the 
experimental groups. The order of samples from groups was mixed on collection. Sample size is 





2.5.3 Determination of faecal bacterial load 
Stool samples were collected on the third day after treatment by gavage with a mix of antibiotics 
or PBS. Bacterial load estimation was performed by the Marco Vinolo group as described in Fellows 
et al. (2018). Fifty milligrams of the samples were used for extraction of the microbial genomic 
DNA using the Invitrogen™ PureLink™ Microbiota DNA purification kit (Thermo Fisher Scientific). 
The concentration and purity of the DNA was assessed using a NanoDrop spectrophotometer. The 
samples were quantified by real time PCR in a 96 well format in the Applied Biosystems 7500 real 
time PCR system using SYBR™ green master mix (Thermo Fisher Scientific). Primers were against 
the 16S rRNA gene in Eubacteria and the sequences were ACT CCT ACG GGA GGC AGC AGT (sense) 
and ATT ACC GCG GCT GCT GGC (anti-sense). A standard curve was generated using extracted 
genomic DNA from Escherichia coli grown in vitro to determine the faecal bacterial load. Results 
were normalised to the untreated condition. 
2.5.4 Short chain fatty acid measurement 
Short chain fatty acid (SCFA) concentration in the colon lumen or serum was determined by gas 
chromatography coupled to mass spectrometry. Sample preparation and analysis was conducted 
by the Caroline Marcantonio Ferreira laboratory as published in Bio-protocols (Ribeiro et al., 2018). 
I performed statistical analysis with t-tests, one-way ANOVA or two-way ANOVA using the GraphPad 
Prism statistical analysis functions as appropriate. Prior to running the analysis, I checked that the data 
met the assumptions for parametric tests. Interpretation of resulting p-values took into account the 
variability and distribution of the pool of data from which the samples were taken.   
2.5.5 Butyrate treatment of germ-free mice 
The germ-free butyrate treatment was performed by José Luís Fachi. Experiments with germ-free 
(microbiota-free) animals were with Swiss mice aged 6-10 weeks old at the Department of 
Microbiology, Institute of Biological Science of the Federal University of Minas Gerais. Treatment 
was for one week with 150 mM butyrate in the drinking water.  
2.5.6 Dietary restriction of mice 
The dietary restriction of mice was performed by the group of Linda Partridge, in accordance with the 
recommendations and guideline of the Federation of the European Laboratory Animal Science 
Association (FELASA), with all protocols approved by the Landesamt für Natur, Umwelt und 




Parental animals were received from Charles River Laboratories (Lyon, France) and animals used in 
this study were 5-month old female F1 hybrid mice (C3B6F1), generated by mating C3H/HeOuJ 
females with C57BL/6 N males. All mice were fed commercial rodent chow (ssniff R/M-H autoclavable, 
ssniff Spezialdiäten GmbH, Soest, Germany) and were provided with acidified water ad libitum. The 
food uptake of ad libitum-fed animals was measured weekly and dietary restriction was applied by 
feeding the animals 40% less food. Adult-onset treatment was started at the age of 12 weeks in a 
stepwise manner, by reducing food amounts fed to dietary restricted animals by 10% each week until 
the 40% reduction was reached. At the age of 5 months, which corresponded to 2 months of 
treatment, mice were killed by cervical dislocation and organs were immediately harvested and flash-
frozen. On the day they were killed, tissue samples were collected in a 3 h time-window in the morning 
prior to the regular feeding of mice.  
2.5.7 Tissue collection and extract preparation for western blot 
Dissected colons or small intestines were cut open longitudinally and washed in PBS. A 1 cm piece was 
cut, dried briefly on a paper towel and flash frozen. For the liver, a 3-5 mm section of the largest lobe 
was cut and flash frozen. A pestle, mortar and two small spatulas were chilled on dry ice. Tissue pieces 
were ground to a fine powder and transferred to a 1.5 ml tube. Quickly, 500 μl of 1x laemmli buffer 
was added and mixed by a combination of pipetting and vortexing. Immediately after, the tube was 
boiled at 95 °C for 5 minutes. Samples were frozen at -20 °C or prepared immediately for western 
blotting. 
2.6 Western Blotting 
2.6.1 Cell sonication and quantitation 
HCT116 cell or organoid extracts in a 60 µl volume were sonicated briefly (two to three seconds) with 
a probe sonicator. Tissue extracts from mouse or colon liver with 500 µl volume were sonicated in two 
bursts of four seconds. Sterile water was sonicated for a few seconds in between each sample to wash 
the probe. Tubes were then spun at 13,000xg and RT for 10 minutes to remove bubbles and pellet 
debris. Supernatants were only transferred to fresh tubes for the tissue extracts, as a pellet did not 
form with cell culture extracts. A 1:5 or 1:10 dilution was made in 1x laemmli sample buffer and 
protein amount of a 1:5 or 1:10 dilution of sample quantitated using the EZQ kit, with a two-fold serial 
dilution of ovalbumin in 1x laemmli sample buffer as the standard. Protein concentration of the 
original sample was then used to prepare 20-30 µl solutions of 1.25 µg/µl in 1x laemmli buffer. This 




2.6.2 SDS-PAGE electrophoresis, dot blot and immunoblotting 
For western blot, 2.5-5 μg of cell or tissue extracts in laemmli buffer containing 2-mercaptoethanol 
were loaded onto pre-cast bis-tris 4-12% gradient gels (Expedeon), according to the EZQ quantitation, 
along with 5 µl pre-stained protein marker. Gels were run at 80-150 V, 250 mA for 1-1.5 hours. After 
rinsing the gel in 1x tris-glycine-SDS (Bio-Rad), the gel was assembled in a semi-dry transfer machine 
with blotting paper and nitrocellulose membrane soaked in transfer buffer (20% methanol, 50 mM 
tris, 40 mM glycine). Protein was transferred to the membrane for 45 minutes at 15 V, 270 mA.  
The dot blot or western blot membrane was rinsed briefly in tris buffered saline (TBS) with tween-20 
(TBS-T, 50 mM tris, 150 mM NaCl and 0.05% tween 20) and blocked with 3% BSA in TBS-T pH 7.5 (TBS-
T BSA) whilst on a rolling platform for 1-2 hours. Incubation with 5 ml of the desired primary antibody 
was overnight in TBS-T BSA followed by washing with TBS-T. After re-blocking with 15 ml TBS-T BSA, 
incubation with 5 ml secondary antibody in TBS-T BSA was for 1 hour followed by washes with TBS-T. 
ECL was added to the membranes, which were sandwiched between transparent acetate sheets and 
sealed with autoclave tape in a cassette. Exposure was conducted in a dark room with x-ray film and 
an automatic developer. The bands from scanned western blot images were quantitated using ImageJ. 
The intensity of the background was subtracted from band intensity. Next, band intensity was 
normalised to the intensity of a reference blot, either anti-H3, anti-H4 or anti-laminB1. Normalised 
band intensity was plotted in GraphPad Prism (version 7 or 8), relative to the control or average of the 
control group. For experiments with multiple replicates per group, t-tests, one-way ANOVA or two-
way ANOVA were performed using the GraphPad Prism statistical analysis functions as appropriate. 
Prior to running the analysis, we checked that the data met the assumptions for parametric tests. 
Interpretation of resulting p-values took into account the variability and distribution of the pool of 
data from which the samples were taken.  
2.7 ChIP-seq and ChIP-quantitative PCR 
2.7.1 Mouse colon chromatin preparation 
Mice for antibiotics treatment experiments were anesthetized in Brazil using isoflurane followed 
by cervical dislocation. Mice used in control only H4K8ac ChIP-seq were sacrificed in the UK by 
exposure to CO2 followed by cervical dislocation. Dissected colons were opened longitudinally and 
washed three times with ice cold HBSS without Ca2+/Mg2+. Colons were cut into 3-5 mm pieces 
and epithelium dissociated by incubating on ice with 30 mM EDTA/HBSS at 60 oscillations per 
minute for 1 h. 50 ml tubes containing tissue pieces were shaken vigorously by hand (2–3 




shaken by hand for 5 min. Solutions were poured through a 70 μM cell strainer to remove mucus 
and sub-mucosa. The extracted cells were pelleted at 480 x g at 4 °C for 10 min, resuspended in 5 
ml ice cold PBS then re-pelleted at 480 x g at 4 °C for 5 min. For the control colon H4K8ac ChIP 
(Figure 5.13) and antibiotics treated colon H4K8ac ChIP (Figure 5.20), three colons were combined 
per replicate. Cells were fixed in 10 ml of PBS with 1% methanol free formaldehyde for 10 min at 
RT with gentle agitation. After quenching with 0.125 M glycine, cells were spun at 480 x g and 4 °C 
for 5 min.  
If sonicated immediately, the cell pellet was resuspended in 5 ml PBS and transferred to a 15 ml 
polystyrene tube before being spun again as before. If it was to be sent from Brazil to the UK, the 
cell pellet was resuspended in 1.2 ml PBS and transferred to a 1.5 ml tube before being spun again 
as before. Then the supernatant was removed and cell pellets flash frozen in l iquid nitrogen. Two 
EDTA free PIC tablets (Sigma, 11836170001) were dissolved in 1 ml water for a 100x solution. 
Frozen pellets or fresh material were resuspended in lysis buffer (50 mM Tris-HCl pH8, 10 mM 
EDTA, 1% SDS) supplemented with protease and HDAC inhibitors (10 mM sodium butyrate, 1 mM 
phenylmethylsulfonyl fluoride (PMSF) and 1x PIC) at a ratio (v/v) of 75-300 µl buffer to 10 µl 
approximate pellet volume. After incubation for 10 min on ice, sonication was performed in a 
water-cooled Biorupter (Diagenode) at high power, 30 sec on and 30 sec off for 12-15 cycles to 
obtain fragment sizes of 200-500 bp. The sonicated material was transferred to a 1.5 ml tube, 
incubated for at least 30 min on ice and then spun at 28,000 x g and 4 °C for 10 min. A 5 µl aliquot 
of the chromatin was digested in elution buffer (0.1 M NaHCO3 and 1% SDS) using 0.25 mg/ml 
proteinase K for 2 h at 65 °C under constant shaking at 300 rpm (Eppendorf ThermoMixer® 
comfort). DNA purification was with the Qiagen PCR purification kit, eluting in 30 µl. 500 ng was 
run on a 1.5% agarose gel at 120V and 250 mA for 40 min to verify fragment size distribution. If the 
chromatin was not sufficiently sonicated, fresh SDS was added and the samples sonicated again 
(up to 40 cycles in total). 
2.7.2 Mouse liver chromatin preparation 
Mice were killed by exposure to CO2 and cervical dislocation. The largest lobe of the liver was 
dissected, chopped into small pieces, placed in a 1.5 ml tube and flash frozen in liquid nitrogen. The 
pieces were ground to a powder using a pestle and mortar on dry ice and transferred to a fresh 15 ml 
polystyrene tube. The powder was resuspended in PBS with 1% methanol free formaldehyde, 
supplemented with protease inhibitors and incubated with gentle agitation for 10 minutes at RT. 
Glycine was added to 0.125 M final concentration and the solution spun at 850xg and 4 °C for 5 




resuspended in 5 ml cell lysis buffer (85 mM KCl, 0.5% IGEPAL (NP40), 5 mM HEPES pH 8.0 and protease 
inhibitors) and incubated on ice for 15 minutes, mixing every few minutes. Material was centrifuged 
at 3000xg for 5 minutes, supernatant removed, 75-100 µl nuclear lysis buffer (10 mM EDTA, 50 mM 
Tris-HCl pH 8.0, 1% SDS and protease inhibitors) added for every 10 µl pellet volume and tubes 
incubated on ice for 10 minutes. Sonication was performed in a water-cooled Biorupter (Diagenode) 
at high power, 30 seconds on, 30 seconds off for 15-20 cycles to obtain fragment sizes of 200-500 bp. 
The sonicated material was transferred to a 1.5 ml tube, incubated for at least 30 minutes on ice and 
then spun at 16,000xg and 4 °C for 10 minutes. After putting the supernatant in a fresh tube, good 
sonication was verified by the same method as for the colon.   
2.7.3 Chromatin immunoprecipitation 
The DNA concentration of the proteinase-K-digested sonication test was measured using the Qubit™ 
dsDNA high sensitivity assay kit (Thermo Fisher Scientific, catalogue number Q32851) and used to 
estimate sonicated chromatin concentration. 100 µg was used for the H4K8cr ChIP, 25 µg for the 
H4K8ac ChIP and 5 µg for the Kcr ChIP.  The chromatin was diluted 5-10 times (v/v) in ChIP dilution 
buffer (1% triton, 1.2 mM EDTA, 16.7 mM Tris-HCl pH 8.0 and 167 mM NaCl) supplemented with 
protease inhibitors. When ChIP reactions were performed on multiple samples, each was made up to 
the same total volume. 2.5 µg of antibody was used for H4K8cr, 1 µg for H4K8ac and 2 µg for Kcr. 
Chromatin and antibody were incubated on a rotating wheel overnight at 4 °C. 5 µl protein A/G 
magnetic beads (Millipore) per 1 µg antibody were washed in 30 volumes of ChIP dilution buffer, in 
respect to the bead volume used. The supernatant was separated on a magnetic rack and removed, 
then the chromatin-antibody mix was used to resuspend the beads. Chromatin-antibody-bead mix 
was incubated for 3 hours on a rotating wheel at 4 °C. Beads were washed once with low salt buffer 
(0.1% SDS, 1% triton, 2 mM EDTA, 20 mM Tris-HCl pH 8.0 and 150 mM NaCl), twice with high salt 
buffer (same as low salt apart from using 500 mM NaCl) and once with TE (1 mM EDTA, 10 mM Tris-
HCl pH 8.0). Kcr ChIPs were washed three times with high salt buffer. Washes were performed by 
spinning briefly at low acceleration, removing the supernatant on a magnetic rack on ice, adding 800 
µl of the required buffer and inverting well to mix before incubating for 5 minutes at 4 °C on a rotating 
wheel. After the last wash, the magnetic beads were resuspended in 200 µl elution buffer and 
incubated in a thermomixer at 65 °C and 1100 rpm for 30 minutes. The supernatant was separated on 
a magnetic rack and transferred to a clean tube. An input was prepared for each biological replicate 
by taking 1% of the volume used for ChIP, and made up to 200 µl in elution buffer. 8 µl of 5 M NaCl 
was added to ChIP and input samples for a final concentration of 190 mM and incubated at 65 °C and 




°C, 300 rpm. DNA purification was performed with the Qiagen PCR purification kit eluting in 40 µl and 
DNA concentration determined using the Qubit high sensitivity DNA assay kit.   
2.7.4 ChIP qPCR and data analysis 
Purified ChIP or input DNA was prepared with nuclease free water and SYBR® green PCR master mix 
(applied biosystems) allowing 0.3 ng per reaction. The master mixes and 300 nM primer were loaded 
on a 384 well plate in triplicate. The run was performed on a BioRad CFX384 quantitative PCR (qPCR) 
system, with 10 minutes initial denaturation at 95 °C, then 45 cycles of 15 seconds at 95 °C and one 
minute at 62 °C, followed by detection and a melt curve. To get ΔCq, triplicates were averaged, outliers 
removed and the Cq values subtracted by the input Cq value minus log(2)100 (adjusting from 1% to 
100%). To get percentage input, 2^-ΔCq value was multiplied by 100 and the resulting value adjusted 
according to the different volumes used in the qPCR master mix. Fold enrichment was determined by 
dividing by at least one negative target and values were plotted in GraphPad Prism version 8. For the 
antibiotics treated qPCR experiments, fold enrichment was calculated by dividing each value by the 
geometric mean of the negative targets (adam23, cys1 and slc4a5). Data were log transformed prior 
to analysis when there was a scale related increase in variability. GraphPad Prism was used to perform 
two-way ANOVA and pairwise comparisons with Holm-Sidak’s correction (to give adjusted p-values 
and generate volcano plots). Fold enrichment for each target was plotted using GraphPad Prism 
version 8. 
2.7.5 ChIP Library preparation 
PEG solutions were prepared with 2.5 M NaCl, 10 mM Tris HCl-pH8, 1 mM EDTA, 0.05 % Tween 20, 
and 15.75%, 22.5% or 27% PEG 8000 and filtered at 20 μM. 40 μl Seramag beads (SpeedBeads, 
carboxylate modified, Sigma Aldrich) were washed twice with 2 ml TE and then mixed well with 2 ml 
of either 15.75%, 22.5% or 27% PEG solution for 7%, 10% or 12% final concentration respectively. For 
each ChIP or input sample, 6 ng of purified DNA was made up to 50 μl with 10 mM Tris-HCl pH8. The 
NEB Ultra II DNA library prep kit (E7645S) was used to perform the end prep and adaptor ligation 
steps. Adaptor was diluted 1:25 in 10 mM Tris-HCl pH8 and 10 mM NaCl. Size selection was performed 
with Seramag beads in 7% PEG to remove large fragments, and then using Seramag beads in 12% PEG 
to remove small fragments. This was done by adding 3.5 μl H2O and 80 μl beads with the 7% PEG 
solution to the 96.5 μl mix with USER enzyme from step 2.6 in the Ultra II manual. After mixing and 
incubating for 10 minutes at RT, the 100 μl supernatant was transferred to fresh tubes with 80 μl 
beads in the 7% PEG solution and 100 μl H2O. After mixing well and incubating for 10 minutes at RT, 




solution. After mixing thoroughly and incubating for 10 minutes at RT, the supernatant was discarded 
and the beads washed twice with 300 μl 80% ethanol. Beads were airdried to remove all ethanol and 
resuspended in 16 μl Tris-HCl pH8. After mixing well and incubating for 5 minutes at RT, the eluate 
was transferred to a fresh tube. PCR ligation was performed according to the Ultra II kit (section 4 in 
the manual) with 8 cycles of denaturation and annealing/extension. Index primers were from NEB set 
1 or 2 (E7335S or E7500S) and chosen according to their barcode differences. After ligation, two clean-
ups of the PCR reaction mix were performed to remove adaptor dimers, using beads with 10% PEG 
solution. 50 μl of ligation mix was made up to 100 μl with H2O and 80 μl beads with 10% PEG added. 
After mixing well and incubating for 10 minutes at RT, the supernatant was discarded and beads 
washed with 200 μl 80% ethanol. After airdrying the beads were resuspended in 102 μl Tris-HCl pH8, 
mixed and incubated for 5 minutes at RT. 100 μl eluate was transferred to a fresh tube with 80 μl 
beads with 10% PEG. The clean-up was repeated, eluting in 15 μl (with 1 μl dead volume).  
To determine library quality and average bp, the prepared libraries were loaded undiluted or at 1:2 
dilution onto a high sensitivity DNA chip along with reagents from the Aligent high sensitvitiy DNA kit 
according to manufacturer’s instructions and analysed with a bioanalyser agilent 2100 system. 
Libraries were quantitated using the NEB library quantitation kit (E7630S) performing 1:10,000 and 
1:100,000 dilutions of the library and using a Biorad CFX96 or CFX384 to perform the run.  
2.7.6 ChIP-Seq and bioinformatic analysis 
H4K8ac HCT116, H4K8ac colon, H4K8ac liver ChIP-Seq libraries were sequenced on a HiSeq2500, 50 
bp Paired End sequencing mode, by the Babraham Sequencing Facility. H4K8ac ABX colon and Kcr ABX 
colon ChIP-seq libraries were sequenced on a BGISeq500 in a 50 bp single end sequencing mode by 
BGI. The H3K18cr colon ChIP-seq data set was previously published (Fellows et al., 2018) and is 
available at GEO under the accession number GSE96035. Downstream processing was performed by 
Babraham Bioinformatics Facility using the clusterflow fastq_bowtie2 pipeline, comprising adapter 
and quality trimming using trim galore v0.6.0 using default paired end parameters followed by 
mapping to the mouse GRCm38 genome assembly using bowtie2 v2.3.2 using options --no-unal --no-
mixed --no-discordant –X 1200. For the paired end H4K8ac and H3K18cr to single end Kcr comparison, 
only the first read of the paired end data was mapped, to avoid mapping biases between single end 
and paired end data. Mapped reads were imported into SEQMONK (version 1.44.0) for data 
exploration and analysis. For single end data, reads were extended by 300 base pairs. 
Probes were generated around TSS +/- 500 bp, were running windows of 500 bp or were generated 




using the feature probe generator selecting MACS peaks generated of each ChIP replicate, normalised 
to the largest data store linear read count quantitated and deduplicated. Enrichment normalisation of 
quantitations were performed on ChIP samples between the 5-20th and 90-98th percentiles, 
depending on the cumulative distribution plot. Regions with high input were excluded. For the 
comparison of H4K8ac ChIP with gene expression levels in Figure 5.12d, annotation tracks of gene 
expression percentile bins from the HCT116 RNA-seq (described below) were used to generate probe 
lists of the H4K8ac ChIP-seq data set with probes generated over TSS (+/- 500 bp) for either the input 
or the combined replicates of the ChIP samples. Gene ontology analysis was performed using the 
Panther statistical overrepresentation test and Panther GO-slim biological process (Mi et al., 2019). 
Terms containing more than 1000 genes in the reference list or depleted terms relative to the 
reference list were removed. For comparison of H4K8ac in liver and colon in Figure 5.13, only the 25-
30 terms with the highest enrichment were used to simplify the plot. Fold enrichment against negative 
log10 of the adjusted failure discovery rate (FDR) was plotted in R using the ggplot2 package. Venn 
diagrams were generated in R using the venneuler package or with meta-chart.com, counting each 
gene or promoter that contained a MACS peak once. For Figure 5.15b, each MACS peak was counted 
separately. Pie charts were generated in Excel, counting each gene, promoter or regulatory element 
that contained a MACS peak once. For Figure 5.13e, each MACS peak was counted separately. The 
mouse candidate cis regulatory element track was generated by the Zhiping Weng laboratory of 8-
week adult male CB57BL/6 mouse colon (accession number was ENCFF387SAQ) from ENCODE (Davies 
et al., 2011; Dunham et al., 2012). The ChIP-seq data were compared to the colon regulatory element 
track as the equivalent liver regulatory element track had the same number of elements and 
boundaries, although the classification of elements does differ (the Zhiping Weng laboratory, 8-week 
adult male CB57BL/6 mouse liver, accession number ENCFF290EVU).  
For the comparison of H4K8ac, H3K18cr or Kcr with gene expression levels in Figure 5.15e, annotation 
tracks of gene expression percentile bins were generated using control samples from the colon ABX 
RNA-seq data set (described below) and used to create probe lists of the ChIP-seq data sets with 
probes generated over TSS (+/- 500 bp). The Limma statistical test (Smyth, 2004) was performed on 
H4K8ac and Kcr ABX ChIP-seq data and used to generate the differentially crotonylated probe list. Only 
probes overlapping genes were exported. In excel, the probe list was deduplicated keeping only one 
MACS peak per gene. The MACS peak with the highest absolute fold change was kept. For Rara and 
Fgfr2, which had MACS peaks in both up and down lists, both MACS peaks per gene were kept. Volcano 
plots were generated on averaged and log transformed data. For the XY plots in Figure 5.18c and 
Figure 5.19, lists of Kcr MACS peaks (deduplicated to keep the most changing peak for each gene) were 




MACS peaks against differentially expressed genes. Figure 5.19 was Kcr MACS peaks (one per gene) 
against all expressed genes (excluding unobserved values). Two-tailed Chi-squared tests with Yate’s 
correction were performed using GraphPad QuickCalcs 2x2 contingency table and the total number of 
expressed genes of 13607 (determined from the RNA-seq data set excluding unobserved probes). For 
Figure 5.20e and f, probes were generated +/- 500 bp of TSS and log2 transformed. Scatter plots are 
of the ChIP replicate set against combined H4K8ac and Kcr inputs. For Figure 5.21, H4K8ac or Kcr data 
was linearly quantitated over MACS peaks that changed significantly in Kcr between treatments and 
enrichment normalised. Values less than 1 (due to the normalisation) were set to 1 and log2 fold 
change between the average of antibiotics and control groups calculated. The graph was plotted in R, 
with points coloured by the group in either data set that contained the most reads. 
2.7.7 Chromatin state analysis 
ChIP-seq data from 8-week old adult mouse liver (C57BL/6), generated by Bing Ren, was downloaded 
from ENCODE. The accession numbers of the aligned BAM files were ENCFF380FAM (H3K4me1 
replicate 1), ENCFF087XCZ (H3K4me1_2), ENCFF538SCQ (H3K4me3_1), ENCFF262ALD (H3K4me3_2), 
ENCFF734PDO (H3K27ac_1), ENCFF726OSP (H3K27ac_2), ENCFF803QFK (H3K27me3_1), 
ENCFF254XUS (H3K27me3_2), ENCFF591CDW (H3K36me3_1), ENCFF730GII (H3K36me3_2), 
ENCFF515GCB (input_1) and ENCFF465JMB (input_2). H3K27me3 ChIP-seq data from 10 to 12-week 
old adult mouse colon was generated by Lo et al. (2017) and is available at GEO under the accession 
GSE82181 (Lo et al., 2017). H3K27ac and H3K4me1 ChIP-seq data from 5-week old adult mouse colon 
was generated by Qin et al. (2018) and is available at GEO under the accession GSE99670 (Qin et al., 
2018). No publically available H3K36me3 data for adult mouse colon could be found. Due to 
incompatibility issues between the mm10 aligned ENCODE ChIP-seq files and the GRCm38 H4K8ac 
ChIP-seq files, Simon Andrews ran a script to remove the ‘chr’ labels from the mm10 ENCODE bam 
files. ChIP-seq BAM files were filtered to a minimum mapping score of 20 and ChIP replicates were 
merged using SAM tools. Merged BAM files were converted to genome-wide binary enrichments at 
200 bp intervals using the ‘BinarizeBed’ ChromHMM function (version 1.12) (Ernst and Kellis, 2012). A 
few different models for a range of overall ChromHMM states were derived using the ‘LearnModel’ 
function (version 1.12), before a 6-state model was deemed optimal for both colon and liver data sets. 
Fold enrichments across all 6 states of the ChromHMM model for a number of genomic features were 
calculated and plotted using the ‘OverlapEnrichment’ ChromHMM function (version 1.12) (Ernst and 






2.8.1 Preparation of RNA lysates from mouse colon 
Dissected colons were flushed gently three times with PBS, cut longitudinally and then cut into 0.5 cm 
pieces. The pieces were washed three times in a falcon tube by adding 10 ml 1x HBSS with 5% FBS 
(HBSS-FBS). 30 ml HBSS-FBS was added and tubes incubated at 37 °C for 1 hour with inverting and 
vortexing every 10 minutes for a few seconds. The solution was passed through a 70 µM cell strainer 
and spun at 840xg, 4 °C for 10 minutes. Cell pellets were resuspended in HBSS-FBS and a 1:20 dilution 
counted. 2 million cells were transferred to a fresh tube and spun at 840xg, 4 °C for 10 minutes. To 
prepare the lysis buffer, 19.8 ml of lysis buffer from PureLink RNAna mini kit (Ambion-Life 
technologies) was mixed with 200 µl β-mercaptoethanol. After a wash with cold PBS, the cell pellet 
was resuspended in 600 µl lysis buffer, vortexed for a few seconds and frozen at -80 °C.  
2.8.2 RNA isolation 
RNA was isolated from mouse colon epithelium at RT using the Qiagen RNeasy micro kit as described 
here. All steps were carried out with low bind tubes and pipette tips at RT. 200 µl of RNA lysate was 
mixed with 333 µl RNAse free water, 1667 µl RLT buffer and 1500 µl of 70% ethanol. After mixing, 750 
µl of solution was added to a RNeasy MinElute column, spun at 8000xg for 15 seconds and flow 
through discarded. This was repeated three times until all solution had been passed through. After 
each spin, flow through was discarded. 350 µl RW1 buffer was added, centrifuged as before and flow 
through discarded. 10 µl of 1x DNase I was cautiously mixed with 70 µl of RDD buffer and added to 
the column for a 15 second spin. The step with RW1 was repeated and another 80 µl of DNase/RDD 
mix was added to the centre of the column and spun followed by another spin with 350 µl RW1. 500 
µl of RPE was added and centrifuged at RT, 8000xg for 15 seconds and then 500 µl of 80% ethanol was 
added and spun at RT, 8000xg for 2 minutes. The collection tube was changed and tubes centrifuged 
for a further 5 minutes with the lid left open. The collection tube was changed again to a 1.5 ml tube, 
53 µl (3 µl lost on column) of 45 °C water was added and the tube centrifuged for 1 minute at 13,000xg. 
The quality of the RNA was assessed by loading 1 µl onto an RNA chip along with reagents from the 
Agilent RNA 6000 Pico kit according to manufacturer’s instructions and analysed with a bioanalyser 
Agilent 2100 system. 
2.8.3 RNA library preparation 
RNA library preparation was prepared using the NEBNext Ultra RNA library prep kit for Illumina 




module with a few modifications. Sections from the manual are referenced with the ‘m’ prefix to 
distinguish from sections in this document. The first strand reaction buffer and random primer mix 
were prepared as described in section m1.1. To perform the isolation, fragmentation and priming, 100 
ng of RNA from each isolated RNA sample was made up to 50 µl with RNAse free water and put on 
ice. Section m1.2 was followed exactly as described in the manual without performing any adjustment 
for insert sizes larger than 200 nt. Care was taken to mix each sample the same number of times. 
Actinomycin D stock solution was prepared in nuclease free water at 5 µg/µl concentration, unused 
aliquots were frozen at -20 °C (stable for one month, protected from light). This stock solution was 
diluted 1:50 in nuclease free water and used immediately. Directional first strand cDNA synthesis was 
performed by adding murine RNase inhibitor, ProtoScript II reverse transcriptase and 5 µl of 0.1 µg/µl 
actinomycin D to the fragmented and primed mRNA (section m1.3). Second strand synthesis was 
performed as described in section m1.4 but the water volume was reduced as the samples had a 
volume of 21.5 µl rather than 20 µl.  
Size selection was performed using Seramag beads as follows. Seramag bead solutions of 10% and 
12% PEG were prepared by combining 2.5 M NaCl, 10 mM Tris HCl pH 8.0, 1 mM EDTA, 0.05% Tween 
20 with 22.5% or 27% of PEG 8000 respectively and filtered at 20 µM. Then, 40 µl of Seramag beads 
(Sigma Aldrich) were washed twice in 1x TE and resuspended in 2 ml of either 22.5% or 27% PEG 
solution to give final PEG concentrations of 10% and 12% respectively. RT beads were vortexed and 
80 µl of the 12% solution added to 80 µl of second strand cDNA synthesis reaction mix (section m1.4) 
along with 20 µl water. After pipetting ten times to mix and incubating for 10 minutes at RT, tubes 
were spun briefly and put on a magnetic rack for 5 minutes. The supernatant was discarded and beads 
washed twice with 200 µl 80% ethanol (prepared fresh). Ethanol was removed and the remainder air-
dried taking care not to over-dry (when the beads crack). The bead pellet was resuspended in 60 µl 
0.1x TE, mixed well, incubated for 5 minutes at RT, spun briefly and put on a magnetic rack for 5 
minutes. 56 µl of eluate was transferred to a fresh 0.2 ml tube.  
The end prep of the cDNA library (section m1.6) and adaptor ligation (section m1.7) were prepared 
according to the NEBNext manual. The seramag protocol was performed a second and third time by 
adding 80 µl 10% PEG and 13.5 µl (second) or 0 µl (third) water to the solution from the previous step. 
Beads were eluted in 103 µl (second) or 23 µl (third) of Tris-HCl pH8 and 100 µl or 20 µl respectively 
taken for the following step. After the third seramag bead purification, PCR library enrichment was 
performed (section m1.9A) with 15 cycles of annealing/extension and NEBNext oligos for Illumina 
from NEB set 1 or 2 (E7335S or E7500S). The seramag bead purification was performed a fourth time 




in 24 µl of Tris-HCl pH8, taking 1 µl for bioanalyser with the Agilent DNA high sensitivity kit and 20 µl 
for sequencing. 
2.8.4 RNA sequencing and data analysis 
RNA-Seq libraries were sequenced on a HiSeq2500 in a 50 bp Single End sequencing run, by the 
Babraham Sequencing Facility. Downstream processing by the Babraham Bioinformatics Facility used 
the clusterflow fastq_hisat2 pipeline, comprising adapter and quality trimming using trim galore v0.6.0 
using default single end parameters followed by mapping to the mouse GRCm38 genome guided by 
gene models from Ensembl release 70 using hisat2 v2.1.0.  Hisat2 mapping parameters were --dta --
sp 1000, 1000. Exploration and analysis of RNA-seq data was performed with SEQMONK (version 
1.44.0). Data was imported as RNA-seq data with a minimum mapping quality of 20. Read counts were 
quantified at the gene level with the seqmonk RNA-seq quantitation pipeline. Differential expression 
analysis was performed using the DESeq2 count-based method (Love et al., 2014). Hierarchical 
clustering was performed on DESeq2 hits. The DESeq2 hit list was exported from SEQMONK, 
annotating with exactly matching genes, and volcano plots made in Excel using log transformed, 
averaged data. Gene ontology analysis was performed using the Panther statistical 
overrepresentation test and Panther GO-slim biological process (Mi et al., 2019). The background list 
was generated from the same data set, excluding the unobserved values, to give 13607 genes. 
Depleted terms relative to the background list and those containing more than 1000 genes in the 
background list were removed. Gene ontology plots were generated in R using the ggplot2 package. 
HCT116 RNA sequencing and analysis 
For the comparison to HCT116 cell H4K8ac ChIP-seq, the DMSO controls of an RNA-seq data set on 
HCT116 cells, previously generated by Claudia Stellato, were used. RNA was isolated from HCT116 
cells (four biological replicates) as described in section 2.8.2. Library preparation was performed from 
500 ng of RNA as described in section 2.8.3. Illumina Tru-Seq adaptors were used and library 
amplification was performed with the KAPA PCR Amplification kit (KAPA, Cat. KK2501) using 14 cycles. 
Libraries were sequenced on a HiSeq2500 sequencer (Illumina) according to the manufacturer’s 
instructions. Sequencing reads were adaptor trimmed using Tim Galore! (version 0.4.2) and mapped 
to the human (GRCh38) reference genome with HiSAT2 (version 2.0.5). Analysis of RNA-seq was 
performed with SEQMONK version 1.44.0 on filtered reads with a MAPQ score of >60 for uniquely 
mapped reads. Read counts were quantified by the SEQMONK RNA-seq pipeline, quantifying only 
probes with at least one read. Probe values were corrected for transcript length and were divided into 




3 Short chain fatty acids influence the abundance of histone 
acylations in cell culture and are regulated by class I histone 
deacetylases 
3.1 Introduction 
Histone acylations are a rapidly growing family of modifications which includes the extensively studied 
acetylation and newly identified modifications crotonylation and butyrylation (Tan et al., 2011). 
Histone acylations are thought to promote gene expression and are found at many of the same 
positions on the histone (Tan et al., 2011; Sabari et al., 2015). These histone modifications are of 
particular interest as their precursors are important metabolic intermediates, creating a mechanism 
for changes to metabolism to influence gene expression. Acetyl-CoA is at the centre of multiple 
metabolic pathways including glycolysis, beta-oxidation, tricarboxylic acid cycle, ketone body 
metabolism and amino acid metabolism; whilst crotonyl-CoA and butyryl-CoA are produced during 
beta-oxidation. In addition, ACSS2 can convert SCFAs such as acetate, butyrate and crotonate into 
their respective acyl-CoAs in the cytoplasm or nucleus (Frenkel and Kitchens, 1977; Wellen et al., 
2009). In the intestine, SCFAs are a major energy source for IECs and are provided in abundance by 
the intestinal microbiota. The acyltransferase p300/CBP can add acetyl-, butyryl- and crotonyl-groups 
to protein lysines including those on histones. This histone acyl-transfer is responsive to the relative 
abundance of acetyl-CoA and crotonyl-CoA, as reducing acetyl-CoA concentrations by ACLY or PDHE1α 
knockdown can promote histone crotonylation and reduce acetylation (Sabari et al., 2015). In 
addition, Sabari et al. (2015) demonstrated that crotonate could increase intracellular crotonyl-CoA 
concentration resulting in upregulation of histone crotonylation but not acetylation in a 
uterine/cervical tumour cell line (HeLa S3). Histone crotonylation has been shown to activate gene 
expression to a greater extent than histone acetylation and it is recognised by the YEATS domain, a 
structurally distinct domain from the acetyllysine reading bromodomain (Zhao et al., 2017). The NAD+ 
deacetylases SIRT1-3 and the Zn2+ dependent HDAC3/NCoR1 have been shown to have decrotonylase 
activity (Madsen and Olsen, 2012; Bao et al., 2014). But other HDAC enzymes including HDAC1 and 





transfer and removal enzymes provides the potential for rapid changes to metabolism to influence 
histone acylations and the use of different specific binding proteins would enable coupling to acylation 
type-specific gene expression programs. In this chapter, we investigate how SCFAs influence histone 
crotonylation and acetylation and identify that these modifications are regulated, at least in part, by 
class I HDACs.  
3.2 Results 
3.2.1 Antibody specificity tests 
Western blot analysis of acylated recombinant histones revealed that anti-Kcr recognised 
crotonylated-H3 but not acetylated-H3, whilst anti-H3K18ac recognised acetylated-H3 but not 
crotonylated-H3 (Figure 3.1a). Analysing tissue extracts by western blot showed that anti-H3K18cr and 
anti-H3K18ac recognised only a single band (Figure 3.1b). In western blot, histone H3 tends to run at 
a higher molecular weight. For example, anti-H3 (ab24834) recognises a band at around 18 kDa when 
H3 has a predicted molecular weight of 15 kDa. Anti-Kcr is specific to protein lysine crotonylation 
rather than only histone crotonylation, but the strongest bands ran at a speed consistent with them 
being histone H3 and H4. Anti-Kcr was also previously validated by other groups studying histone 
crotonylation (Tan et al., 2011; Bao et al., 2014; Sabari et al., 2015). 
 




(a) Recombinant histone H3 was either acetylated or crotonylated with acetyl-CoA or crotonyl-CoA at a 
concentration of 100 µM, 50 µM, 25 µM, 12.5 µM, 6.25 µM or 3.13 µM (lanes 3-8 and 11-16). 100 µM was used 
for reactions 2 and 10. Reactions were incubated with the recombinant catalytic domain of p300 and analysed 
by western blot using the specified antibodies. (b) The anti-H3K18cr, anti-H3K18ac and anti-Kcr antibodies 
detect primarily histone modifications in colon extracts as tested by western blot. Migration positions of 
molecular weight markers are on the left in kDa.  
3.2.2 The effect of SCFAs on histone crotonylation in cell culture 
To investigate how different nutrients influence histone acylation in intestinal cells, we used a colon 
carcinoma cell line (HCT116) as many conditions could be tested with ease. SCFAs can be converted 
into their CoA activated form by ACSS2 and these acylated-CoAs are substrates for histone modifying 
enzymes. As crotonate treatment of HeLa S3 cells was previously shown to promote histone 
crotonylation (Sabari et al., 2015), we added it to the media of HCT116 cells and tested how 
crotonylation changed (Figure 3.2a). The western blots are shown in Figure 3.2a and the combined 
quantitations are shown in Figure 3.2b-c. Experiments 1a and 1b are technical repeats of western 
blotting on the same cell extracts (Figure 3.2b). Experiments 1, 2, 3 and 4 are biological repeats on 
independently cultured cells, with the quantifications for experiment 1 being the average of the 
technical repeats (Figure 3.2c). H3K18cr increased above 20 mM in experiment 1 and at 10 mM in 
experiment 2 (Figure 3.2b and c). No changes were seen in experiments 3 and 4, but these only tested 
concentrations up to 5 mM. From these experiments, it appears that crotonate does not affect histone 
crotonylation at concentrations of 5 mM and below. Crotonate may promote histone crotonylation 
above 10 mM, but further experiments with more biological replicate conditions are required to test 
this. We also tested the effects of β-HBu treatment of HCT116 cells by western blotting (Figure 3.3a). 
The combined quantitations of two biological repeat experiments showed only very small changes in 
H3K18cr, suggesting that β-HBu does not influence histone crotonylation even at 20 mM (Figure 3.3b).  
Acetate, propionate and butyrate exist in high concentrations in the colon lumen, reaching 
concentrations of as much as 70 mM on certain diets (Topping and Clifton, 2001). As they are 
physiologically important, we tested the effect of these SCFAs on histone crotonylation. When acetate 
was added to colon carcinoma cells, H3K18cr, Kcr H3 and Kcr H4 were reduced to different extents 
(Figure 3.4). H3K18cr showed the biggest decrease whilst Kcr H3 decreased only slightly. It is clear 
from these experiments that acetate does not increase histone crotonylation. A third repeat 
experiment would enable statistical testing to determine if these reductions are significant. Future 
experiments should run repeat conditions on the same blot. This would allow treatment conditions to 




for variability. Propionate treatment of colon carcinoma cells did not change H3K18cr at 
concentrations up to 1 mM but promoted a striking increase in H3K18cr above 5 mM in two biological 
repeat experiments (Figure 3.5a and b). When butyrate was added to the media of colon carcinoma 
cells, it promoted H3K18cr at 0.5 and 1 mM in four biological repeat experiments and to a greater 
extent at 5 mM in two of those experiments (Figure 3.6a and b).  
To see if the effects of crotonate and butyrate on crotonylation were additive, butyrate and crotonate 
were added in combination at different concentrations (Figure 3.7a and b). With a constant 
concentration of 1 mM crotonate, an increase was seen in H3K18cr from 0.5 to 5 mM butyrate in two 
biological repeat experiments. The 5-fold increase in H3K18cr at 5 mM butyrate and 1 mM crotonate 
was similar to the 5.6-fold increase seen in H3K18cr with 5 mM butyrate alone (Figure 3.7 and Figure 
3.6). The reverse, of 5 mM crotonate and 1 mM butyrate, produced only a 3.8-fold increase in 
H3K18cr. Whilst crotonate alone only promoted H3K18cr at concentrations above 10 or even 20 mM 
(Figure 3.2), when combined with 1 mM butyrate, an increase could be seen at concentrations as low 
as 0.5 mM crotonate. This suggests that crotonate and butyrate together have an additive effect on 
H3K18cr, but also that butyrate is a more effective promoter of crotonylation than crotonate in colon 





Figure 3.2. The effect of crotonate on histone crotonylation in colon carcinoma cells 
Crotonate was added to the medium of colon carcinoma cells for 24 hours and whole cell extracts were analysed 
by western blotting using anti-H3K18cr. (a) Western blot images from two technical repeats of experiment 1 and 
the biological repeats of experiments 2-4. (b-c) Band quantifications of biological repeat experiments relative to 
the H3 or H4 blot and the untreated group. Where there are at least two repeats for a condition in the western 
blots, the average of band quantifications is shown with error bars as standard deviation. All concentrations are 





Figure 3.3. β-HBu does not promote crotonylation in colon carcinoma cells 
β-HBu was added to the medium of colon carcinoma cells for 24 hours and whole cell extracts were analysed by 
western blotting using the anti-H3K18cr antibody. (a) Western blot images from two biological repeat 
experiments. (b) Band quantification is shown relative to the H4 blot and the untreated group. The average of 
band quantifications from the two experiments is shown with error bars as standard deviation. All 






Figure 3.4. Acetate does not promote histone crotonylation in colon carcinoma cells 
Acetate was added to the medium of colon carcinoma cells for 24 hours and whole cell extracts were analysed 
by western blotting using the specified antibodies. (a) Western blot images from three biological repeat 
experiments. (b-d) Band quantification was relative to the H3 or H4 blot and the untreated group. The H3 and 
H4 bands of the anti-Kcr blot were quantified separately and are shown on different graphs. Where there are at 
least two repeats for a condition in the western blots, the average of band quantifications is shown with error 





Figure 3.5. Propionate promotes crotonylation in colon carcinoma cells 
Propionate was added to the medium of colon carcinoma cells for 24 hours and whole cell extracts were 
analysed by western blotting using the specified antibodies. (a) Western blot images from two biological repeat 
experiments. (b) Band quantifications are relative to the H3 or H4 blot and normalised to the untreated group. 
The average of band quantifications from two biological repeats is shown with error bars as standard deviation. 






Figure 3.6. Butyrate promotes histone crotonylation in colon carcinoma cells 
Butyrate was added to the medium of colon carcinoma cells for 24 hours and whole cell extracts were analysed 
by western blotting using the specified antibodies. (a) Western blot images from four biological repeat 
experiments. (b) Band quantifications are relative to the H3 or H4 blot and normalised to the untreated group. 
Where there are at least two repeats for a condition in the western blots, the average of band quantifications is 






Figure 3.7. The combined effects of crotonate and butyrate on crotonylation in colon carcinoma cells 
Butyrate and crotonate were added in combination to the medium of colon carcinoma cells for 24 hours and 
whole cell extracts were analysed by western blotting using the specified antibodies. (a) Western blot images 
from three biological repeat experiments. (b) Band quantifications are relative to the H3 or H4 blot and 
normalised to the untreated group. Where there are at least two repeats for a condition, the average of band 
quantifications is shown with error bars as standard deviation. All concentrations are in millimolar.  
3.2.3 The dynamics of histone crotonylation response to crotonate and butyrate treatment in cell 
culture 
For chromatin state changes to reflect changes in nutrient availability, histone crotonylation would 
need to change rapidly so that the cell could respond quickly to changing conditions. We therefore 
tested the timescale over which crotonylation of histones occurs when crotonate or butyrate is added 
to the medium of colon carcinoma cells. When crotonate was added, H3K18cr showed a time-
dependent increase over 8 hours that was consistent between two technical repeat experiments 
(Figure 3.8a). 20 mM crotonate was used because an initial test with 10 mM showed no change, 
although 10 mM treatments were not tested any further. A time-dependent increase in H3K18cr was 
also seen when butyrate was added to the cell culture medium, and was around 2-fold higher after 1 
hour in three technical repeat experiments (Figure 3.8c). The increase was not significant when tested 
by repeated measures one-way ANOVA with pairwise comparisons. The lack of significance may be 




can be easily influenced by small changes in the control. However, an increase of 2-fold or greater was 
reached in all three repeats suggesting that crotonylation is promoted by butyrate over a timescale of 
0.25 to 8 hours. In an initial test of removing crotonate to decrease crotonylation, HCT116 cells were 
cultured with 10 mM crotonate for 24 hours followed by washing out the SCFA and harvesting the 
cells at regular intervals. A rapid decrease was seen when crotonate was removed from the cell culture 
media, although further experiments are required to verify this (Figure 3.8b). These results suggest 
that histone crotonylation is a dynamic modification, but biological repeat experiments rather than 
technical repeats would make this conclusion more robust.  
 
Figure 3.8. Histone crotonylation changes dynamically in response to crotonate and butyrate 
SCFAs were added to the medium of colon carcinoma cells for the specified time and whole cell extracts were 
analysed by western blotting using the specified antibodies. Band quantification was normalised to the H4 band 
intensity and to the untreated group. Where technical repeats were performed, the average band intensity is 
shown with error bars as standard deviation. (a) 20 mM crotonate was added to the medium of HCT116 cells for 




to the medium of HCT116 cells for 24 hours and then washed out at specified time points up to 8 hours. (c) 1 
mM butyrate was added to the medium of HCT116 cells for up to 24 hours.  
3.2.4 The effects of SCFAs on histone acetylation in colon carcinoma cell culture  
Adding acetate to ACLY knock-down cells was found to promote histone acetylation (Wellen et al., 
2009), therefore we added acetate to HCT116 cell culture media and tested changes to histone 
acetylation by western blot. There was no change in H3K18ac or H4K8ac in two biological repeat 
experiments (Figure 3.9). As butyrate and propionate promoted histone crotonylation in colon 
carcinoma cells, we hypothesised that they might promote histone acetylation, as metabolism of 
these SCFAs can generate acetyl-CoA. Butyrate treatment increased H3K18ac at 0.5 and 1 mM in two 
biological repeat experiments but did not consistently change H4K8ac (Figure 3.9). Butyrate treatment 
did not produce a clear increase in H4K8ac; perhaps this modification is regulated in a different 
manner to H3K18ac. Crotonate did not change either H4K8ac or H3K18ac. It is interesting that acetate, 
which is closest in chemical structure to acetylation, did not upregulate H3K18ac but butyrate did. In 
cell culture, acetyl-CoA levels are high and the metabolism of SCFAs may not produce a large fold 
increase in acetyl-CoA above steady-state levels that result in changes to histone acetylation. Donohoe 
et al. (2012) demonstrated that carcinoma cells grown in plenty of glucose do not metabolise butyrate 
to any great extent as glycolysis is the predominant pathway, thus allowing butyrate to accumulate in 
the cell. Butyrate, but not acetate, can act as a HDAC inhibitor (Cousens et al., 1979), which could 





Figure 3.9. The effect of acetate, butyrate and crotonate on histone acetylation in colon carcinoma cells 
SCFAs were added to the medium of colon carcinoma cells for 24 hours and whole cell extracts were analysed 
by western blotting using anti-H4K8ac and anti-H3K18ac. (a) Western blot images from four independent 
experiments. The black lines on the blots in experiment 1 indicate where some n=1 conditions have been spliced 
out. (b-c) Band intensity relative to the quantified bands of the H3 or H4 blot and normalised to the untreated 
group. Where there are at least two repeats for a condition in the western blots, the average band intensity is 
shown with error bars as standard deviation. 
 
3.2.5 The effects of SCFAs on histone crotonylation in intestinal organoid culture 
Carcinoma cells by their nature are prone to mutations and are grown in conditions that select for 
highly proliferative cells. Additionally, malignant cells frequently have altered metabolism. Therefore, 
we chose to test the effect of SCFAs on gut organoid cultures which are a more representative system. 
Mouse small intestinal or colon stem cells are collected and grown with the required growth factors 
in a 3D gel where they organise into ‘mini-guts’ that mimic the gut structure, consisting of a lumen, 
buds reflecting the crypt zone and differentiated cell types. As these are derived from healthy adult 
mice, the cells contain a genome with few mutations. We added crotonate or butyrate to the medium 




crotonate treatment produced a 2.8-fold average increase in H3K18cr. The fold change between 
experiments was quite variable with the standard deviation from 1.8- to 3.5-fold for H3K18cr. This 
variability in fold change in H3K18cr was also seen when HCT116 cells were given 10 mM crotonate 
(Figure 3.2), with standard deviation from 1- to 5-fold. This could be due to differences in the intensity 
of the control or small variations in the H3 or H4 normalisation blot. 1 mM butyrate increased H3K18cr 
but β-HBu did not change H3K18cr in two biological repeat experiments, which reproduces what was 
seen in colon carcinoma cells. To determine if these fold-changes are significant, and to account for 
small variations in the control group, four repeats of each condition should be compared in the same 
western blot. 
The colon contains a larger and richer microbiota, resulting in the generation of more SCFAs than the 
small intestine. We therefore wanted to confirm if SCFAs promoted histone crotonylation in colon 
organoids, particularly as the growth conditions are not the same as for small intestinal organoids. 
When crotonate was added to the media of colon organoids, it produced a dose-dependent increase 
Kcr H3 and H3K18ac in two biological repeat experiments (Figure 3.11a and b). Although the 0.5 and 
1 mM conditions were similar to the untreated group, 5 mM crotonate clearly increased Kcr H4 in two 
experiments. Butyrate increased Kcr H4 and possibly also Kcr H3. 5 mM butyrate increased H3K18ac 
but this was not repeated and 1 mM either did not change or slightly decreased H3K18ac. These 
experiments suggest that crotonate and butyrate can promote histone crotonylation in colon and 
small intestinal organoids, in agreement with the results seen in colon carcinoma cells. However, 
further experiments are required to make sure that these conclusions are robust and to determine at 
what concentration a significant increase is seen.  
 
Figure 3.10. The effects of crotonate, butyrate and β-HBu on crotonylation in small intestinal organoids 
SCFAs were added to the growth medium of small intestinal organoids for 48 hours. Whole cell extracts were 




three biological repeat experiments. (b) Band quantification relative to the H3 or H4 band intensity and 
normalised to the untreated group. Propionate (Pr), crotonate (Cr), butyrate (Bu) and β-HBu. Average band 
intensity is shown with error bars as standard deviation when there are at least two repeats for a condition. 
 
 
Figure 3.11. Crotonate and butyrate promote histone crotonylation in colon organoids 
SCFAs were added to the medium of colon organoids for 48 hours and whole cell extracts were analysed by 
western blotting using the specified antibodies. (a) Western blot images from two biological repeat experiments. 
(b) Band quantification is relative to the anti-H3 band intensity and the untreated group. Average band 
intensities are shown with error bars as standard deviation where there are at least two repeats for a condition. 
 
3.2.6 Non-butyrate HDAC inhibitors promote histone acetylation and crotonylation 
It is difficult to elucidate the mechanism of the effect of butyrate on histone acylations as it can act on 
the cell through multiple pathways. However, other HDAC inhibitors exist which have a distinct 
structure and are not precursors to metabolic intermediates. To compare the effect of HDAC inhibition 
on histone crotonylation and acetylation, we added TSA, SAHA or butyrate to the media of colon 
carcinoma cells and analysed whole cell extracts using specific crotonyl and acetyl antibodies. As 
shown in Figure 3.12, all of these HDAC inhibitors promoted both acetylation and crotonylation in 
three biological repeat experiments. For butyrate, this is in agreement with the experiments in Figure 
3.6 and Figure 3.9 which also saw that butyrate could promote Kcr and H3K18ac. As seen from the 
quantifications of band intensity, this occurred in a dose-dependent manner with the highest 
concentrations of TSA, SAHA and butyrate producing a significant increase in Kcr H4 relative to the 
untreated group (Figure 3.12). There was also a significant increase compared to the control in Kcr H3 




western blots show a clear dose-dependent increase in H3K18ac in each experiment with all inhibitors 
tested. So the lack of significance may be because experiment 1 shows different fold changes to 
experiments 2 and 3 resulting in variability in the band quantifications. The clearest example of this is 
for 0.2 μM TSA which produces low acetylation and crotonylation for experiment 1 but is increased 
relative to control in experiments 2 and 3. These experiments suggest that non-butyrate HDAC 
inhibitors can promote histone crotonylation and the striking consistency between experiments 2 and 
3 suggests that these effects are biologically relevant.  
 
Figure 3.12. HDAC inhibitors promote histone acetylation and crotonylation in HCT116 cells 
HCT116 cells were treated with the indicated amounts of TSA, SAHA or butyrate for 24 hours. Three biological 
repeat experiments are shown. The first control group is untreated, the second control group was treated with 
0.5% DMSO which was also in all of the treatment conditions. Western blot was performed with anti-H3K18 
acetyl, anti-Kcr and anti-H4 or anti-H3. Quantified bands are shown below the blot relative to H4 band intensity 




bars as standard deviation. One-way ANOVA was performed with pairwise comparisons and the p values of 
significant pairwise comparisons are shown on the graph. 
3.2.7 HDAC1 can remove crotonyl-groups from H3 histones but not H3 peptides. 
As we have shown, inhibition of HDACs in cell culture promoted crotonylation as well as acetylation 
but it was not known if HDACs could act directly by decrotonylating the histone or if these changes 
occurred through an indirect method where increased histone acetylation promoted histone 
crotonylation. Prior to our study, some evidence did exist to suggest that HDACs could use larger acyl 
chains. One study using a fluorogenic crotonylated H4 peptide found measureable activity with 
HDAC3/NCoR1 but no other HDAC enzymes (Madsen and Olsen, 2012). We incubated different 
amounts of biotinylated acetyl or crotonyl H3K18 peptides with or without HDAC1 for 2 hours at 30 
°C. HDAC1 reaction mixes were spotted in quadruplicate onto nitrocellulose membranes and western 
blot with anti-H3K18cr or anti-H3K18ac performed. The dot blot shows that there was no difference 
between the reactions with HDAC1 or without HDAC1 for either substrate (Figure 3.13a). To further 
test the ability of HDAC1 to remove acetyl- or crotonyl-groups from H3 peptides, we tested different 
amounts of HDAC1 and different durations of the reaction with an intermediate concentration of 
acylated peptide (4 μM). No changes in spot intensity could be seen, although high background in 
some places of the blot did make this more difficult to interpret (Figure 3.13b). Quantifications of the 
60 and 100 nM HDAC1 timecourses, which had low background, were compared to zero time (the 0 
nM HDAC1 and 60-minute conditions without high background). There was a slight reduction in acetyl-
peptide from 1 to 60 minutes, but the zero time was the lowest. The crotonyl-peptide reactions 
revealed an equally inconclusive picture.  
HDAC1 may be able to remove acetyl- and crotonyl-groups from these H3 peptides with other reaction 
conditions, but we saw no convincing evidence of removal in our initial tests. Therefore, we performed 
a preliminary test with acylated recombinant histone H3. The recombinant catalytic domain of the 
acyltransferase p300 and acetyl-CoA, butyryl-CoA or crotonyl-CoA were used to acylate recombinant 
histone H3.1 in vitro. The resulting acylated histone was then tested against HDAC1, HDAC2 or HDAC3-
NCoR1. The NCor1 protein is required for the full HDAC3 activity (You et al., 2013). The reaction mixes 
were analysed by western blot with specific antibodies. The acyltransferase reaction by p300 was 
successful as there is a strong H3K18ac, H3K18bu or H3K18cr band without any HDAC (Figure 3.14). 
The highest concentration of each HDAC was sufficient to remove all (or nearly all) of the acetylation, 
crotonylation and butyrylation. Strikingly, even the lowest concentration of HDAC1 (0.03 μM) was 




Whilst these experiments suggested that class I HDACs could remove crotonyl- and butyryl-groups 
from histones, we did not have repeats for each condition. Additionally, these reactions were 
incubated for 2 hours to ensure that the reaction had gone to completion, but we did not know how 
quickly the acyl-group removal had been. We chose to focus on HDAC1 as it appeared to be the most 
effective decrotonylase out of the three enzymes tested. A time course experiment was performed, 
incubating HDAC1 with crotonyl-H3 or acetyl-H3 for different durations. After 60 minutes, a significant 
reduction could be seen in H3K18ac with HDAC1 in three repeat experiments (Figure 3.15). 
Interestingly, decrotonylation by HDAC1 was faster, with a significant reduction in the modification 
after just 10 minutes in three experiments.  
To fully assess whether HDAC1 has comparable decrotonylation efficiency to deacetylation, a kinetic 
assay must be performed with repeats of different substrate concentrations to determine reaction 
constants. This is because enzymes can have a residual or promiscuous activity which can be detected 
in vitro but may not occur to any functional extent in vivo (Khersonsky and Tawfik, 2010). We 
performed in vitro enzymatic assays by incubating a constant concentration of HDAC1 with different 
concentrations of crotonyl-H3 or acetyl-H3 for different durations to plot a substrate rate curve that 
enables estimation of Vmax, Km and Kcat. Vmax describes the maximum rate that is possible with a given 
enzyme concentration. Km is the Michaelis constant and describes the substrate concentration 
required to achieve half maximal rate. This constant gives a measure of how effective the enzyme is 
with lower substrate concentrations. Finally, Kcat is the turnover number, as in the number of 
molecules of substrate turned over to product per unit time, and gives a measure of the enzyme’s 
efficiency with that substrate. Reactions were performed in triplicate with multiple concentrations of 
acetyl-H3 or crotonyl-H3 and different time points. The reactions were dot blotted in quadruplicate 
and western blot performed followed by spot quantification using image J. The result in Figure 3.16 
shows that deacetylation can reach a higher maximal rate and is around 2.5 times more efficient than 
decrotonylation. However, the fact that the Kcat of decrotonylase activity is only 2.5-fold lower than 
the Kcat of deacetylation suggests that it is not a residual activity of this enzyme. Interestingly the Km 
of the decrotonylase reaction is lower than that of the deacetylase reaction meaning HDAC1 can act 
efficiently on lower concentrations of crotonyl-H3 compared to acetyl-H3. This difference in Km may 
be because the Vmax of deacetylation is higher. At 0.25 μM of acetyl-H3 or crotonyl-H3, the rate of 
decrotonylation and deacetylation are very similar, between 0.4 and 0.5 μM/min. This kinetic study 






Figure 3.13. Removal of acyl groups from biotinylated peptides by HDAC1 
(a) The specified concentration of acetyl- or crotonyl-H3 peptide was incubated with 0.12 µM HDAC1 or without 
HDAC1 for two hours followed by spotting onto nitrocellulose membrane and performing western blot with anti-
H3K18ac or anti-H3K18cr. The quantifications are shown as an average of the spot intensity of four replicate 
spots with error bars as standard error. (b) 4 µM acetyl- or crotonyl-H3 peptide was incubated with the specified 
amount of HDAC for the specified duration, followed by spotting onto nitrocellulose membrane and performing 




quadruplicate spots with error bars as standard error of the mean. The zero time quantifications are of the 0 nM 
HDAC1 and 60 minute reactions without background. 
 
 
Figure 3.14. Histone deacetylation, debutyrylation and decrotonylation by HDAC1, HDAC2 or HDAC2/NCoR1 
5.65 μM histones were acetylated, butyrylated or crotonylated in vitro, using the relevant acyl-CoA and 
recombinant p300, and then subjected to removal of the modification by the indicated HDACs  at the 
specified concentrations. Western blot was performed with antibodies against H3K18 acetyl, butyryl or crotonyl 
depending on the acyl-H3 substrate in the reaction. A representative anti-H3 blot is shown for one set of 
reactions to show that the protein loading is equal. Band quantifications are shown below using image J and are 





Figure 3.15. HDAC1 decrotonylation occurs over a similar timescale to deacetylation 
Recombinant acetylated or crotonylated histone H3 (5.65 μM) was incubated with 0.12 μM HDAC1 for the 
specified time and stopped reactions were analysed by western blot using anti-pan-crotonyllysine or anti-H3K18 
acetyllysine. A separate gel was run and blotted for anti-H3 to measure protein loading. Quantifications were 
normalised to H3 band intensity and are shown relative to the start reaction. The HDAC1 quantifications are an 
average of three separate experiments with error bars as standard deviation. One-way ANOVA was performed 
which was significant with a p value of 0.0001 for H3K18ac and < 0.0001 for Kcr. Comparisons were performed 
between each timepoint at the start reaction and significant p values are shown on the graph. Western blots 






Figure 3.16. Comparitive kinetics of HDAC1 decrotonylation and deacetylation 
5.65 µM histones were crotonylated or acetylated using recombinant p300 and crotonyl or acetyl-CoA. 
Acylated histones were subjected to removal of the modification by 0.03 µM HDAC1 for different lengths of 
time and different initial substrate concentrations. Samples were analyzed by dot  blotting using antibodies 
against H3K18cr and H3K18ac. Initial rates of reaction were determined by plotting substrate removal over 
time. Kinetic parameters Vmax, Km, and Kcat are shown on the graph, error bars are standard error of the 
mean, n = 3.  
3.2.8 The effect of HDAC inhibitors on decrotonylation and deacetylation 
Having confirmed that HDAC1 is an efficient decrotonylase, we then tested if different HDAC inhibitors 
could prevent decrotonylation as well as deacetylation in vitro. After recombinant H3 acylation using 
p300, we added HDAC1 and different concentrations of TSA or butyrate to see if this would prevent 
acyl-group removal. Whilst crotonylation was completely removed without inhibitor, a reduction in 
removal of crotonylation could be seen as the dose of TSA or butyrate increased in two experiments 
(Figure 3.17a and b). In one experiment, the highest dose of TSA or butyrate produced a level of 
crotonylation similar to that of the positive control without any HDAC1, whilst in the other the final 
level was less than the control. Reassuringly, TSA and butyrate could also reduce removal of 
acetylation as expected. As butyrate and TSA could inhibit both activities, this suggests that HDAC1 
may use the same active site for both deacetylation and decrotonylation reactions. As for the 
treatments of cells with inhibitors (Figure 3.12), TSA was more potent than butyrate as much lower 
concentrations were required to achieve maximum inhibition. We also found that crotonate could 
reduce deacetylase and decrotonylase activity of HDAC1 (Figure 3.17c), although the extent of 
inhibition of deacetylation was quite variable between the two experiments. The concentrations of 
butyrate, crotonate and TSA used in cell culture to promote histone acetylation and crotonylation 
(Figure 3.2, Figure 3.6 and Figure 3.12), are very similar to the concentrations able to inhibit HDAC1 




decrotonylation by HDAC1 but variability between some experiments makes it hard to determine at 
what concentration this occurs. Performing these experiments again with additional repeats will 
enable determination of inhibition constants, such as the concentration required to achieve half 
maximal inhibition for both HDAC1 activities. 
 
Figure 3.17. TSA, butyrate and crotonate inhibit decrotonylation and deacetylation by HDAC1 
Recombinant acetylated or crotonylated histone H3 was incubated with 0.12 µM of HDAC1 and different 
concentations of TSA, butyrate and crotonate as specified above. Western blot was performed using anti-Kcr 




the average of two independent experiments each normalised to the condition without HDAC1. Error bars are 
standard deviation. Black lines on blots are where miss-loaded samples were spliced out or the order of samples 
was rearranged (b). These experiments were performed with some help from Szabina Balázsi and Zoltán 
Hajnády. 
3.2.9 HDAC1 can use crotonate as a substrate to transfer crotonyl groups to histones 
One interesting thing that we noticed from Figure 3.17c is that at 25 mM crotonate the level of histone 
crotonylation was slightly higher than the control where no HDAC1 or crotonate was added to the 
crotonyl-H3 protein solution. This did not happen in the acetyl-H3 assay with HDAC1 and crotonate. 
Could additional crotonyl groups be transferred from crotonate to the histone during the reaction? 
HDAC1 deacetylation generates acetate in the nucleus (Bulusu et al., 2017), so it is likely HDAC1 
decrotonylation generates crotonate. This reaction has the potential to reverse with higher 
concentrations of product. Alternatively, non-enzymatic transfer of crotonyl-groups from crotonate 
could occur. Studies have shown that non-enzymatic acylation of protein lysines can occur due to high 
acyl-CoA concentrations and an alkaline pH (Wagner and Hirschey, 2014). Therefore, we performed 
an in vitro assay in which reactions with recombinant H3 and different concentrations of crotonate 
were incubated with HDAC1 or without HDAC1 for 2 hours (Figure 3.18). Reactions were analysed by 
dot blot. We observed a dose-dependent increase in histone crotonylation with crotonate in the 
presence of HDAC1 in two repeat experiments. Histone crotonylation did not change when HDAC1 
was absent, although this should be repeated to verify the result (Figure 3.18). It is possibile that 
crotonate transfer is non-enzymatic but dependent on the concentration of protein in the reaction. 
However, HDAC1 is at a concentration of 0.18 µM, compared to 5.65 µM histone H3.1, meaning that 
the change in protein concentration without HDAC1 is small. To control for this in future experiments, 
0.18 µM BSA could be used for the no-HDAC control. This result suggests that this was an enzymatic 
transfer of the crotonyl group by HDAC1 and highlights the reversible nature of HDAC1 decrotonylase 
activity. However, as concentrations of crotonate as high as 50 mM are unlikely to exist in the cell, 





Figure 3.18. HDAC1 can use crotonate as a substrate to decrotonylate histones 
Recombinant H3 was incubated with different concentrations of crotonate and a constant concentration of 
HDAC1 or no HDAC1. Dot blot of two independent repeats of the reactions with HDAC1 and one repeat without 
HDAC1. Spot intensity was averaged for each reaction. For HDAC1 reactions, quantifications are the average of 
combined reaction spots and error bars are the standard deviation of the two repeats. Squares around spots 
indicate the spots that were used in the quantifications as some spots were miss-loaded. 
 
3.3 Discussion 
3.3.1 HDAC1 is an efficient histone decrotonylase 
We found that treating HCT116 cells with HDAC-inhibiting TSA or SAHA resulted in promotion of 
histone crotonylation as well as histone acetylation, suggesting that HDACs could be involved in 
histone decrotonylation. Preliminary tests suggested that HDAC1 was ineffective against short H3 
acetyl- or crotonyl-peptides but HDAC1-3 could remove acyl-groups from recombinant H3. Using a 
kinetic assay, we identified for the first time that HDAC1 has a similar capacity to remove crotonyl 
groups as it does to remove acetyl groups. The Km of HDAC1 with the acetylated H3 was 1.5 ± 0.3 μM, 
higher than the Km of 0.4 ± 0.2 μM with crotonylated H3, suggesting that HDAC1 is responsive to low 




around 3 times higher than decrotonylation, indicating a higher maximal capacity with the acetyl 
substrate but also that the decrotonyl activity is not a trace activity of the enzyme.  
The only previous kinetic analysis of HDAC decrotonylase activity was of HDAC3/NCoR1 with a 
fluorescent crotonyl H4 peptide. The Km was 19 μM ± 15, suggesting that HDAC3 is less responsive to 
low substrate concentrations. However, the turnover was much higher as the Kcat was 0.18 ± 0.06 min-
1, compared to HDAC1 which was 38.1 ± 6.7 min-1 (Madsen and Olsen, 2012). As both the enzyme 
(HDAC1 or HDAC3/NCoR1) and substrate (H3-crotonyl or fluorescent-crotonyl) are different, it is 
unclear whether this difference in efficiency is due to the enzyme or the substrate. Km values of HDAC1 
determined with different acetylated fluorescent or tritiated substrates vary considerably from 0.68 
to 78 μM (Hoffmann et al., 1999; Wegener et al., 2003; Schultz et al., 2004; Halley et al., 2011; Henkes 
et al., 2012). The properties of the substrate may influence HDAC efficiency and therefore using the 
physiological substrate, as we have done here, may be important for determining true in vivo activity. 
That said, this assay only provides estimates of kinetic parameters, as substrate concentration could 
not be determined directly. HDAC enzymes are part of multisubstrate complexes in vivo which 
influence substrate specificity and enzyme rate. A subsequent study to our work found that a ternary 
complex of HDAC1, CoRest and LSD1 could hydrolyse H3K18cr peptides (Kelly et al., 2018). In their 
study, the HDAC1 complex could use H3K18cr peptides suggesting that only HDAC1 alone requires the 
full histone H3 and emphasing the importance of the complex in regulating substrate specificity. The 
assay we have developed would enable investigation of how different complexes change the kinetic 
parameters of various enzymes, provided that the complex could be produced recombinantly.  
Whilst this work was in revision, another study was published showing that the class I enzymes HDAC1, 
HDAC2, HDAC3 and HDAC8 have decrotonylase activity in embryonic stem cells using an 
immunofluorescence approach (Wei, Liu, et al., 2017). They treated cervical/uterine cancer HeLa S3 
cells, with TSA and saw also a large increase in histone crotonylation. Interestingly there was only a 
modest increase with the SIRT inhibitor, nicotinamide. Knockdown of HDAC1/2/3 using RNA silencing 
revealed a dramatic increase in histone crotonylation and acetylation, whilst knockdown of SIRT1/3/5 
did not noticeably affect either modification (Wei, Liu, et al., 2017). In combination with our results, 
and the findings by Madsen et al. (2012) and Kelly et al. (2018), this provides strong evidence that 
class I HDACs are major histone decrotonylases in cell culture and may also be in vivo.  
3.3.2 The therapeutic potential of HDAC inhibitors 
HDAC inhibitors have important therapeutic potential particularly in the treatment of cancer. HDACs 




proliferation and poor prognosis (Yoon and Eom, 2016). The HDAC inhibitor SAHA has been licensed 
to treat cutaneous T cell lymphoma, but the responses of different cancer types to HDAC inhibitors 
have been varied (Bojang and Ramos, 2014). The explanation for this could be in part due to the action 
of HDACs on non-acetyl histone acylations, as we found that treatment of cells with SAHA or other 
HDAC inhibitors upregulated histone crotonylation in addition to acetylation. This novel finding that 
class I HDACs are decrotonylases suggests that drugs which were previously developed to target 
histone acetylation may have wider effects than anticipated. As HDAC inhibitors can prevent both 
deacetylation and decrotonylation, these enzymes may use the same active site for both reactions 
making it difficult to design selective inhibitors. However, we found that TSA inhibited the 
deacetylation reaction of HDAC1 at lower doses than the decrotonylation reaction in vitro. These dose-
dependent divergences in the effect of TSA on deacetylation or decrotonylation suggests that there 
might be differences in how HDAC1 uses either substrate. Excitingly, Wei et al. were able to mutate 
HDAC1 so that it retained HDCR activity but lost HDAC activity. Expression of this HDAC1 mutant in 
HeLa cells could repress transcription of several housekeeping genes to the same levels as wild type 
HDAC1, demonstrating the importance of histone crotonylation in gene regulation (Wei, Liu, et al., 
2017). The structural differences between wild type HDAC1 and the HDAC1 mutant could be exploited 
to generate inhibitors targeting only one activity. These more specific inhibitors may have fewer side 
effects or a more potent therapeutic action.  
3.3.3 The effect of SCFAs on histone crotonylation on colon carcinoma cells and organoids 
We show that butyrate and propionate treatment can upregulate histone crotonylation in a dose-
dependent manner in colon carcinoma cells. The effect of butyrate treatment on histone crotonylation 
was rapid, occurring within two hours of treatment. Our results also suggest that crotonate can 
promote histone crotonylation, in agreement with a previous study that found crotonate treatment 
could promote histone crotonylation in cervical/uterine carcinoma cells (Sabari et al., 2015). Further 
experiments are required to demonstrate this conclusively in colon carcinoma cells, as 10 mM 
crotonate promoted crotonylation in some experiments but not others. Interestingly, butyrate and 
propionate seemed to be more effective than crotonate at promoting histone crotonylation in colon 
carcinoma cells as concentrations of 1-5 mM butyrate or propionate could promote crotonylation as 
opposed to 10-20 mM crotonate. However, β-HBu did not change crotonylation and acetate even 
slightly decreased crotonylation. The effects of acetate, butyrate, propionate and β-HBu were 
reproducible across two or more blots. In particular, butyrate promoted histone crotonylation at 
H3K18cr in colon carcinoma cells in four independent experiments. However, the fold changes at 




We showed that butyrate and crotonate could also promote histone crotonylation in mouse small 
intestinal and colon organoids. These increases were seen in two or more experiments. In particular, 
10 mM crotonate produced a significant increase in crotonylation in small intestinal organoids, but 
there was some variability in fold-change between the three experiments. Additionally, the 
concentrations of SCFA used in organoid culture were similar to those used in colon carcinoma cells, 
but did not result in the same fold changes. This may be because repeat experiments, for either 
HCT116 cells or organoids, were run on separate blots and so normalisation to the control group had 
to be done to compare them. This meant that small variations in the intensity of the control group 
resulted in larger variations in fold change. Whilst overall crotonate and butyrate appear to promote 
crotonylation in organoids, in some cases only one or two repeats were performed for a particular 
treatment concentration making the confidence in the conclusion less high. If fewer concentrations of 
each treatment were tested, more repeats could be included on the same blot to reduce technical 
variability and determine if the fold change observed is significant.  
3.3.4 The effect of SCFAs on histone acetylation in colon carcinoma cell and organoid culture  
Our finding that acetate, which can be directly converted into acetyl-CoA by ACSS2, did not promote 
histone acetylation in HCT116 cells is curious. This could be because acetyl-CoA levels are already high 
as it is an abundant metabolite and is central to many metabolic pathways (Pietrocola et al., 2015). 
Previous studies found that acetate could rescue histone acetylation but this was only when important 
metabolic enzymes were knocked down such as ACLY, which is a major source for nuclear acetyl-CoA 
(Wellen et al., 2009). Acetyl-CoA concentration has been measured in the range of 2-13 µM in human 
gliobastoma and hematopoietic cell lines (Lee et al., 2014), and in HCT116 cells was around 50 µM (X. 
Liu et al., 2018, pre-print). The Km of human lysine acetyltransferases is typically lower, for example 
KAT2A (GCN5) and P/CAF have Km values of 0.62 µM and 0.28 µM respectively for acetyl-CoA with 
histone H3 (Langer et al., 2002; Leemhuis, Nightingale, et al., 2008). Therefore, further increasing 
acetyl-CoA concentration with acetate treatment may not influence acetyltransferase activity. Our 
results suggest that butyrate can promote acetylation at H3K18 in HCT116 cells, and may also do in 
colon organoids although further experiments are required to verify this. We are confident that the 
change we see is due to modulation of acetylation as the H3K18ac antibody did not recognise 
crotonylation in our specificity test. There seems to be no requirement for the structure of the SCFA 





3.3.5 What is the mechanism by which SCFAs promote histone crotonylation in colon carcinoma 
cells and organoids? 
Whilst butyrate was more potent than crotonate in HCT116 cells, these SCFAs had a similar effect on 
histone crotonylation in organoid culture. Our current hypothesis is that because fatty acid 
metabolism is higher in organoids, as they do not undergo the Warburg effect, HDAC inhibition is less 
dominant and promotion of crotonylation is dependent on acyl-transfer to the histone. Therefore, 
crotonate and butyrate would have similar effects as they each contain one acyl-group. In HCT116 
cells, butyrate is not metabolised as these cells rely on glycolysis rather than beta-oxidation for energy 
(Vander Heiden et al., 2009; Donohoe et al., 2012). Therefore, it can accumulate to a level where it 
functions as an HDAC inhibitor and results in hyperacetylation (Donohoe et al., 2012). Our in vitro 
assays revealed that butyrate can inhibit HDAC1 decrotonylation at lower concentrations than 
crotonate can. We suggest that in HCT116 cells, butyrate is a more effective upregulator of histone 
crotonylation than crotonate because HDAC inhibition is dominant and butyrate is a more potent 
HDAC inhibitor (Donohoe et al., 2012). This may also explain why butyrate could promote histone 
acetylation in HCT116 cells, as it can inhibit HDACs, whilst acetate does not. 
The regulation of histone crotonylation by butyrate is dynamic in HCT116 cells, occurring within two 
hours of treatment. The opposing actions of p300/CBP and HDAC1-3 in the nucleus may allow histone 
acetylation and crotonylation to fluctuate dynamically in response to the changing environment. The 
abundance of each acylation would then depend on the balance between crotonyltransfer and 
decrotonylation. An increase in acyl-CoA would cause more transfer to histones by p300 but with 
HDAC1-3 continually removing acyl groups from lysines, a return in acyl-CoA to basal levels would 
mean that histone acylation would shift to reflect this. This rapid change could mean that regulation 
of crotonylation is through modulation of enzymatic activity, for example by changing substrate 
availability, rather than requiring synthesis of new enzymes which would take more time. To test this, 
a western blot could be performed to test how the abundance of key enzymes involved in regulating 
crotonylation, such as ACAD, ACSS2, p300 or HDAC1, change over time after crotonate treatment. If 
their abundance is constant, then changes to crotonylation are likely to be due to changes in enzyme 
activity. Knock-down of these enzymes, followed by SCFA treatment, would also help us understand 
which mechanism is used in HCT116 cells and organoids. For example, if butyrate treatment no longer 
promoted histone crotonylation in HDAC1-knockdown HCT116 cells it would suggest that HDAC1 
inhibition is the main mechanism involved. Heavy label tracing using 13C versions of butyrate, 
propionate and crotonate combined with mass spectrometry analysis of histone proteins would be a 




crotonylation by SCFAs. It will be interesting to see whether this differs substantially between colon 
carcinoma cells and organoids. There is some evidence that HDACs can remove crotonyl groups from 
non-histone proteins as SAHA treatment changed the abundance of crotonylated proteins across 
cellular compartments (Wu et al., 2017). Crotonylated non-histone proteins identified in mass 
spectrometry analysis are involved in many cellular processes including nucleic acid metabolism, RNA 
processing, DNA recombination, chromosome organisation and translation (Wu et al., 2017). As non-
histone lysine acetylation has been shown to alter protein function (Tang et al., 2008), this should be 
taken into consideration when analysing the effects of SCFAs on cell function. The identification of 
class I HDACs as decrotonylases suggests that this modification is not simply metabolic noise, but is 
modulated by specific enzymes in a regulated manner. Basal crotonyl-CoA levels are low compared to 
acetyl-CoA, meaning that changes to cell metabolism could cause greater fold changes to histone 
crotonylation and result in a greater sensitivity to certain aspects of cellular metabolic state than 
acetylation. As histone crotonylation is linked to gene regulation, it provides a mechanism for gene 
expression to rapidly respond to changing metabolic state. 
Whilst these results in colon carcinoma culture and organoids are interesting, further work is needed 
to confirm these findings and apply them to the whole organism. The in vivo system is much more 
complex with immune cells, mucus layer, gut bacteria, gut transit times and diet composition having 
the potential to alter the effects that SCFAs have on coloncyte epigenetic state. Additionally in the gut, 
differentiated colonocytes metabolise butyrate to protect the stem cells at the crypt base (Kaiko et 
al., 2016). However, in the gut organoid system the stem cells are on the outside and directly exposed 
to the culture medium. Importantly, SCFAs are thought to be derived from the intestinal microbiota 
so manipulation of microbiota and dietary composition is critical to be able to develop our 
understanding of this system and improve therapies to treat disease. The influence of diet 
composition and microbiota on colonocyte histone acylation and gene expression will be addressed 






4 The effect of diet on histone acylations in mouse colon 
4.1 Introduction 
In the gut, microorganisms ferment long chain carbohydrates from the diet and release SCFAs such as 
butyrate, acetate and propionate (Cook and Sellin, 1998; Flint et al., 2012; den Besten et al., 2013). 
Butyrate is the major energy source for colon epithelial cells, whilst much of the acetate and 
propionate produced is released into the portal circulation and used by the liver (den Besten et al., 
2013). Dietary fibre, including cellulose, inulin and pectin, are derived from plant materials and are 
resistant to degradation by enzymes encoded in the mammalian genome. The wide diversity and high 
metabolic capability of bacteria in the gut means that a much greater range of complex molecules can 
be harvested for their energy (Gill et al., 2006; Ley et al., 2006). The presence of microorganisms is 
thought to have occurred early in the evolution of multi-cellular organisms as it confers a distinct 
advantage in digestion, immune development and protection from pathogens (Ley et al., 2008). In 
addition to the symbiosis between bacteria and their host, there are also beneficial interactions 
between bacteria. Different bacterial species have varying capacities to break down resistant 
molecules from the diet and many rely on cross-feeding of intermediate molecules from other bacteria 
for their energy. An example of this is the butyrate producing F. prausnitzii which benefits from lactate 
and acetate production by Bifidobacteria species (Rivière et al., 2016).  
SCFAs are important for gut health as they are modulators of intracellular pH, cell volume, ion 
transport, proliferation, differentiation, gene expression and apoptosis (Cook and Sellin, 1998). In 
particular, butyrate is thought to protect against colon cancer and inflammation (Cook and Sellin, 
1998; Ferreira-Halder et al., 2017). However, it is important to note that SCFAs have been found to 
have both pro- and anti-inflammatory effects in different studies, possibly because they influence so 
many aspects of gut function (Corrêa-Oliveira et al., 2016). In a previous study, supplementation of 
fibre to the diet of rats increased total SCFA levels and histone acetylation. Interestingly, butyrate 
levels were highest in the 5 and 10% wheat bran groups but cell proliferation was lowest compared 





butyrate could upregulate histone crotonylation in cell culture and this may be through inhibition of 
HDACs. Therefore, supplementation of fibre to increase luminal SCFAs could influence host epithelial 
cell histone crotonylation as well as histone acetylation. In this chapter, we will test the effects of 
modulating fibre content in conventional mice and SCFA supplementation in both conventional and 
germ-free mice. We predict that these will promote histone acylations in intestinal epithelial cells. We 
will also test dietary restriction, which we hypothesise will reduce histone acylations as there would 
be less substrates for microbial fermentation.  
4.2 Results 
4.2.1 Dietary restriction, crotonate and butyrate treatment do not change histone crotonylation 
or acetylation 
As SCFAs are derived from the diet, we first tested the effect of dietary restriction on histone 
acetylation and crotonylation in liver and colon. However, no difference could be seen in histone 
crotonylation or acetylation in either tissue (Figure 4.1). Possibly, there was sufficient fibre present in 
the restricted diet to maintain SCFA concentrations in the colon lumen and serum meaning that these 
histone acylations did not change. Our previous results suggested that crotonate could promote 
histone crotonylation in both colon carcinoma cells and colon organoids (Figure 3.2, Figure 3.8, Figure 
3.10 and Figure 3.11). Therefore, we added crotonate to the drinking water of mice and tested histone 
crotonylation in colon extracts by western blot to see if it increased. We observed a downward trend 
in histone crotonylation with increasing dose, but this was not statistically significant (Figure 4.2). 
H3K18cr ChIP-qPCR on small intestinal crypts from the same mice found that H3K18cr associated with 
the promoters of Klf11 and Klf13 genes did increase in this modification on the 10 mM and 50 mM 
treatments (Figure 4.3). Possibly, changes to histone crotonylation do occur at many genes but are 
not large or widespread enough to see using western blot, which looks at global changes to hPTMs. 
Crotonate treatment was performed on mice fed a normal chow diet and containing a healthy 
microbiota, meaning that the steady-state level of microbial derived SCFAs may have been high 
already. To eliminate the supply of SCFAs by the endogenous microbiota, we tested how microbiota-
free mice responded to butyrate treatment. We showed previously that butyrate could upregulate 
histone crotonylation in colon carcinoma cells and organoids (Figure 3.6, Figure 3.10 and Figure 3.11). 
However, there was no difference in histone crotonylation as a result of butyrate treatment in the 
colon or small intestine (Figure 4.4). One possibility is that butyrate was absorbed as it passed along 
the small intestine and colon, meaning that it never reached high concentrations in any part of the 




consumption may have varied between mice, resulting in more variability between biological 
replicates within a group.  
 
Figure 4.1. Dietary restriction does not change histone crotonylation or acetylation in liver or colon 
Western blots of liver (a) and colon extracts (b) from mice given a standard chow diet (control) or a restricted 
diet and probed with anti-H3K18ac, anti-pan-crotonylation (Kcr) and anti-histone H4. (c) Quantifications of 
western blot bands was performed using image J, normalised to H4 band intensity and are shown relative to 
average of the control group. Statistical analysis used an unpaired t-test with a threshold p-value of 0.05, all 






Figure 4.2. Crotonate treatment does not change histone crotonylation in the small intestine 
Western blots using anti-H3K18cr or anti-histone H4 of small intestinal extracts from wild type BL6 mice given 
0, 10 or 50 mM crotonate in their drinking water for two weeks. Band quantification is shown below relative to 
H4 and the average of the 0 mM group. The overall difference between the groups was not significant (p = 0.11) 
as tested by one-way ANOVA. The pairwise comparison between 0 mM and 10 or 50 mM is shown on the graph. 







Figure 4.3. H3K18cr ChIP-qPCR on small intestine of crotonic acid fed mice 
Wild type BL6 mice were fed 0, 10 or 50 mM crotonate for two weeks followed by ChIP of small intestinal crypts 
against H3K18cr. This was followed by real time qPCR of two candidate genes, Klf11 and Klf13, as inferred from 
previous H3K18cr ChIP-seq data from our group, as well as Cys1 as a negative control. A two-fold enrichment of 








Figure 4.4. Butyrate treatment of microbiota-free mice does not change histone crotonylation or acetylation 
Western blots and quantifications of colon or small intestine extracts from germ-free mice probed with specified 
antibodies. Mice were given 150 mM butyrate in their drinking water for one week. Quantifications are relative 
to the H4 loading control and the average of the butyrate treated colon group. Labels are butyrate (Bu), small 
intestine (SI), treated (+) and control (-). One-way ANOVA was used to determine that the overall differences 
between groups were not significant. Pairwise comparisons are shown on the graph, with multiple testing 
correction using the Holm-Sidak method, n = 3. 
 
4.2.2 The effect of high fibre diet on histone acetylation, histone crotonylation and HDAC 
abundance in conventionally raised mice 
As the gut microbiota ferments dietary fibre to produce SCFAs, we sought to increase colonic luminal 
SCFAs by increasing the fibre content of the diet and investigated how this affected histone acylations. 
For one month, mice were given a normal chow diet containing 5% cellulose (the control) or chow diet 




histone acylations, but found that diets supplemented with 10% inulin or 10% pectin did not 
significantly increase histone acetylation or crotonylation in any of three independent experiments 
relative to the control diets (Figure 4.5). Instead, crotonylation and acetylation either decreased or 
stayed the same in a manner that was not consistent across experiments. Inulin reduced H3K18ac in 
both experiment 1 and 3, but these two experiments differed in their effects on histone crotonylation. 
On the pectin supplemented diet, H3K18ac was significantly reduced in experiment 3 and Kcr was 
significantly reduced in experiment 1. However, no significant changes could be seen in acetylation or 
crotonylation in experiment 2.  
To see if the high fibre diets had increased SCFA concentrations, we measured acetate and butyrate 
concentrations in the serum (Figure 4.6). Previous studies have found that blood acetate 
concentrations in human and murine blood range from 25 to as much as 600 µM (Richards et al., 1976; 
Tollinger et al., 1979; Rémésy et al., 1980; Pomare et al., 1985; Davies et al., 2011; Tumanov et al., 
2016). Over both experiments, serum acetate showed a statistically significant increase (p = 0.0006) 
from 50±16 µM on the cellulose 5 diet to 232±34 µM on the pectin 10 diet, with inulin 10 at an 
intermediate concentration between the two (169±28 µM). This is similar to a previous study in human 
subjects which saw an increase from ~50 µM to 96±12 µM plasma acetate after giving a 20 g pectin 
diet (Pomare et al., 1985). In contrast, no increase was seen in butyrate serum concentrations. Instead, 
butyrate significantly decreased from 108±10 µM on the cellulose 5 diet to 88±5 µM on the inulin 10 
diet. Both of these concentrations are higher than previously measured plasma or serum butyrate 
concentrations in mice or human of 3-8 µM (Wolever and Chiasson, 2000; Nishitsuji et al., 2017). The 
low serum concentration of butyrate is thought to be due to high absorption of microbial generated 
butyrate by colonocytes (Topping and Clifton, 2001). However, in another study 100 µM butyrate was 
recorded in the portal vein of rats (Rémésy et al., 1980). SCFA measurements are often variable 
between studies which is thought to be due to differences in diet and the extent of fermentation by 
the microbiota (Topping and Clifton, 2001). The changes to histone acylations are more similar to the 
changes in serum butyrate rather than serum acetate. Experiment 2 showed no change in butyrate 
and also no change in histone acylations on either diet. In experiment 1, butyrate decreased on the 
inulin diet, which matches the decreases seen in histone acetylation and crotonylation (Figure 4.5 and 
Figure 4.6). This could mean that it is butyrate rather than acetate that influences histone acetylation 
and crotonylation in the gut, but this would require further investigation.   
We also tested the effect of these high fibre diets on HDAC abundance, as HDAC2 levels were 
previously shown to be affected by butyrate (Kramer et al., 2003) and could be the mechanism for the 
effects of SCFAs on histone acylations. Figure 4.7 shows western blots of HDAC1, HDAC2 and HDAC3 




for each experiment separately, rather than combined, as the fold change was much higher in 
experiment 2 due to substantial changes in the lamin B1 normalisation blot. HDACs and lamin B1 may 
be more susceptible to degradation than histones due to their higher molecular weight. The effect of 
inulin and pectin diets on HDAC abundance was not consistent between experiments (Figure 4.7). In 
experiments 1 and 2, HDAC1-3 increased significantly on the inulin diet. In experiment 3, HDAC1 and 
HDAC3 remained the same, whilst HDAC2 decreased on the inulin diet. The pectin diet significantly 
reduced HDAC2 and HDAC3 in experiment 1 and HDAC2 in experiment 3. But HDACs remained the 
same or increased in the other blots. The expectation was that changes to HDAC abundance would be 
in the opposite direction to histone acylation changes, as HDACs remove acetylation and crotonylation 
from histones. However, whilst the increase in HDAC1 or HDAC2 abundance on the inulin diet in 
experiment 1 was matched by a reduction in histone acetylation and crotonylation (Figure 4.5 and 
Figure 4.7), the decrease in HDAC2 and HDAC3 abundance with pectin diet in experiment 1 was not 





Figure 4.5. High fibre diet does not increase histone crotonylation or acetylation 
Western blots on colons from mice given a standard chow diet containing 5% cellulose (cellulose 5), chow with 
added 10% inulin (inulin 10) or chow with added 10% pectin (pectin 10). Three independent experiments were 
performed with five mice in each group, for some blots only four cellulose 5 samples were loaded due to a 
limited number of wells in the gel. Quantifications were normalised to H3 or H4 band intensity and are shown 
relative to the average of the cellulose 5 group. Two-way ANOVA was performed with pairwise comparisons 
between each diet within an experiment. Overall, there was a significant difference between both diet, 
experiment and an interaction between the two for H3K18ac (p = 0.0002, p = 0.0011 and p = 0.0037). There was 
a significant difference between experiment for H3K18cr (p = 0.0004) and for Kcr there was a significant 




0.0425). Significant differences in the pairwise comparisons between diets for each experiment, are shown on 




Figure 4.6. High fibre diet increases acetate but not butyrate in serum 
Acetate and butyrate were measured in the serum by gas chromatography from mice given a standard chow 
diet containing 5% cellulose (cellulose 5), chow with added 10% inulin (inulin 10) or chow with added 10% pectin 
(pectin 10. Two-way ANOVA statistical tests were conducted using diet and experiment as the variables, with 
pairwise comparisons between diets within an experiment. Values of zero were below detectable levels. For 
acetate there was a significant difference between diets but no difference between experiments. For butyrate 
there was a significant difference between experiments; experiment 1 had significant differences between diets 
but experiment 2 had no differences between diets. Significant pairwise comparisons between diets are shown 









Figure 4.7. High fibre diet does not cause consistent changes in class I HDACs 
Western blots of colon extracts from mice given a standard chow diet containing 5% cellulose (cellulose 5), chow 
with added 10% inulin (inulin 10) or chow with added 10% pectin (pectin 10) using the specified antibodies. 
Three independent experiments were performed with five mice in each group. Quantifications of HDAC band 
intensity were normalised to the lamin B1 band intensity which has a similar molecular weight to the HDACs. 
Quantifications of all bands are shown relative to the average of the cellulose 5 group to make the three 
experiments easier to compare. One-way ANOVA was performed which gave a significant effect of diet overall 
for all except HDAC1 and HDAC3 in experiment 3. Pairwise comparisons between cellulose 5 and the high fibre 





4.2.3 The effect of high fibre diet on histone acylations in wild type or ACAD deficient mice 
A further experiment was conducted, comparing a normal diet (5% cellulose) to diets with 10% inulin 
supplement. This was performed with wild type mice and also those with a deficiency in ACAD, to see 
if an absence of short chain fatty-acyl CoA dehyrogenation would change how histone acylations are 
influenced by the high fibre diet. Band quantifications from wild type and ACAD deficient mouse 
colons are shown on the same graph and the effect of diet compared together using two-way ANOVA 
because almost no differences were seen in histone acylations between the wild type and ACAD 
deficient mice when cellulose and inulin diets were compared directly (Figure 4.8). The effect of inulin 
diet on histone acylations was broadly consistent between wild type and antibiotics treated mice 
(Figure 4.9). A reduction was seen on inulin diet in H4K8ac, H3cr and H4cr in both wild type and ACAD 
deficient mice (Figure 4.9). Additionally, a significant increase was seen in HDAC2 in wild type mice on 
the inulin diet (p = 0.006), although this was not observed in the ACAD deficient mice (p = 0.962). The 
differences in the effect of high fibre diet on histone acylations between experiments 1, 2 and 3 in 
wild type BL6 mice (Figure 4.5), could be due to differences in their microbiotas because they were 
housed at different time periods in the same facility. Wild type and ACAD deficient mice were all 
cohoused as part of the same experiment and would therefore have more similar microbiotas, which 
could explain why a high fibre diet had a more consistent effect between groups of mice in this 
experiment (Figure 4.9). Whilst each histone acylation was similar between wild type and ACAD 
deficient mice, there were differences between histone acylations. For example, H4K8ac and Kcr 
decreased whilst H4K8cr did not change. Importantly, and in contrast to our hypothesis, high fibre diet 
did not increase histone acetylation or crotonylation in any of these experiments but stayed the same 






Figure 4.8. No difference is seen between ACAD -/- and wild type mice on different diets 
Wild type mice or those with a deficiency in ACAD were given a normal chow diet with 5% cellulose (cellulose 5) 
or a diet with added 10% inulin (inulin 10) and extracts of colons investigated by western blot using the specified 
antibodies. Quantifications are shown relative to the histone H3 loading control and cellulose 5 condition. Two-




of genotype are shown on the graph. There was no significant effect of diet or an interaction between diet and 
genotype for any of the blot quantifications, n = 5. 
 
 
Figure 4.9. The effect of high fibre diet on HDAC2 and histone acylations in wild type or ACAD deficient mice 
Wild type mice or those with a deficiency in ACAD were given a normal chow diet with 5% cellulose (cellulose 5) 
or a diet with added 10% inulin (inulin 10) and extracts of colons investigated by western blot using the specified 
antibodies. The lines on the blot show where the order of the bands was changed to match other blots due to 




5 condition. Two-way ANOVA was performed with ACAD -/- and WT. The effect of diet is shown on each graph. 
HDAC2 also gave a significant effect of genotype and significant interaction between diet and genotype, n = 5. 
 
4.2.4 Diet supplementation with 25% inulin increases butyrate concentrations in the colon 
Increasing the fibre content of the diet did not yield consistent effects on histone acetylation but this 
could be because changes in butyrate concentration in the serum on 10% inulin or 10% pectin were 
small (Figure 4.6, experiment 1) or did not change (Figure 4.6, experiment 2) compared to the control 
diet. To see if further increasing the fibre content of the diet could impact SCFA concentrations, we 
performed an initial test measuring SCFA concentrations on more diets with two biological repeats for 
each. Statistical testing was not performed as there were only two replicates. The inulin 10 and pectin 
10 diets had higher colon luminal acetate concentrations than cellulose 5 (Figure 4.10), a similar 
pattern to that in Figure 4.6. Propionate only showed an upward trend for inulin 10. Only 25% inulin 
produced a clear increase in colon luminal butyrate concentration (Figure 4.10), which could explain 





Figure 4.10. 25% inulin supplementation increases butyrate concentration 
Acetate, propionate and butyrate were measured in luminal colon content of mice given different diets using 
gas chromatography, n = 2. SCFA measurement was performed by Caroline Marcantonio Ferreira’s group.  
4.2.5 Fibre free diet reduces histone acylations in conventional mice 
As 25% inulin significantly increased butyrate concentration in the colon lumen (Figure 4.10), we 
tested supplementing 25% inulin to the diet. In addition, we tested a no fibre condition, as the control 
diet contains 5% cellulose, to see if there would be a bigger difference in histone acylation relative to 
the high fibre diet. Cellulose is a resistant polysaccharide that might be used in microbial fermentation, 
resulting in high SCFA concentrations in the colon lumen. The 25% inulin supplemented diet 
significantly reduced H4 crotonylation relative to the 5% cellulose diet, whilst other modifications did 
not change (Figure 4.11). This was similar to the reduction in histone acetylation and crotonylation 
with inulin supplementation seen in some of our previous experiments. Many acylations did change 
in the same way as a result of inulin treatment between different experiments. H3K18ac reduced on 




H4K8ac and Kcr reduced on inulin 10 in Figure 4.9, and H4K8cr, H3K18ac and Kcr H4 reduced on inulin 
25 in Figure 4.11. Not every acylation changed in each experiment, but we can conclude that inulin 
supplementation does not increase histone acylations relative to the cellulose 5 diet in our hands. 
Only H3K18ac showed a significant increase between no fibre and inulin 25, which were both lower 
than the cellulose 5 diet. The diet without fibre reduced H3K18ac, H4K8bu and H4K8cr relative to 
cellulose 5 but did not significantly change Kcr or H4K8ac. This agrees with our hypothesis that 
removing fibre would reduce histone acylations. Perhaps, SCFA levels are already high in the cellulose 
5 treated mice, so we only see reductions in histone acylations when fibre is removed from the diet, 
but no increase when fibre is added to the diet. These more consistent effects on histone acylations 
of no fibre, compared to inulin or pectin supplementation, may also be because they are less 
dependent on the species composition of the microbiota. However, further experiments with no fibre 
are necessary to determine if this is a robust effect.  
SCFA measurements of the colon content of these mice show that there was a statistically significant 
increase in acetate and propionate on the 25% inulin diet (Figure 4.12). Although a preliminary test of 
the effect of different high fibre diets on SCFA concentrations produced a striking increase in butyrate 
on the 25% inulin diet (Figure 4.10), in Figure 4.12 the concentration of butyrate on the 25% inulin 
diet is similar to the 5% cellulose diet. There is a significant decrease in butyrate in the no fibre diet 
whilst acetate and propionate do not change. The changes to butyrate concentration correlate better 
with the changes in histone acylations than the changes to acetate and propionate. Inulin 10 reduced 
serum butyrate and H3K18ac in experiment 1 (Figure 4.5 and Figure 4.6), whilst no fibre diet reduced 
colon luminal butyrate and H3K18ac, H4K8ac and H4K8cr (Figure 4.11 and Figure 4.12). However, 
further experiments are required to determine if fibre-derived butyrate is the cause of changes to 
histone acylations. We have not seen consistent effects of increasing the fibre content of the diet on 
butyrate concentration. Whilst inulin 10 reduced serum butyrate in experiment 1 it did not change in 
experiment 2 (Figure 4.6). Additionally, an inulin 25 diet increased colon luminal butyrate in an initial 
test (Figure 4.10), but did not significantly change colon luminal butyrate in the subsequent 






Figure 4.11. The effect of no fibre diet on histone crotonylation, acetylation and butyrylation in mouse colon 
Western blots of colons from mice given a normal chow diet containing 5% cellulose (cellulose 5), chow diet 
without cellulose (no fibre) or chow diet plus 25% inulin (inulin 25) probed with the specified antibodies. Each 
lane is the colon extract from a separate mouse. Quantifications of western blot bands are shown relative to the 
anti-histone H3 loading control and the average of the cellulose 5 condition. One-way ANOVA was performed, 
H4K8cr and Kcr H4 had a significant effect of diet overall (p = 0.0009 and p = 0.0169 respectively). P values of 
pairwise comparisons between the diets are shown on the graph, the threshold p value was 0.05. Multiple 






Figure 4.12. Changes to acetate, propionate and butyrate in the colon lumen of mice on different diets 
Acetate, propionate and butyrate were measured in the luminal colon content by gas chromatography. One-
way ANOVA was performed and the overall effect of different diets on acetate, propionate or butyrate was 
significant. Pairwise comparisons between diets are shown on the graphs with a threshold p value of 0.05, 
multiple testing correction used the Holm-Sidak method, n = 5. 
 
4.3 Discussion 
4.3.1 The effect of dietary fibre on histone acylations in mouse colon 
We found that removing all fibre (including cellulose) from the diet produced a reduction in some 
acetyl- and crotonyl-marks, as well as a slight decrease in luminal butyrate concentration. However, 
increasing the fibre content of the diet either decreased or did not change histone crotonylation and 




our hypothesis, as we had anticipated that more fibre would enable increased generation of SCFAs. 
However, whilst we observed increases in acetate and propionate on 10 or 25 % inulin, there were no 
increases in butyrate. A previous study found that 10% inulin shifted the relative production of SCFAs 
from acetate to propionate and butyrate, and increased total SCFA concentrations in rat caecum. 
However, in this study there was no linear correlation between the total SCFA concentrations and 
percentage of inulin, as SCFA levels were lower with 20% than with 10% inulin (Levrat et al., 1991). 
This suggests that the relationship between dietary fibre and SCFA levels in the healthy gut may be 
more complex.  
4.3.2 Differences in microbiota between mice could contribute to variation in the response to 
high fibre diets 
The differences between experiments could be due to differences in gut microbiota composition 
between these mice. We observed more consistent changes to histone acetylation and crotonylation 
between ACAD deficient mice and wild type mice on high fibre diets. As ACAD deficiency did not 
change histone acylation abundance, the similarity of effect could be because mice were cohoused 
and therefore had more similar microbiotas. The environment is a key contributor to the composition 
of the microbiota and it has been well documented that mice can vary substantially in their microbiota 
between facilities due to differences such as water acidity, bedding and food. The inoculum that a 
mouse receives from its mother is a key factor in establishing the microbiota and cohousing of 
unrelated mice can result in similar microbiota. Additionally, mice can even differ in their microbiota 
within a facility (Goodrich et al., 2014). We chose to use mice with enriched microbiota relative to 
standard laboratory mice which are specific or pathogen free (SOPF) and have low microbiota 
diversity. This was because the generation of SCFAs from fibre by the microbiota is dependent on 
particular species, such as those present in Clostridium clusters, which may be less prevalent in low 
microbiota diversity mice. Furthermore, the generation of some SCFAs, in particular butyrate, relies 
on cross-feeding between microbial species and therefore will be enhanced by greater diversity. 
Whilst this diversity may be important to observe the full effects of fibre supplementation, it also 
results in high inter-individual variability in microbiota composition which is known to influence the 
response to dietary manipulation and can make interpretation of the results difficult (Flint et al., 
2012).  
4.3.3 Microbial adaptation and the other potential effects of fibre in the gut 
Another component of this study is that high fibre diets were given for one month in our experiments, 




short-term changes to diet, involving switching from a plant-based to animal-based diet in humans, 
could dramatically alter adult microbial community structure, although another study found that the 
microbiota differed more between people than diet (David et al., 2014; Korem et al., 2017). As 
bacterial metabolites modulate the composition of the microbiota (Ferreira-Halder et al., 2017), an 
increase in SCFA concentrations could have resulted in a compensatory change in the abundance or 
diversity of gut bacteria. In these experiments with high fibre diets we do not know how the relative 
abundance of different bacterial species changed. Furthermore, fibre can influence many components 
of gut physiology. Fibre is known to influence water absorption, gut transit times, cholesterol and 
glycaemic levels and trap potentially harmful substances, in addition to promoting fermentation by 
the gut flora. Whilst different types of fibre can differently influence gut motility, in general it is 
associated with increased frequency of bowel movements (Dhingra et al., 2012). SCFA concentrations 
in the gut are a balance of microbial production and colonocyte absorption. Shortened gut transit may 
mean that SCFA concentrations are not able to accumulate as much and could counter balance the 
effect of adding increased SCFA substrate. Further studies could test shorter periods of dietary 
manipulation to reduce microbial adaptation. Additionally, more steps should be taken to standardise 
the microbiota between experiments and the composition of key bacterial species monitored using 
16S rRNA sequencing. This needs to be understood if the knowledge gained is to be applied to humans, 
which are considerably more variable in their microbiota composition.  
4.3.4 Which SCFA is responsible for changes to histone acetylation and crotonylation? 
In the high fibre diet experiments, changes to histone acylations seemed to be linked to changes in 
butyrate rather than acetate or propionate. This suggests that the actions of butyrate producing 
bacteria could be the drivers for changes to histone acylations. In chapter 3, butyrate and propionate 
but not acetate could upregulate histone crotonylation in cell culture. Butyrate is mainly metabolised 
in colon cells whereas acetate and propionate are metabolised in the liver and other organs. This raises 
the exciting possibility that changes to the abundance of butyrate producing bacteria differentially 
affect histone acylations in colonocytes rather than changes to acetate producing bacteria. Therefore, 
addition of a diet or probiotic that promotes butyrate production could also promote histone 
acylations. This may be complicated avenue to investigate as there is much cross-feeding between 
bacteria in the gut lumen. An interesting further study could test transplantation of butyrate 
generating bacteria, such as E. rectale which can use complex polysaccharides, into germ-free mice. 
This would reduce inter-experimental variability and enable more direct assessment of the effect of 




4.3.5 How do histone acylations relate to the effects of fibre SCFAs on gut health? 
Fibre is thought to protect against colon cancer (McIntyre et al., 1993; Cook and Sellin, 1998; Topping 
and Clifton, 2001; Aune et al., 2011). However, the beneficial effects of fibre may be dependent on 
the composition of the microbiota and its ability to ferment fibre into SCFAs. The presence of fibre in 
the diet has been studied in relation to the presence of different microbial species and biomarkers of 
health (Flint et al., 2012), but has not been investigated in relation to the presence of histone 
modifications in the colon. We observed that changing the fibre content of the diet can influence 
histone acetylation and crotonylation, but we did not see any increases in these hPTMs with higher 
fibre doses. However, we have observed reductions in histone acetylation and crotonylation with 
reducing fibre dose. The pleiotropic effects of SCFAs are thought to be due to their multiple modes of 
action on intestinal cells. GPCR activation has been linked to energy homeostasis, HDAC inhibition to 
apoptosis and metabolism of butyrate to cell proliferation (Donohoe et al., 2012; Corrêa-Oliveira et 
al., 2016; Kaiko et al., 2016). Histone acylations may couple fibre and SCFAs to their effects on gut 
function and health, but whether this is a consistent interaction and under what circumstances this 






5 Antibiotics induced microbial depletion influences histone 
acylations and gene expression in mouse colon 
5.1 Introduction 
The partnership between the microbiota and host is important for host digestion, immune 
development and defence against pathogens. The molecular mechanisms of this interaction are poorly 
understood but rapidly improving techniques have enabled research into the effects of the microbiota 
to progress and the microbiota have now been implicated in various diseases (Lynch and Pedersen, 
2016). A key part of microbiota-host interactions are the biproducts of microbial metabolism which 
can influence host metabolism and epigenetic state. Microbiota-derived epigenetic modulators 
include folate which is essential for DNA methylation, succinate which inhibits histone demethylases 
and butyrate which is a histone acylation precursor and HDAC inhibitor (Crider et al., 2012; Xiao et al., 
2012; Koh et al., 2016). As host epigenetic state can regulate diverse sets of cellular functions, it is 
essential to determine how the epigenome responds to the microbiota in the context of the intestine. 
There is some evidence that changes to the microbiota can influence histone modifications and gene 
expression in intestinal epithelial cells. Colonization of germ-free mice was shown to promote histone 
acetylation and SCFA supplementation of germ-free mice could partially match histone acetylation 
and methylation patterns of conventional mice (Krautkramer et al., 2016). Zarrinpar et al. (2018) 
observed reductions in SCFAs in the gut lumen, changes to microbial metabolic pathways and 
dysregulation of metabolic genes in the caecum. In this chapter, we will investigate how antibiotic 
treatment influences histone crotonylation, acetylation, butyrylation and hydroxybutyrylation in the 
colon. In addition to testing how global levels of histone acylations change, we plan to investigate 
what the distribution of some of these modifications is across the genome and how it changes in 
response to depletion of the microbiota. Our group previously showed that H3K18cr is abundant in 
intestinal epithelial cells and is associated with TSS and H3K4me3 (Fellows et al., 2018). However, we 





to genomic elements such as enhancers and promoters. In addition, no studies so far have investigated 
how crotonylation or acetylation change at specific sites in response to depletion of the microbiota. 
To provide a direct comparison to H4K8cr we plan to investigate H4K8ac, a mark which has been linked 
to cancer progression, male germline programming and transcriptional changes in the lifecycle of 
Plasmodium falciparum (Morinière et al., 2009; Vlaicu et al., 2010; Gaucher et al., 2012; Sánchez-
Molina et al., 2014; Gupta et al., 2017). However, little is known about the distribution of H4K8ac in 
colon and liver, both microbial metabolite-influenced tissues. Therefore, we will profile H4K8ac in 
these tissues, determining if it is related to enhancers or promoters and whether it changes in 
response to microbial depletion by antibiotic treatment.   
5.2 Results 
5.2.1 Antibiotic treatment reduces histone acylations  
In chapter 4, we observed that the no fibre diet showed a significant reduction in many histone 
acylations, which could be due to the reduction in butyrate concentration in the colon lumen. We 
hypothesised that depleting the microbiota by antibiotic treatment would have a similar effect to 
removing fibre in that it would reduce the production of SCFAs and may therefore reduce abundance 
of histone acylations. We performed two independent experiments where mice were gavaged for 
three days with a mixture of antibiotics to deplete the microbiota. 16S sequencing of faecal samples 
confirmed that the gut bacterial load had been reduced (Figure 5.1) and SCFA measurements in serum 
and colon lumen showed a clear reduction in acetate, propionate and butyrate concentrations (Figure 
5.2). Western blotting of colon extracts showed that many histone acylations were significantly 
reduced, as can be seen from the blots (Figure 5.3). The quantifications of band intensity relative to 
H3 loading from both experiments are shown on the same graph (Figure 5.4). In particular, H4K8cr 
showed a strong reduction in both experiments on antibiotics treatment, with a p value of 0.0004 
from the two-way ANOVA test. H4K8ac, H4K12ac, H3K18cr and Kcr H4 were also significantly reduced 
but H4K8bu, H3K18ac and Kcr H3 did not significantly change. HDAC abundance was also tested, 
showing a significant upregulation in HDAC2, but not HDAC1 or HDAC3. In a previous chapter, 
preliminary data suggested that HDAC2 could remove acetyl and crotonyl-groups from histones in 
vitro (Figure 3.14). This could explain the reduction in histone acylations on antibiotics treatment. 
Interestingly, H3K18β-HBu increased significantly. Potentially, it could respond to a different set of 
cues to the other histone acylations tested here. 
These results were interesting, particularly the striking reduction in H4K8cr suggesting a sensitivity to 




treatment, meaning that we wanted to perform a further experiment to make sure that these changes 
were biologically relevant. Kcr H3 produced a slight reduction which was potentially interesting but 
the change overall was not significant. A power calculation revealed that the statistical test was 
underpowered and for the effect size observed here, more samples would be required to achieve 
enough power to reach significance. Therefore, a further experiment was performed with the BL6 
mice but with more biological replicates in each group. As in Figure 5.3 and Figure 5.4, a significant 
reduction was seen in H4K8cr, H4K8ac, H4K12ac and Kcr H4 (Figure 5.6 and Figure 5.6). This time, 
H3K18ac and Kcr H3 were also reduced significantly. Interestingly, the effect of antibiotic treatment 
on H4K8ac was more pronounced compared to the experiments in Figure 5.3 and Figure 5.4, whilst 
H4K8cr was less. It seems that the direction of the change is consistent between experiments but the 
degree of difference and significance varies. This could simply be due to technical differences in how 
the experiment was performed. In this experiment, we also observed significant reductions in 
H4K16ac, H3K9ac and Kac H4, whilst Kac H3 was borderline significant (p = 0.0502). This suggests that 
the effect of antibiotics treatment is not limited to H4K8ac or H4K12ac but broadly affects many acetyl 
marks. However, we cannot rule out that some other histone acetyl marks may not change particularly 
as the effects on Kac were less pronounced. In conclusion, in three independent experiments, histone 
crotonylation and acetylation show a clear reduction on antibiotics treatment. 
To see if antibiotics treatment reduced more than just histone acetylation and crotonylation, we also 
tested how paradym histone methylation marks changed. Figure 5.6 shows that whilst a downward 
trend was observed in the active mark H3K4me3, this was not significant. No significant changes were 
observed for the repressive H3K9me2, H3K9me3 or H3K27me3 which showed a slight upward trend. 
As histone methylation marks are not thought to be influenced by SCFAs, this suggests that the effect 
of antibiotics treatment on histone acetylation and crotonylation could be due to changes in SCFA 
concentrations. However, we cannot conclusively state this as the abundance of other histone methyl 
marks or the gut luminal concentrations of other microbial metabolites such as folate have not yet 
been tested. 
The effect of antibiotic treatment on HDAC abundance was also investigated. HDAC2 did not change, 
in contrast to the previous experiments with antibiotics (Figure 5.3 and Figure 5.4), whilst HDAC1 
decreased slightly (Figure 5.6). We would expect a reduction in HDAC1 abundance to increase histone 
acetylation and crotonylation, but they decrease. Furthermore, the changes to HDAC1 and HDAC2 are 
not consistent between the experiments in Figure 5.3 and Figure 5.6. This result, in combination with 
the inconsistent changes to HDAC abundance on high fibre diet suggests that this is not the main 





Figure 5.1. Antibiotic treatment in mice reduces gut bacterial load 
Bacterial load of mouse faecal samples was determined by qPCR pf 16S rDNA and is expressed as relative amount 
of bacterial DNA per gram of faeces. Faecal samples were from mice used in experiment 2 (Figure 5.3). Bacterial 
load estimation was performed by Marco Aurelip Ramirez Vinolo’s group. 
 
 
Figure 5.2. Antibiotic treatment in mice reduces luminal and serum SCFA concentrations 
SCFA concentrations in the colon luminal content and serum of mice from experiment 2 (Figure 5.3) were 
measured using gas chromatography (n≥3). Unpaired t-tests were conducted for luminal measurements and one 
sample t-tests for serum measurements (due to values of zero), both with a threshold p value of 0.05. Values of 







Figure 5.3. Antibiotic treatment reduces histone acylations in mouse colon 
Mice were gavaged with a mixture of antibiotics for three days followed by western blotting of mouse colon 
extracts using the specified antibodies. Two independent experiments (experiment 1 in parts a, c and e and 
experiment 2 in parts b, d and f) are shown with three or four mice per condition. Blots are grouped into different 





Figure 5.4. Quantifications of western blots on antibiotics treated mice 
The western blots from Figure 5.3 were quantified and plotted relative to the histone loading control and the 
average of the control group. The anti-H3K18bu blot was not quantified due to high background. Both 
experiments are shown on the same graph and two-way ANOVA was performed using experiment and treatment 




difference between experiments, meaning that antibiotics treatment had the same effect on all histone 
modifications or HDAC abundances in both experiments, except HDAC3.  
 





Mice were gavaged with PBS or a mixture of antibiotics. Five mice were used in the untreated group and six mice 
in the antibodies treated group. Western blots of mouse colon extracts probed with the specified antibodies. 
The black lines indicate where a band was spliced out due to a problem with one of the samples.  
 
Figure 5.6. Quantifications of western blots on antibiotics treated mice  
Mice were gavaged with PBS or a mixture of antibiotics. Five mice were used in the untreated group and six mice 




and the average of the control group. Unpaired t-tests were performed and the p values are shown on the 
graphs. The p value threshold for significance was 0.05.  
5.2.2 The effect of antibiotic treatment on histone acylations in colon organoids 
Whilst the effect of antibiotics treatment on histone acetylation and crotonylation in mice may be due 
to the reduction in luminal bacterial content and subsequent reduction in SCFAs, it is also possible 
that the antibiotics themselves can have an effect. We planned to treat colon organoids with the same 
mixture of antibiotics as those used to gavage the mice. The dose used to treat mice was high, but we 
could not be sure how much the concentration had been diluted by the stomach and small intestine 
during transit. Therefore, we performed an initial test of different concentrations of the antibiotics 
mix whilst keeping the ratio between the antibiotics the same and monitoring the organoids to check 
that they were still growing well. Figure 5.7 shows western blotting of colon organoid extracts using 
different acyl antibodies. Antibiotics treatment did not change H3K18ac or Kcr H3. Treatment 
increased H4K8cr but only at the A3 condition. There was no linear relationship between antibiotics 
concentration and H4K8ac, H3K18cr or Kcr H4 as the modification was lower with higher antibiotic 
doses (A1 and A2) than lower antibiotic doses (A3 and A4), but was lowest in the untreated condition 
(A0). Therefore, whilst antibiotics treatment produced a reduction in histone crotonylation and 
acetylation in the mouse colon, in colon organoids there is no linear change in these modifications 
because of treatment (Figure 5.7). However, although there are no dose-dependent changes to 
histone acetylation or crotonylation, antibiotics treatment does influence their abundance in this 
experiment. As this experiment was only performed once, further experiments are required to 
determine if the antibiotics themselves can influence these histone modifications. The in vivo situation 
is much more complex. Antibiotics are diluted in their transit through the gastrointestinal tract and 
may be modified by host and microbial enzymes. Furthermore, the colon contains thick mucus layers, 
which could protect the colonocytes from the immediate effects of antibiotics and the crypt structure 
further protects stem cells, which in colon organoids are directly exposed to the media. Therefore, to 
assess whether antibiotics can influence histone modifications in colonocytes in vivo, antibiotics 





Figure 5.7. The effect of antibiotics treatment of colon organoids on histone acylations 
Colon organoids were treated with a mix of antibiotics in the same ratio as that used in the mouse. A0 is without 
antibiotics, and A1 is with 500 μg/ml metronidazole, 250 μg/ml vancomycin hydrochloride, 500 μg/ml ampicillin 
sodium salt, 500 μg/ml neomycin sulphate and 500 μg/ml gentamicin. Concentrations decrease two-fold 
stepwise from A1 (500/250 μg/ml), to A2 (250/125 μg/ml), to A3 (100/50 μg/ml) and finally to A4 (50 or 25 
μg/ml). Western blots of whole organoid extracts were analysed by western blot using the specified antibodies. 
Quantification is shown to the right with background subtracted and relative to anti-H3 blot and the A0 
condition. For the anti-H4K8ac blot, quantifications are relative to the A1 condition as no band was visible for 
A0. The anti-Kcr blot was quantitated separately as H3 and H4 bands.  
5.2.3 Antibiotic treatment reduces histone acylations in Balb/c mouse colon but the effect of 
treatment is not changed by ACAD deficiency 
We were interested in the mechanism by which antibiotic treatment reduced histone acylations. ACAD 
catalyses the conversion of butyryl-CoA to crotonyl-CoA as part of the beta-oxidation pathway and 
would be important in the metabolism of butyrate to histone crotonylation. When mice were treated 
with antibiotics, both the wild type and ACAD deficient mice showed significant reductions in all 
histone acetylation, crotonylation and butyrylation marks tested in the colon (Figure 5.8). These 
results seen in Balb/c mice are consistent with those seen in BL6 mice (Figure 5.3, Figure 5.4, Figure 
5.5 and Figure 5.6). We then ran the western blots with the order switched around, to compare ACAD 
deficiency with wild type in control mice or in antibiotics treated mice. No clear differences could be 
seen from the western blots of colon extracts (Figure 5.9) and two-way ANOVA of the band 
quantifications confirmed that the effect of genotype was not significant (Figure 5.9). This agrees with 














Wild type mice or those with a deficiency in ACAD were treated with antibiotics or PBS (control) by gavage and 
extracts of colons investigated by western blot using the specified antibodies. Mouse colon extracts were probed 
with different antibodies for ACAD deficient (ACAD -/-) (a) or wild type mice (b). The line on one of the blots 
indicates where a band was spliced out due to missloading of a sample which was reloaded in the lane to the 
right. (c) Quantifications of the western blots. Both genotypes are shown on the same graph with band 
quantifications relative to the anti-histone H3 quantification and the average of the control group. For ACAD 
deficient acetyl- and crotonyl-lysine blots, the third antibiotics H3 band was also used to quantify the fourth acyl 
band as the fourth H3 band had a transfer problem. Two-way ANOVA was performed using genotype and 
treatment factors. The p values of the effect of treatment are plotted on the graphs, with p values of > 0.05 as 








Figure 5.9. ACAD deciciency does not alter histone acylations in colon 
Wild type mice or those with a deficiency in ACAD (ACAD -/-) were treated with antibiotics or PBS (control) by 
gavage and extracts of colons investigated by western blot using the specified antibodies. Mouse colon extracts 
probed with different antibodies for control mice (a) or antibiotics treated mice (b). Gaps in part a are where 




where a band was spliced out due to missloading of a sample which was reloaded in the lane to the right. These 
are the same samples as in Figure 5.8 but the order is switched to compare genotypes rather than treatment. 
(c) Quantifications of the western blots. Both treatments are shown on the same graph with band quantifications 
relative to the anti-histone H3 quantification and the average of the control group. Quantifications of H3 
intensity only included the upper band, the lower band likely being due to a small amount of protein 
degradation. Two-way ANOVA was performed with genotype and treatment factors. The p values of the effect 
of genotype are plotted on the graphs, with a threshold p value of 0.05, n = 5. 
 
5.2.4 The effect of antibiotics treatment and ACAD deficiency in mouse liver 
Some SCFAs, in particular acetate and propionate, are released into the portal circulation where they 
are metabolised in the liver (den Besten et al., 2013). To test if antibiotics treatment altered histone 
acetylation in the liver, we performed western blots on liver extracts from wild type or ACAD deficient 
mice treated with antibiotics (Figure 5.10). Histone acetylation was reduced in wild type mice, as 
detected with an anti-Kac antibody, in agreement with that seen in the colon. In addition, ACAD 
deficiency reduced histone acetylation in control or treated mice to a level similar to the antibiotics 
treated wild type. As ACAD catalyses an important step in beta-oxidation to produce acetyl-CoA, ACAD 
deficiency could mean that liver cells cannot effectively use fatty acids resulting in low acetyl-CoA 
levels and histone acetylation even with a healthy microbiota. If acetyl-CoA is already low in ACAD 
deficient mice, this could also mean that antibiotics does not reduce it any further. The difference in 
the effects of ACAD deficiency between colon and liver may be due to the role of the liver as an 
essential metabolic organ which performs a variety of biochemical transformations meaning that 
ACAD is more important for the functions of the liver. Further experiments are necessary to elucidate 
the effect of antibiotics treatment and ACAD deficiency on Kac in the liver. Interestingly, H3K18ac was 
reduced only in the ACAD deficient mice on antibiotics treatment. This suggests that other acetyl 
marks are responsive to ACAD activity, possibly including H4K8ac, but the blot has too high 
background to be sure. A technical repeat is needed to investigate how H4K8ac changes in the liver 
on antibiotics treatment. It would also be interesting to determine the effects on ACAD deficiency on 






Figure 5.10. The effect of antibiotics treatment on histone acetylation in mouse liver 
Wild type mice or those with a deficiency in ACAD were treated with antibiotics or PBS (control) by gavage and 
extracts of livers investigated by western blot using anti-Kac, anti-H3K18ac, anti-H4K8ac and anti-histone H3 
antibodies. Quantifications are shown for each band with values relative to the H3 quantification and the 
average of the control wild type group. CTL is control, ABX is antibiotics. The anti-H4K8ac blot was not quantified 
due to high background. One-way ANOVA was performed and the pairwise comparisons of the difference 
between control and antibiotics are shown on the graph (correction with Holm-Sidak method), n = 4. 
 
5.2.5 Characterisation of H4K8 acetylation and crotonylation in colon carcinoma cells 
Histone crotonylation and acetylation are associated with active gene expression (Sabari et al., 2015). 




antibiotics treatment and whether these changed in expression. H4K8cr was highly responsive to 
antibiotics treatment in previous experiments (Figure 5.3 and Figure 5.6), making it a good target for 
investigating how its genomic localisation changed. As H4K8cr ChIP had not been performed before 
and the available antibodies were not validated for ChIP, we first tested it in colon carcinoma cells. 
We did not know what the genomic distribution of H4K8cr would be but we supposed that it might be 
similar to H3K18cr. KLF11 and KLF13 had high H3K18cr, whilst CYS1 had low H3K18cr in a previous 
ChIP-qPCR experiment on small intestinal crypts (Figure 4.3). QPCR analysis of H4K8cr suggested that 
crotonyl marks had been specifically pulled down as KLF11 was 2 to 7-fold higher than the negative 
target CYS1 (Figure 5.11a). There was some variability between technical repeats and no clear 
difference between crotonate treated and untreated cells. However, when the ChIP DNA library was 
sequenced, the enrichment was marginal to non-existent with no difference between the crotonate 
treated and untreated conditions (Figure 5.11b). This lack of enrichment over input was also seen in 
the scatter plot of read counts in the H4K8cr ChIP against input, showing that read density in the ChIP 
was very similar to input (Figure 5.11c). Additionally, a cumulative distribution plot did not show any 
clear differences between the crotonate treated H4K8cr ChIP, untreated H4K8cr ChIP and input 
(Figure 5.11d). As the ChIP had low recovery relative to input (0.07 – 0.44 % of input for KLF11), small 
differences between targets in qPCR could easily be interpreted as high fold-enrichment. Additionally, 
with only one positive target in the qPCR it is hard to know if the antibody could effectively pull down 
the crotonylated chromatin. Crotonylation is low in abundance relative to acetylation. In the colon 
H3K18cr is present on 2 % of H3 histones, compared to H3K18ac on 30 % of H3 histones (Fellows et 
al., 2018). This mass spectrometry analysis, performed by members of the Tiziana Bonaldi group, 
found that H4 crotonylation was less abundant than H3K18cr. The abundance of H4K8cr across the 
genome could have been so low in HCT116 cells that many of the reads in ChIP-seq were distributed 
to background regions.   
We also tested H4K8ac by ChIP-seq as this mark was also reduced on antibiotics treatment. In contrast 
to H4K8cr, H4K8ac ChIP-seq produced clear enrichment over input with mostly sharp peaks (Figure 
5.12a). Investigating where H4K8ac peaks were relative to genes revealed an enrichment for the TSS 
(Figure 5.12b), in agreement with a study by Hayashi-Takanaka et al. (2015) that found H4K8ac was 
associated with TSS in embryonic stem cells. Filtering MACS peaks by their position showed that the 
majority of peaks are at the start of genes (63 %), with a lesser proportion in the gene body (23 %) and 
only a small proportion outside of genes (12 %) (Figure 5.12c). Wang et al. (2008) found that H4K8ac 
was present in transcribed regions of active genes, which could explain the presence of this mark in 
the gene body. Out of 58270 genes annotated in the human genome, 10632 contained a MACS peak 




coding genes were included, 8264 out of 19836 protein-coding genes contained a H4K8ac MACS peak 
(41.6%). The abundance of H4K8ac was correlated with gene expression (Figure 5.12d). When read 
counts at TSS were grouped according to the expression of that gene as determined by RNA-seq, the 
level of H4K8ac at TSS increased with increasing gene expression. There was no correlation in the 
input. There were a few outliers, meaning that for some genes, high H4K8ac does not mean high gene 
expression. It could also be because in some cases the TSS of two genes are overlapping. A high level 
of H4K8ac at the TSS of one gene could result in high gene expression but an adjacent gene, which is 
lowly expressed, would still be counted as having high H4K8ac. H4K8ac MACS peaks were present at 
many housekeeping genes, including EIF3A, GAPDH and ACTB. To understand the function of genes 
associated with H4K8ac, we performed gene ontology analysis comparing genes containing H4K8ac 
MACS peaks to a standard reference Homo sapiens list (Figure 5.12e). Chromatin organisation and 
protein acetylation were enriched, suggesting that histone acetylation is involved in the regulation of 
other epigenetic marks and chromatin conformation. Interestingly, a group of dual specificity protein 
phosphatases (MAPK inactivation term) were enriched, along with the cell cycle term and terms 





Figure 5.11. H4K8cr ChIP was not enriched relative to input 
ChIP was performed on sonicated chromatin from HCT116 cells using anti-H4K8cr antibody. Two biological 




DNA from the ChIP procedure using primers against the promoters of the specified genes. CYS1 and SLC4A5 are 
thought to be negative for crotonylation. CA- is untreated cells, CA+ indicates cells treated with 5 mM crotonate 
for 24 hours, A and B are technical replicates. (b) Browser view of a segment from chromosome 6 showing a 
representative profile of H4K8cr ChIP-seq. (c) Comparison of H4K8cr and input by scatter plot with running 
window probes quantitated by linear read count quantitation relative to the largest data store. (d) Cumulative 











Figure 5.12. Characterisation of H4K8 acetylation in human carcinoma cells 
ChIP was performed on sonicated chromatin from HCT116 cells using anti-H4K8ac. Two biological replicates 
were prepared for the ChIP plus an input sample. (a) Browser view of a segment from chromosome 2 showing 
a representative profile of H4K8ac peaks compared to input. (b) Quantitation trend plot of H4K8ac ChIP and 
input using linear read count quantitation of running window probes showing distribution relative to TSS. (c) 
Distribution of MACS peaks at the start of genes, in the gene body or outside genes as shown by a pie chart. 
MACS peaks were created using Seqmonk standard pipeline. (d) Number of H4K8ac reads at TSS relative to gene 
expression. Genes were put into percentile bins according to their enrichment by RNA-seq. The read counts of 
H4K8ac over TSS were quantified and box plot generated according to the expression of that gene for input and 
H4K8ac ChIP. (e) Gene ontology analysis using Panther statistical overrepresentation test of genes containing 
H4K8ac MACS peaks. The standard Homo sapiens reference list was used as background. Terms are grouped in 





5.2.6 Comparison of H4K8ac in mouse colon and liver  
We were interested to see the distribution of H4K8ac in mouse and how it differed between tissues. 
We chose colon and liver as these were most relevant to the microbiota and therefore this data would 
be useful generate qPCR primers for use in further experiments. In agreement with the H4K8ac 
analysis in colon carcinoma cells, H4K8ac in colon and liver are also associated with TSS (Figure 5.13b). 
The browser view of a segment of chromosome 6, shows that in some places H4K8ac is present in 
both liver and colon, whilst in other places it is only present in the liver (Figure 5.13a). Some of the 
differences in the H4K8ac signal between the tissues could be due to technical differences in the 
quality of the libraries as the liver H4K8ac ChIP is more enriched relative to input than the colon 
H4K8ac ChIP. However, this was adjusted for when MACS peaks were generated and enrichment 
normalised between samples. There were 68953 H4K8ac MACS peaks in colon and 92157 H4K8ac 
MACS peaks in liver, of which 14185 and 15013 were in protein coding genes respectively (64.6 and 
68.4 % of total protein coding genes). MACS peaks were present at housekeeping genes such as Eef2, 
Ppia, Actb and Eif3a which have low tissue specificity. Looking at certain genes that are known to be 
tissue specific, liver specific genes such as Itih4, Serpinc1 and Fga only have H4K8ac peaks in the liver 
samples whilst the colon specific genes Vil1, Isx and Mep1a only have H4K8ac peaks in the colon 
samples. To investigate the overlap of H4K8ac peaks in these two tissues at a genome wide level, we 
plotted read counts in MACS peaks in the colon against those in the liver. A large number of H4K8ac 
MACS peaks are present in both tissues (Figure 5.13c). Those MACS peaks with acetylation in only 
colon have the highest enrichment relative to liver and vice versa, as would be expected. To better 
visualise the overlap between liver and colon, we generated Venn diagrams counting every gene or 
promoter that contained a MACS peak in liver or colon (Figure 5.13d). There was a substantial overlap 
between liver and colon which increased when only peaks in promoters were counted. Interestingly, 
of the colon specific acetylated peaks, a greater proportion are at the promoter compared to the 
proportion of promoter associated peaks that are specific to the liver.  
As in the colon carcinoma cells, the majority of H4K8ac in liver and colon was present at the start of 
the gene or in the gene body. However, a substantial proportion (15-25%) of MACS peaks were present 
outside genes. It is well known that many regions outside genes have an important regulatory function 
including in regions called enhancers. We were interested to understand what genomic feature was 
best associated with H4K8ac and if the regions containing H4K8ac outside genes were enhancers. 
Defining regions that are enhancers is problematic, as there is no consensus sequence. So far, we have 
described promoters as 500 bp upstream or downstream of the transcription start site but in fact, 




best estimate of enhancer and promoter regions we used a mouse candidate regulatory element track 
from ENCODE, a higher-level analysis, which assembled data from ChIP-seq on histone modifications 
and chromatin accessibility analysis such as ATAC-sequencing. Figure 5.13e shows the proportion of 
H4K8ac peaks that overlap regulatory elements in liver only, colon only or those peaks that are present 
in both tissues. For the tissue specific genes, the regulatory element track overlapped with around 78-
81% of H4K8ac peaks. Most interestingly, the regulatory element track explained 99% of the H4K8ac 
peaks that were present in both tissues. In conclusion, the localisation of H4K8ac appears to be broad 
and is not restricted to a single tissue.  
To investigate the function of genes that contain H4K8ac in a tissue specific manner, we performed 
gene ontology analysis. This included only peaks that were overlapping a gene, as it is difficult to 
identify which gene or group of genes that an enhancer element is regulating. We made gene ontology 
plots that compare the fold enrichment to statistical significance with the size of the points differing 
based on the number of genes in an ontology term (Figure 5.13f). We also coloured the terms by 
categories that were based on their functions. Many of the terms that come up in the gene ontology 
analysis of H4K8ac in only colon or only liver, imply regulation of tissue specific functions. In the colon, 
terms including homeostasis, sequestering of calcium ions and regulation of cellular component 
biogenesis are identified as particularly significant or enriched. The colon is a highly regenerative tissue 
meaning that generation of new biomolecules would be constantly required. In the liver, terms such 
as lipid translocation, metabolism, transport and localisation come up strongly in line with the liver’s 
important role in lipid processing. Intriguingly, terms such as development and signalling also appear. 
For those genes with acetylation in both liver and colon, the function seems to be more associated 
with active gene expression including nucleic acid metabolism, translation initiation, elongation and 
termination. Fascinatingly, chromatin remodelling is highly enriched, matching what was seen 
previously in the colon carcinoma cells. This makes sense as histone acetylation is involved in switching 
the chromatin to a more open state. As the same background list was used for gene ontology analysis 
of the liver and colon specific H4K8ac and those present in both tissues, the significantly enriched 
terms may reflect the patterns of gene expression present in each tissue or of housekeeping genes 
present in both. As histone acetylation is associated with active genes, this still suggests that H4K8ac 





Figure 5.13. Comparison of H4K8 acetylation in liver and colon 
ChIP was performed on sonicated chromatin from mouse colon or liver using anti-H4K8ac antibody. Three 
biological replicates for the ChIP and an input were generated for each tissue. (a) Browser view of a segment 




plot of H4K8ac ChIP and input using linear read count quantitation of running window probes showing 
distribution relative to TSS. (c) Scatter plot of MACS peaks comparing colon and liver with peaks only in colon or 
only in liver highlighted in blue and red respectively. (d) Venn diagrams of genes or promoters containing H4K8ac 
MACS peaks showing the overlap between colon and liver (e) Comparison between H4K8ac peaks and a 
regulatory element track from ENCODE which compiles various markers of enhancers and promoters. Pie charts 
show the overlap for MACS peaks only in the colon, only in the liver or those only in both tissues. (f) Gene 
ontology analysis using Panther statistical overrepresentation test of genes containing H4K8ac MACS peaks in 
just colon, in both tissues or in just liver. The standard Mus musculus reference list was used as background. 
Terms are grouped in to colours by function and interesting terms are labelled on the graph. 
5.2.7 Chromatin state analysis in the liver 
As H4K8ac was strongly linked to regulatory elements in liver and colon, we wanted to find out how it 
was related to other histone marks and in particular those associated with different chromatin states. 
In the liver, we compared H3K27me3 which is associated with gene silencing, H3K4me3 which is 
associated with promoters, H3K27ac and H3K4me1 which are marks of enhancers and H3K36me3 
which is a mark of transcription elongation to H4K8ac. It is important to note that there is some 
overlap between these categories, as H3K27ac and H3K4me1 can be found at promoters and 
H3K4me3 can be found at enhancers (Pekowska et al., 2011). We used the ChromHMM tool, which 
groups the genome into states according to the presence of different chromatin markers, to identify 
the optimal number of chromatin states (Ernst and Kellis, 2012). Figure 5.14 shows heat maps of the 
emission (part a) and transition (part b) parameters of a six-state model. Each state has been assigned 
a label, such as promoters or enhancers, according to which histone modifications were present. 
Chromatin state 1 (promoters) typically contains regions with high H3K4me3, whilst chromatin state 
3 (enhancers) typically contains high H3K27ac. Actively transcribed (state 4, high H3K36me3), 
repressed (state 6, high H3K27me3) and background (state 5) regions contained little H4K8ac. Instead 
H4K8ac strongly associates with both enhancer and promoter marks in agreement with the findings 
in Figure 5.13. Fascinatingly, state 2 contains mostly H4K8ac with a low level of H3K4me1 (Figure 
5.14a). In Figure 5.14c, a representative browser view is shown of the profiles of the different histone 
modification ChIP-seq data used in the ChromHMM analysis along with with six states derived from 
this data. This reveals that chromatin state 2 contains H3K4me1 and H4K8ac and lower levels of 
H3K4me3 or H3K27ac. These are often close to promoter and enhancer regions. There are also some 
regions of chromatin state 2 are distinct from state 1 or 3 and could have their own regulatory 
function. However, further investigation will be necessary to determine the role of this predominantly 
H4K8ac/H3K4me1 state. Interestingly, Rhbdl3 gene at the left of the browser view appears to be in a 




along with repressive-associated H3K27me3 (state 6 surrounding the TSS-associated state 1). Rhbdl3 
contains very low levels of the transcription-associated H3K36me3 (state 5) over its gene body. This is 
in contrast to Zfp207 and Psmd11, which contain high H3K4me3 but low H3K27me3 at the gene start 
and high levels of the transcription-associated H3K36me3 over the gene body. This suggests that 
Rhbdl3 is poised for transcription, whilst Zfp207 and Psmd11 are being actively transcribed. 
 
Figure 5.14. Chromatin state analysis using histone modifications in mouse liver 
Chromatin state analysis performed using ChromHMM using H4K8ac ChIP-seq data from liver (shown in Figure 
5.13) and publicly available ChIP-seq data from adult liver for the specified histone modifications from ENCODE. 
Two biological replicates are used for the ENCODE data and three biological replicates for H4K8ac. A six-state 
model was used with a 200 bp window size. (a) Heat map of emission parameters with chromatin state numbers 
on the left, histone modifications below and state descriptions shown to the right. (b) Heat map of transition 




representative distribution profile of H3K4me3, H3K27ac, H3K4me1, H3K36me3, H3K27me3 from ENCODE, 
H4K8ac and input data sets used in the ChromHMM program along with the chromatin state annotation tracks 
determined from the six-state model (S1-6).  
5.2.8 Comparison of Kcr, H4K8ac and H3K18cr in untreated mouse colon 
Histone acetylation and crotonylation occur at many of the same positions on the histone (Tan et al., 
2011) but relatively little is known about how their genomic distributions compare. Therefore, we 
compared the ChIP-seq profiles of H4K8ac, Kcr and H3K18cr in untreated mouse colon (Figure 5.15). 
H3K18cr ChIP-seq data was previously generated by Payal Jain and Claudia Stellato (Fellows et al., 
2018). A representative segment from chromosome 2, including close-ups of the distribution over four 
genes, shows that the position of the peaks in H4K8ac, Kcr and H3K18cr are strikingly similar (Figure 
5.15a). We grouped the genome into percentile bins based on the level of gene expression in an RNA-
seq data set from untreated mouse colon. The box plots in Figure 5.15e show the number of read 
counts over the TSS in each percentile bin for H4K8ac, H3K18cr or Kcr. All three modifications show 
increasing read counts at the TSS as gene expression increases, whilst input shows no change. We 
called MACS peaks of each ChIP-seq data set and investigated how these peaks overlapped, looking at 
peaks in genes. The H4K8ac, Kcr and H3K18cr peaks were highly overlapping (Figure 5.15b). Nearly all 
of the H3K18cr MACS peaks overlapped with H4K8ac and Kcr peaks (9649/10,086 or 96 %). 52 H3K18cr 
MACS peaks did not overlap with H4K8ac or Kcr MACS peaks. This was not because H4K8ac or Kcr 
were absent in these regions but just that the level did not reach the threshold to be called as a peak. 
Two examples of this are shown in Figure 5.15d, a peak is called only for H3K18cr but there is some 
enrichment for H4K8ac and Kcr as well. For H4K8ac, a lower proportion of peaks overlapped with 
H3K18cr and Kcr (9649/18,558 or 52 %). The lower proportional overlap of H4K8ac may be because 
there were more MACS peaks for H4K8ac than H3K18cr (18,588 and 10,086 respectively), possibly 
because the H4K8ac data set was more enriched relative to input than H3K18cr. To investigate what 
the function of genes containing all three modifications could be, we performed gene ontology 
analysis of the 9649 genes containing H4K8ac, Kcr and H3K18cr MACS peaks. In Figure 5.15c the 
significance of each gene ontology term is plotted against fold enrichment, with the size of point 
corresponding to the number of genes in that term and the colour to the functional category. Terms 
associated with a range of functions are significantly enriched relative to the Mus musculus 
background list. These include protein polyubiquitination, protein lipidation, autophagosome 
assembly, protein targeting, protein folding, cytoskeleton organisation and carbohydrate derivative 
biosynthetic process. Phosphatidylinositol metabolic process shows the greatest enrichment relative 




number of genes in that term. Fewer genes reach higher enrichment more easily whilst a large number 
of genes in a term are more likely to be significant. In conclusion, H4K8ac, H3K18cr and Kcr are highly 
overlapping, correlated with higher levels of gene expression and diverse cellular functions. 
The quantitation trend plot in Figure 5.15f, summarising read counts over TSS for the whole genome, 
shows that H4K8ac, H3K18cr and Kcr are highest enriched at the TSS. However, when exploring the 
ChIP-seq profiles of H4K8ac, Kcr and H3K18cr in SEQMONK, it seemed that whilst many peaks were at 
the start of genes, there were also peaks present in the gene body or outside genes, as the 
representative browser view in Figure 5.15a shows. Histone acylation MACS peaks were present at 
the gene start (+/- 500 bp of the TSS), gene body (the gene excluding the start region) and outside 
genes, as shown in the pie chart in Figure 5.15g. The proportions of MACS peaks in different regions 
did vary between the histone modifications. 34.5 % of H4K8ac MACS peaks were present at the gene 
start compared to 56.8 % for H3K18cr or 48.8 % for Kcr. H3K18cr also had the least peaks outside 
genes of 17.3 % compared to 19.7 % for Kcr or 27.2 % for H4K8ac. H3K18cr and Kcr were more similarly 
distributed between the three categories than H4K8ac. As some peaks were present outside genes, 
we thought that some of these might be related to enhancer elements. We compared each ChIP-seq 
MACS peak set to a mouse candidate regulatory element track from ENCODE. The majority of H4K8ac, 
Kcr and H3K18cr MACS peaks overlapped with regulatory elements (Figure 5.15h). If anything, 
H3K18cr and Kcr overlapped slightly more than H4K8ac, although they were very similar. The overlap 
of H4K8ac with regulatory elements is intermediate between what we previously observed for H4K8ac 
in colon only and H4K8ac in both liver and colon (Figure 5.13e).  
Whilst this is interesting, it does not tell us about how these marks relate to other paradym marks 
such as those associated with promoters or repressive regions. Therefore, we compared these marks 
with H3K4me1, H3K4me3, H3K27ac and H3K27me3 using ChromHMM in the same way as for liver. 
No adult colon data could be found from ENCODE but some relevant data was available on GEO. Only 
one replicate was available for H3K27me3 and the transcription-associated H3K36me3 ChIP-seq has 
not been done in mouse colon, to our knowledge. The emission and transition parameter heat maps 
from the ChromHMM analysis in colon are shown in Figure 5.16a and b. A six-state model was chosen 
as it revealed three enhancer-like states (1-3) with slightly different abundances of H3K18cr, Kcr, 
H3K27ac, H4K8ac and H3K4me1 and a promoter-like state (state 4) containing all of these marks and 
also H3K4me3. States 1 and 2 mainly contained H4K8ac, H3K27ac and H4K4me1. State 5 was 
background and state 6 was repressed, as it was mainly H3K27me3. The heat map of transitions from 
the ChromHMM analysis shows that there was some similarity between state 1 (enhancer-like) and 
state 5 (background). The positions of each state were added as annotation tracks into SEQMONK to 




Slc26a4 may be a poised gene as it contained state 4 (promoter), surrounded by state 6 (repressed) 
at the start of the gene. Whilst H3K4me3 was only present at promoters, the other active-associated 
marks were also distributed over the gene body and showed a highly similar profile. States 1-3 tended 
to be in the same regions and may be marking slight differences in the relative distribution of each 
modification. Possibly, a four- or five-state model could be adopted in further analysis. This 
ChromHMM study supports our previous findings that H4K8ac and Kcr are associated with active 
marks, as they were found in many of the same positions as the enhancer- and promoter- associated 









Figure 5.15. The association of H4K8ac, H3K18cr and Kcr with genomic features in mouse colon 
Analysis was using anti-H4K8ac (blue), anti-Kcr (green) and anti-H3K18cr (red) antibodies in control (PBS or 
untreated) mouse colon epithelium extracts. Input is in yellow. H3K18cr ChIP-seq data was from Fellows et al. 
(2018) (a) Browser view of a segment from chromosome 2 showing a representative profile of ChIP peaks as 
well as close-ups of some genes around that region of chromosome 2. Linear read count quantitations of running 
window probes are shown with enrichment normalised. H3K18cr is a combination of two biological replicates, 
H4K8ac is a combination of three biological replicates, Kcr is a combination of four biological replicates and input 
is a combination of four biological replicates from H4K8ac, H3K18cr and Kcr data sets. (b) Overlap between 
H4K8ac, H3K18cr and Kcr data sets. MACS peaks were generated against each data set, combined in an 
annotated probe list and deduplicated. Gene lists were made based on their overlap in one or more data sets 




genes have MACS peaks only in H3K18cr, 9 genes have MACS peaks in H3K18cr and Kcr, and 230 genes have 
MACS peaks only in the Kcr data set. (c) Gene ontology analysis of genes containing H4K8ac, H3K18cr and Kcr 
MACS peaks using Panther statistical overrepresentation test against a standard Mus musculus reference list. 
Fold enrichment is plotted against significance. Terms are coloured based on functional categories, with size 
corresponding to the number of genes in the term in the input list. (d) Browser view of Pde4dip and Nod1 genes 
with positions of MACS peaks shown as annotation tracks, coloured according to the ChIP-seq data set. (e) 
Number of reads at TSS relative to gene expression. The read counts of H4K8ac, H3K18cr, Kcr or input over TSS 
were quantified and enrichment between ChIP-seq data sets normalised. Genes were put into percentile bins 
according to their normalized RNA-seq read counts from lowly expressed (0-20 %) to highly expressed (80-100 
%) and box plots generated. (f) Quantitation trend plot of H4K8ac, H3K18cr, Kcr ChIP and input using linear read 
count quantitation of running window probes showing distribution relative to TSS. (g) The proportion of MACS 
peaks in the gene start (500 bp +/- TSS), gene body or outside genes in the H4K8ac, H3K18cr and Kcr data sets 
shown as pie charts. (h) Pie charts showing overlap of H4K8ac, Kcr or H3K18cr peaks and a mouse regulatory 
element track from ENCODE which compiles various markers of enhancers and promoters.  
 




Chromatin state analysis performed using ChromHMM on mouse colon ChIP-seq data. Data sets were H4K8ac 
and Kcr ChIP-seq data (3 and 4 replicates respectively) that I generated. H3K18cr ChIP-seq data were generated 
by Payal Jain and Claudia Stellato (2 replicates), H3K4me3 ChIP-seq data were generated by Jeremy Denizot (3 
replicates) and are available at GEO under the accession GSE96035. H3K4me1 and H3K27ac data were generated 
by Qin et al. (2018), taking the low fibre diet, male samples (3 replicates for each) and are available at GEO under 
the accession GSE99670 (Qin et al., 2018). H3K27me3 data were generated by Lo et al. (2017) (1 replicate) and 
are available at GEO under the accession GSE82181 (Lo et al., 2017). A six-state model was used with a 200 bp 
window size. (a) Emission parameters with chromatin state numbers shown on the left, histone modifications 
below and state descriptions to the right. (b) Transition parameters showing the similarity between the six 
states. (c) Browser view from SEQMONK showing a representative distribution profile of H3K4me3, H3K27ac, 
H3K18cr, Kcr, H4K8ac, H3K4me1, H3K27me3 and input data sets used in the ChromHMM program along with 
the chromatin state annotation tracks determined from the six-state model (S1-6).  
5.2.9 Antibiotics treatment induces differential expression of a large subset of genes 
To understand how antibiotics treatment changes gut physiology, we conducted mRNA-seq on control 
and antibiotics treated mouse colon epithelium to identify how gene expression changes. Differential 
expression analysis was performed using DESeq2 and hits are highlighted on a scatter plot of control 
against antibiotics treated mouse colon (Figure 5.17a). Hierarchical clustering of the more than 800 
dysregulated genes produced two clusters, as would be expected. Cluster 1 is of the 292 down 
regulated genes, labelled in green and cluster 2 is of the 551 up regulated genes, labelled in blue 
(Figure 5.17a and b). The cluster plot in Figure 5.17b shows that there is some variability between 
samples, particularly for the antibiotics treated replicates, but overall the up or down regulation is 
fairly consistent. Gene ontology analysis was performed for up and down regulated gene lists 
separately. Only one gene ontology term, cell adhesion, was identified in the downregulated group 
(Figure 5.17c, right panel). Some bacterial species, such as Bifidobacterium infantis, are thought to 
promote tighter junctions between IECs so that the barrier is maintained (Ewaschuk et al., 2008). 
Therefore, when the microbiota is removed this pathway is downregulated. Ontology analysis of genes 
that were upregulated in gene expression on antibiotics treatment showed enrichment of many terms 
involved in respiration, oxidative phosphorylation, electron transport and ATP synthesis relative to the 
background list of expressed genes in the colon (Figure 5.17c, left panel). Occurance of gene ontology 
terms related to metabolism including lipid metabolism, TCA cycle and isoprenoid biosynthesis were 




compensate for the lack of microbial generation of energetic metabolites. The identification of terms 
such as immune system process, leukocyte activation and response to stimulus in this analysis may 
point towards changes in gut epithelium-environment interactions. Fascinatingly, circadian rhythms 
are also an enriched term, which could mean that the microbiota is involved in maintaining biological 
rhythms of gut functions, a link which has also been proposed in other studies (Paschos and FitzGerald, 
2017).  
 
Figure 5.17. Antibiotics treatment produces substantial changes in gene expression in mouse colon 
RNA-seq was performed on colons from antibiotics treated or control mice. (a) Scatter plot comparing RNA-seq 
of antibiotics treated colon to control colon after probes were generated using the SEQMONK RNA-seq pipeline 




respectively, with a few genes indicated. (b) Hierarchical clustering of differentially expressed genes as identified 
by DESeq2 with a threshold p value of 0.05. Gene labels on the right are approximate positions of that gene in 
the clustering. (c) Gene ontology analysis of antibiotics up regulated (left) or down regulated genes (right) using 
Panther statistical overrepresentation test against a reference list of all expressed genes in the RNA-seq data set 
(13607 genes, excluding unobserved probes). Fold enrichment is plotted against significance. Terms are coloured 
based on functional categories, with size corresponding to the number of genes in the gene ontology term in 
the DEseq2 up or down regulated list.  
5.2.10 Changes to crotonylation correlate with a subset of gene expression changes on antibiotics 
treatment 
As histone crotonylation showed striking reductions by western blot on antibiotics treatment (Figure 
5.3 and Figure 5.6), we wanted to see how its genomic distribution changed and how this was related 
to differentially expressed genes. Initial tests of H4K8cr ChIP-seq in colon carcinoma cells had been 
unsuccessful (Figure 5.11) and whilst H3K18cr ChIP-seq was previously performed on mouse colon 
epithelial cells (Fellows et al., 2018), further ChIP experiments with this antibody were unsuccessful 
(attempted by Mariana Portovedo). Therefore, we performed ChIP-seq experiments on antibiotics 
treated and control mice with anti-Kcr. We found hundreds of MACS peaks which significantly 
increased or decreased crotonylation between control and antibiotics treated mice (Figure 5.18a). In 
particular Schlafen 2 (Slfn2), which is associated with negative regulation of cell growth (Schwarz et 
al., 1998), increased in crotonylation with the highest significance. Erythroid differentiation regulator 
1 (Erdr1) was up-crotonylated 3.7-fold on antibiotics treatment. Expression of Erdr1 has been 
demonstrated to be suppressed by the microbiota (Weis et al., 2018). Gene ontology analysis of the 
genes with higher crotonylation in the antibiotics treated group revealed enrichment of terms related 
to regulation of biosynthetic processes (Figure 5.18e, left panel). Terms such as responses to acid 
chemical, hormone stimulus and retinoic acid were enriched terms in the down crotonylated gene 
group, along with enzyme linked receptor signalling and negative regulation of transcription (Figure 
5.18e, right panel). This last term suggests that loss of crotonylation could be associated with reduced 
gene expression. B4galnt2 was the most significantly down crotonylated gene. This encodes for Beta-
1,4-N-acetyl-galactosaminyltransferase 2 which is an important part of the biosynthesis of Sd(a) 
antigen, a colon specific carbohydrate determinant (Montiel et al., 2003).  
Highlighting the genes that increased in expression (red) or decreased in expression (green) on the Kcr 




expression (Figure 5.18a). This can also be seen if up crotonylated genes (yellow) and down 
crotonylated genes (purple), are highlighted on the RNA-seq volcano plot that shows significantly 
differentially expressed genes (Figure 5.18b). Very few significantly up crotonylated genes overlap 
with significantly down expressed genes and vice versa. We therefore plotted RNAseq fold change 
against Kcr ChIP-seq fold change, of only the significantly changing genes, to see if there was a 
correlation between the two. Figure 5.18c shows that there is a strong positive correlation (R2=0.63), 
revealing that up crotonylated genes tend to also go up in expression. Some such as Slfn2 and Ttyh1, 
which encodes a chloride ion channel, change considerably in both gene expression and crotonylation. 
When the fold changes of all crotonylated genes that overlapped expressed genes were plotted, 
including ones that did not significantly change, there was only a weak positive correlation (R2=0.05, 
Figure 5.19). The overlaps between differentially crotonylated and differentially expressed genes are 
visualised in venn diagrammatic form in Figure 5.18c. Up crotonylated and up regulated genes, and 
down crotonylated and down regulated genes, have highly significant overlaps relative to total 
expressed genes. 9.1% of the total up regulated genes and 4.5% of the total down regulated genes 
also changed in crotonylation. In contrast, the overlaps between up crotonylated and down regulated, 
or down crotonylated and up regulated were not significant. These results suggest that, in a subset of 






Figure 5.18. Changes to histone crotonylation correlate with changes to gene expression in a subset of genes 
on antibiotics treatment 
RNA-seq and Kcr ChIP-seq was performed on colon extracts from control mice or mice treated with antibiotics. 
(a) Volcano plot of genes containing MACS peaks that changed in crotonylation, as identified using Limma 




In cases where there was more than one MACS peak in a gene, only the MACS peak with the greatest fold change 
was included. Unannotated genes e.g. Gm20442 are not labelled. The most significant genes and those that 
changed the most on treatment are labelled. Genes that increase or decrease in gene expression, as identified 
by RNA-seq, are coloured red or green respectively. (b) Volcano plot of differentially expressed genes identified 
using DEseq2 analysis of the RNA-seq data set, using a threshold p value of 0.05 and adjusting for multiple 
testing. Particularly significant or changing genes are labelled, excluding unannotated genes. Genes that increase 
or decrease in histone crotonylation, as identified by Kcr ChIP-seq are coloured yellow or purple respectively. (c) 
XY plot showing the fold change of genes that change in both crotonylation and expression, with a trend line 
showing the relationship between the two. (d) Four-way Venn diagram showing the overlap between up-
crotonylated, up-regulated, down-crotonylated and down-regulated genes on antibiotics treatment (ABX). The 
significance of overlap was tested using a 2x2 two-tailed Chi-square test with Yates correction and the total 
number of expressed genes of 13607, as determined from the RNA-seq data set excluding unobserved probes. 
(e) Gene ontology analysis of more crotonylated (left panel) or less crotonylated genes (right panel) on 
antibiotics treatment using Panther statistical overrepresentation test against a standard Mus musculus 
reference list. Fold enrichment is plotted against significance. Terms are coloured based on functional 
categories, with size corresponding to the number of genes in the gene ontology term in the DEseq2 up or down 





Figure 5.19. Comparison of changes in crotonylation over MACS peaks and changes in gene expression of 
associated genes between colon epithelial extracts from control and antibiotics treated mice 
XY plot showing the fold change of MACS peaks in the Kcr ChIP-seq data set against fold change in the RNA-seq 
data set of control and antibiotics treated mouse colon. When there were more than one MACS Kcr peaks in a 
gene, the MACS peak with the greatest absolute fold change was used. Unobserved values were excluded from 
the RNA-seq list. The trend line was generated in excel and the R squared value is shown on the chart. 
Significantly differentially crotonylated and differentially expressed genes between untreated and control, as 
shown in Figure 5.18c, are highlighted on the graph. 
5.2.11 Effect of antibiotic treatment on the genomic positions of H4K8ac in mouse colon 
We had identified that H4K8ac is a broadly distributed modification across the genome and was 
associated with genes involved in a range of cellular functions (Figure 5.12 and Figure 5.13). As we had 
observed a correlation between crotonylation and gene expression, we wanted to see if this was true 
for H4K8ac which is also depleted globally on antibiotics treatment. H4K8ac ChIP-seq was performed 
on antibiotics treated and control mice, and was compared to the equivalent Kcr ChIP-seq data set 
(Figure 5.20). Over 900 hits were identified in the Kcr ChIP-seq using the LIMMA statistical test, 
although the majority of MACS peaks did not change (Figure 5.20a). In contrast, no LIMMA hits were 
identified in the H4K8ac ChIP-seq data set, despite a similar number of total MACS peaks (20608 in 




up regulated genes (red) were closer to the antibiotics treated group on the y-axis, whilst the Kcr 
MACS peaks that overlapped with antibiotics down regulated genes (green) were more towards the 
control group on the x-axis (Figure 5.20c). In contrast, no such split of red and green was seen for the 
H4K8ac MACS peaks as up and down regulated genes were mixed in their distribution (Figure 5.20d). 
These differences are particularly intriguing considering the striking overlap between H4K8ac and Kcr 
seen in Figure 5.15. Many differentially expressed genes had higher Kcr or H4K8ac levels over TSS 
relative to input (Figure 5.20e and f), but the association of these genes with higher H4K8ac was less 
pronounced. Higher or lower expressed genes were equally associated with the level of Kcr or H4K8ac 
ChIP enrichment. Fold change in Kcr was plotted against fold change in H4K8ac between control and 
antibiotics for those MACS peaks that significantly changed in the Kcr data set (Figure 5.21). MACS 
peaks with higher read counts (in at least one of the replicates) are mainly those that change the least, 
whilst MACS peaks with fewer read counts have higher fold changes. One exception is Erdr1 which 
changes 3.7-fold in Kcr and has high read counts in the MACS peak. The fold changes in H4K8ac are 
similar to the changes in Kcr suggesting that changes to H4K8ac do occur on antibiotics treatment but 
high variability between samples has meant that these changes are not significant. 
In ChIP-seq, changes in enrichment between treatments at particular region can be hard to identify as 
reads are distributed across the genome, meaning that enrichment of a sample at a locus is relative 
to the rest of the genome. Therefore, we tested candidate genes by H4K8ac ChIP-qPCR. We designed 
primers against the start region of genes that had changed most in gene expression, either up or down. 
For the downregulated genes we verified that H4K8ac was present in the ChIP-seq of the untreated 
colon and designed the primer region at that peak site. We also designed some primers against the 
promoter region of genes that were not identified in differential expression analysis. We performed 
ChIP-qPCR and gene targets are grouped into upregulated, downregulated or unchanged in gene 
expression on antibiotics treatment (Figure 5.22). Log scale is used as there was a scale related 
increase in variability between targets. Of the upregulated gene targets tested, two-way ANOVA 
statistical analysis found that overall the effect of treatment was not significant (Figure 5.22, upper 
panel). In the downregulated group, most gene targets were reduced in H4K8ac on ABX treatment 
and two-way ANOVA analysis found that there was overall a statistically significant decrease as a result 
of treatment (Figure 5.22, middle panel). In the group of gene targets which had not changed in gene 
expression, the difference in H4K8ac between treatments was not significant (Figure 5.22, lower 
panel).  We plotted individual graphs of gene targets that changed most on antibiotics treatment, as 
seen from the volcano plots on the right of Figure 5.22, to better visualise the differences in H4K8ac 




Hmgcs2 showed a downward trend and this gene decreased in expression. However, none of these 
changes were significant, possibly due to high variability between samples. 
Klf11 is a gene that showed enrichment in H4K8cr and H4K8ac ChIP-qPCR analysis in colon carcinoma 
cells (Figure 5.11 and Figure 5.12). Additionally, it was downregulated in gene expression on antibiotics 
treatment. Comparing H4K8ac at the start of Klf11 gene between control and antibiotics treated 
mouse colons by ChIP-qPCR showed that this modification is slightly reduced on antibiotics treatment, 
although this difference was not statistically significant (Figure 5.22). We wondered whether this could 
be because the level of H4K8ac was much higher than the other targets. Antibiotics treatment might 
change the breadth of the peak without changing its height. We therefore tested different sites 
around the start of the Klf11 gene by ChIP-qPCR. We then aligned the ChIP-qPCR result to the 
distribution of the H4K8ac ChIP-seq according to the position of the primer at the start of the Klf11 
gene (Figure 5.24). Whilst the level of H4K8ac in qPCR analysis correlated with the level of H4K8ac in 
sequencing analysis, the abundance of H4K8ac actually increased the difference between control and 











Scatter plot of MACS peaks (grey) in Kcr ChIP-seq (a) or H4K8ac ChIP-seq (b) in control against antibiotics treated 
mouse colon IECs. Peaks changing in Kcr or H4K8ac as determined by Limma statistical testing are highlighted in 
blue. No hits were identified for H4K8ac. Scatter plots of MACS peaks (grey) in antibiotics treated mice against 
control, for Kcr (c) or H4K8ac (d). Peaks overlapping with up regulated (red) or down regulated (green) genes, 
as determined by DEseq2 on the RNA-seq data set in mouse colon, are highlighted. Scatter plots of probes 
generated over TSS (+/- 500 bp of gene start) and log2 transformed (grey) in combined Kcr ChIP-seq (e) or 
H4K8ac ChIP-seq (f) against input (two replicates). Peaks overlapping with up regulated (red) or down regulated 
(green) genes are highlighted. 
 
Figure 5.21. Comparison of fold changes on antibiotics treatment of Kcr and H4K8ac ChIP-seq 
XY plot showing the log2 fold change of Kcr ChIP-seq against H4K8ac ChIP-seq, looking only at MACS peaks that 
were statistically different in the Kcr data set. Points are coloured in linear scale by read counts in the group (Kcr 






Figure 5.22. ChIP-qPCR of H4K8ac in antibiotics treated mouse colon 
ChIP was performed on sonicated chromatin from colons from mice gavaged with antibiotics or PBS (control) 
using anti-H4K8ac. Quantitative PCR was performed using primers against the promoters of the specified genes 
and normalised to negative targets Adam23, Cys1, March11 and Slc4a5 to show relative enrichment in log10 
scale. Two-way ANOVA was performed for each set of targets. The up-regulated and unchanged genes gave a 
significant difference between targets only (p < 0.0001), whilst the down-regulated genes gave a significant 
difference between treatments (p = 0.0002) and targets (p < 0.0001), with no interaction between the two. 
Pairwise comparisons of log transformed data of control against antibiotics were not significant and are shown 
as volcano plots to the left, with the difference between control and antibiotics against the significance of that 






Figure 5.23. Interesting genes from ChIP-qPCR of H4K8ac in antibiotics treated mouse colon 
The genes which were gave the lowest p-values by multiple comparison tests in Figure 5.22 are shown separately 
here with relative enrichment to negative targets plotted in linear scale. The p values of pairwise comparisons 






Figure 5.24. H4K8ac ChIP-qPCR compared to ChIP-seq at the Klf11 gene 
ChIP on sonicated chromatin from antibiotics treated or control colons using an anti-H4K8ac antibody was tested 
in qPCR using primers against different positions around the start of the Klf11 gene. Position 4 is the same as 
the Klf11 primer in Figure 5.22. Positions of these primers are annotated on the browser view of H4K8ac ChIP-
seq that was performed on samples from the same ChIP experiment. The ChIP-seq data is the same as that 
shown in Figure 5.20. 
 
5.3 Discussion 
5.3.1 Antibiotics induced depletion of the gut microbiota reduces histone acetylation, 
crotonylation and butyrylation but not methylation 
We found that antibiotics treatment reduced histone acetylation, crotonylation and butyrylation in 
the mouse colon. These changes to histone acylations were consistent between two different mouse 
strains, C57BL6 and Balb/c, indicating that this robust change is not dependent on a property of one 
particular mouse strain. We suggest that these changes in histone acylations are due to antibiotics 
induced depletion of gut microbial generated SCFAs, as serum and luminal SCFA concentrations were 
also reduced and some SCFAs could promote histone acylations in cell culture. We identified that 
histone acetylation abundance in IECs responds over a short period of time (3 days of antibiotic 
treatment) and that it can occur in mice that are adapted to the presence of the microbiota. As 
antibiotics are used to deplete the microbiota to treat certain diseases (Zarrinpar et al., 2018), 




of these treatments may be. However, we have not directly shown that microbial generated SCFAs 
are the cause of changes to histone acylations in vivo. The gut microbiota releases many different 
molecules that have potential to induce epigenetic changes in colonocytes (Krautkramer et al., 2017). 
Depletion of the microbiota could also indirectly affect colonocyte histone modifications due to 
changes in immune activity or gut motility. Treating germ free mice with antibiotics would be a useful 
way to test if the antibiotics themselves can influence colonocytes in the whole organism, as 
experiments with organoids were inconclusive. Further experiments could introduce labelled SCFAs 
to mice in combination with mass spectrometry analysis to determine if these are the source of 
crotonyl- and acetyl-moeities on histones. Additionally, the abundance of other microbial metabolites 
could be compared between control and antibiotics-treated mice to identify potential acyl-modifiers.  
Whilst many different histone acetyl- and crotonyl-marks were depleted, we saw no significant 
changes to paradym histone methylation marks such as H3K4me3 or H3K27me3. This is intriguing 
since broad depletion of the microbiota should reduce the concentration of many different microbial 
metabolites. The microbiota generates folate, which is essential for DNA methylation, and succinate, 
which inhibits demethylases (Crider et al., 2012; Xiao et al., 2012). As far as we are aware, no current 
evidence suggests that methylation can be influenced by acetate, propionate or butyrate. A different 
study tested the effect of increasing the microbiota, and thereby its metabolites, by colonising germ 
free mice with a microbiota from conventionally raised mice. They observed increases in histone 
acetylation in liver, colon and adipose tissue, along with increases in caecal acetate, propionate and 
butyrate concentrations, in colonised mice relative to germ-free mice (Krautkramer et al., 2016). This 
is in agreement with our study and suggests that histone acetylation is responsive to increases and 
decreases in the microbiota. Krautkramer et al. (2016) also found changes to methylation marks but 
these were not consistent across tissues as some modifications increased, whilst others decreased. 
Histone methylations are thought to be less dynamic and have slower turnover times than histone 
acylations (Barth and Imhof, 2010), therefore we suggest that methylation might be more involved in 
the development of an organism in symbiosis with the microbiota, whilst histone acylations may 
dynamically respond to short-term changes in the microbiota. Here, we have studied acute microbiota 
depletion over just three days. If antibiotic treatment was given over a longer period, it is possible that 
other modifications may change as a result of adaptation to this new environment.  
5.3.2 The effect of antibiotics treatment on histone acetylation in the liver 
In the liver, we observed a reduction in histone acetylation on antibiotics treatment in wild type mice 
with the anti-Kac antibody. 70% of acetate and 30% of propionate produced by the gut microbiota is 




70-90% of butyrate produced by the gut microbiota is consumed by colonocytes in preference to 
acetate or propionate (Cook and Sellin, 1998). Therefore, the reduction in histone acetylation in the 
liver on antibiotics treatment could be due to the reduction in serum propionate. However, this was 
a preliminary experiment and needs to be repeated to verify if acetylation does reduce, especially 
since H3K18ac did not change in wild type mice. The differences in the SCFA use by liver and colon 
provides an opportunity to investigate the how these SCFAs differentially affect histone acylations. In 
a further experiment, it would be informative to include measurement of propionate concentrations 
in the liver in control and antibiotics treated mice to see if it matched the propionate reduction in the 
gut lumen. An experiment to track labelled propionate in the liver would also help determine if 
propionate is involved in this change.   
5.3.3 Characterisation of H4K8ac in liver and colon 
H4K8ac was highly responsive to antibiotic induced microbial depletion in the colon and initial studies 
suggested that acetylation might also change in response to antibiotic treatment in the liver. 
Compared to some other histone acetylation marks, much less is known about H4K8ac and ChIP-seq 
analysis of H4K8ac had not been performed before in liver or colon. We therefore characterised 
H4K8ac in liver and colon and found that it has a broad distribution across the genome, enriched at 
TSS but also present in the gene body and outside genes. H4K8ac marks were associated with 
regulatory elements, particularly those that were present in both liver and colon, where 99% of 
H4K8ac peaks were at previously annotated regulatory elements. We found that H4K8ac was involved 
in a broad range of functions, including those involved in signalling, metabolism and transcription. 
Additionally, its function was not restricted to one tissue as it was associated with many functional 
gene ontology terms in both liver and colon. The terms identified were associated with many tissue 
specific functions, such as lipid metabolism in the liver and ion homeostasis and biogenesis in the 
colon. H4K8ac was also associated with gene transcription and translation related terms, particularly 
for the genes present in both tissues. As H4K8ac is associated with activation of gene expression and 
the background list used in the gene ontology analysis was not tissue specific, these terms identified 
might reflect which genes are expressed in different tissues.  
When we compared H4K8ac to other well-characterised histone marks using chromatin state analysis, 
we found that this modification was associated with H3K4me3, H3K27ac and H3K4me1, marks of 
promoters and enhancers, in both colon and liver. This suggests that H4K8ac could also be involved in 
gene regulation, as H3K4me1, H3K27ac and H3K4me3 are associated with promoting gene expression. 
Interestingly, the presence of the gene silencing mark H3K27me3, along with H3K4me3, in some 




making them poised for gene expression. A recent study found that H4K8ac and H3K27ac were highly 
correlated, both associating with intergenic regions, introns and promoter TSS (Li et al., 2019). We 
also found that H4K8ac is present at gene start, body and outside genes in both liver and colon. In 
agreement with our findings, Li et al. (2019) found that H4K8ac and H3K27ac are associated with 
H3K4me3, at regions known as super enhancers which are implicated in tumourigenesis. Interestingly, 
H4K8ac and H3K27ac were found at a similar percentage of enhancers in CD4+ T cells, at 12 and 17 % 
respectively (Wang et al., 2008). As H3K27ac is a well described mark of active enhancers (Bonn et al., 
2012), H4K8ac could also have an important role in marking this genomic feature. In summary, our 
study adds further evidence that H4K8ac is a marker of regulatory regions, in particular enhancers and 
promoters. 
5.3.4 Antibiotics treatment results in substantial changes in gene expression 
Antibiotics treatment is a useful tool to study the effects of the microbiota as, unlike germ-free mice, 
the immune and homeostatic regulatory systems have developed normally. Whilst studies have been 
done on low dose antibiotics treatment to reduce microbiota diversity (Cho et al., 2013; Cox et al., 
2014; Mahana et al., 2016), less is known about the effects of higher dose antibiotic treatment to 
severely deplete the microbiota. Antibiotics are used routinely to deplete the microbiota to treat 
bacterial infections or prepare for microbial transplantation, therefore understanding how they 
impact colon function is essential. We identified hundred of genes that change in expression in mouse 
colon epithelial cells as a result of a short course of antibiotics treatment. Genes involved in mediating 
juctions between cells were reduced, which agrees with current evidence that the microbiota promote 
increased barrier function and prevent harmful bacteria from penetrating the underlying tissue 
(Pedicord et al., 2016). Only one term was identified in the down-regulated gene group, despite it 
containing around a third of the total number of dysregulated genes. Other cellular pathways might 
be involved, but if low numbers of genes were dysregulated for each function it would not be 
identified by gene ontology analysis. In contrast, a large number of gene ontology terms were 
identified from the list of upregulated genes including oxidative phosphorylation, ATP synthesis, 
electron transport, respiration, lipid metabolism, TCA cycle and fatty acid metabolism. This suggests 
that colonocytes increase energy generation and endogenous metabolism to compensate for the lack 
of microbial derived butyrate. This is in agreement with recent study which also investigated the 
effects of antibiotics treatment on gene expression and investigated how this altered intestinal 
homeostasis (Zarrinpar et al., 2018). They observed reductions in SCFAs in the gut lumen, changes to 
microbial metabolic pathways including involving lipid metabolism and differential regulation of 




glucose metabolism was upregulated, with changes to hormones such insulin and leptin, along with 
reduced expression of genes involved in fatty acid receptors, binding proteins and enzymes involved 
in beta-oxidation, including ACAD. Together our findings suggests that as a result of antibiotic induced 
depletion of the microbiota, host metabolism switches to accomodate the loss of microbial 
metabolites.   
5.3.5 Histone crotonylation links to gene expression in a subset of genes on antibiotics treatment 
In this study, we have found that changes to gene expression on antibiotics treatment are positively 
correlated to changes in crotonylation. Histone crotonylation is associated with active chromatin and 
has even been shown to activate the transcription of p53 to a greater extent than acetylation in a cell 
free assay (Sabari et al., 2015). In addition, crotonylation preferentially binds different classes of 
reader proteins, the YEATS and DPF domains, rather than the acetylation binding bromodomains. 
Therefore, this suggests that modulation of crotonylation in the colon consitutes novel mechanism to 
regulate gene expression in response to the microbiota, an interaction that is critical for the normal 
functioning of the colon. Crotonylation was widely distributed across the genome with enrichment at 
TSS but with peaks also present in the gene body and outside genes. Despite its broad genomic 
localization, gene ontology terms linked to genes that changed in crotonylation on antibiotics 
treatment were specific, suggesting key functions for crotonylation in this context. However, the 
differentially regulated genes that changed significantly in crotonylation upon antibiotics-treatment 
were only a subset of the total number of differentially regulated genes. Furthermore, genes related 
to energy generation were differentially expressed but were not identified in the differentially 
crotonylated genes. Other epigenetic switches might mediate the changes in regulation for the 
remaining differentially expressed genes. Interestingly, there were also many genes which changed in 
crotonylation but which did not change in gene expression. The activity of a particular gene is thought 
to be dependent on the combinatorial action of multiple epigenetic switches. Some genes may gain 
crotonylation, but remain in a poised state due to the presence of repressive modifications. 
Conversely, some genes may be depleted in crotonylation but remain active due to the presence of 
transcription promoting marks. Changes to crotonylation may also decorate region not directly 
involved in gene regulation, e.g., origins of replication, as we have observed that this mark is not only 
present at TSS. Due to poor performance by anti-H4K8cr and anti-H3K18cr antibodies we used an anti-
Kcr antibody, which also can recognise non-histone crotonylation. The ChIP experiment enriches for 
DNA associated proteins, but we cannot exclude that DNA-associated non-histone crotonylation may 




Kcr antibody indicates that by far the most abundant crotonylated proteins migrate in a way that is 
consistent with them being histones H3 and H4. 
5.3.6 Histone crotonylation co-localises with H4K8 acetylation in the colon 
We found that MACS peaks of H4K8ac, H3K18cr and Kcr were highly overlapping, with a striking 
similarity in profiles across the genome. Their close overlap could be because p300/CBP and class I 
HDACs are responsible for both their addition and removal. These modifications were also present in 
the same enhancer-like states in the ChromHMM analysis in the colon where they all associated with 
H3K27ac and H3K4me1. H3K18cr and Kcr were more similar to each other than to H4K8ac as state 1 
mainly contained H4K8ac and H3K4me1 but not the crotonyl marks. This high correlation between 
modifications may be because the same writers (p300) and the same erasers (class I HDACs) can act 
on all of these modifications. These enzymes could specifically target certain regions of the genome 
resulting in a similar distribution of these modifications. However, whilst only p300/CBP and MOF 
have been shown to have histone crotonyltransferase activity (Sabari et al., 2015; X. Liu et al., 2017), 
many HATs have been identified, which would mean that acetylation is present at more sites. In fact, 
we did observe that there were more H4K8ac peaks than H3K18cr or Kcr peaks, although this may be 
in part due to differences in enrichment. The pattern of distribution could reflect regions of more open 
chromatin. Furthermore, the presence of one type of acylation on a histone could promote the 
addition of other histone acylations on neighbouring nucleosomes. Mass spectrometry analysis of 
histone H3 crotonylation revealed that H3K18cr associated with H3K23ac, suggesting co-regulation of 
these modifications (Fellows et al., 2018). As this analysis did not include H4 modifications, it remains 
to be seen whether H4K8ac is highly associated with H3K18cr in a nucleosome. H4K8ac, H3K18cr and 
Kcr were all associated with higher levels of transcription, enriched at TSS and strongly overlapped 
with candidate regulatory elements. This raises the question of whether histone crotonylation has a 
distinct function from histone acetylation in the gut. The genes containing all three modifications were 
associated with diverse functions including metabolism and protein modification. The presence of all 
three modifications, and potentially others, could have an additive function to maintain transcription 
of essential genes for housekeeping functions. As YEATS domains have a preference for histone 
crotonylation whilst bromodomains prefer histone acetylation (Flynn et al., 2015b; Andrews et al., 
2016; Li, Benjamin R. Sabari, et al., 2016; Zhang et al., 2016; Zhao et al., 2016), these hPTMs could 
interact with different complexes and induce separate cellular responses even if they are present at 
the same genomic sites. Additionally, there may be as yet unidentified crotonyl-interacting factors 
which do not interact with other histone acylations. We and others have demonstrated that the anti-




al., 2014; Sabari et al., 2015). H4K8ac and H3K18cr have also been validated, although the poor 
performance of subsequent batches of anti-H3K18cr does mean that a new antibody will need to be 
developed for studies on this modification to be continued. 
5.3.7 H4K8ac does not change over genomic elements on antibiotics treatment 
Comparing H4K8ac ChIP-seq in control and antibiotics treated mouse colon found that there were no 
significant changes in the enrichment of MACS peaks between the two groups. Furthermore, 
comparison of H4K8ac ChIP-qPCR did not reveal any significant changes in the individual targets 
tested, despite some targets such as Isg15 and Hmgcs2 changing in the same direction as gene 
expression. This is surprising since H4K8ac did change when control and antibiotics groups were 
compared by western blot and hundreds of genes changed in crotonylation. However, there was a 
significant reduction in H4K8ac ChIPqPCR over all genes that reduced in expression. When we 
compared the fold changes of Kcr and H4K8ac, for genes that significantly changed in Kcr, the 
enrichment of H4K8ac was changing to a similar extent to Kcr. Possibly, the samples used in the 
H4K8ac ChIP-seq had higher variability making it more difficult to reach significance. Li et al. (2019) 
observed that H4K8ac changed between normal tissue and tumour tissue, particularly in intergenic 
regions and introns (Li et al., 2019), so this modification can be responsive to changing conditions. As 
this H4K8ac ChIP-seq was the first comparison of acetylation between control and antibiotics treated 
mice, further analysis should be performed. Additionally, as Kcr detects all lysine crotonylation but 
H4K8ac is only specific to one mark, a better comparison could include H3K18ac. Ideally, H3K18cr 
would be compared to H3K18ac and H4K8cr with H4K8ac, but the current lack of ChIP-compatible 
crotonyl-specific antibodies makes this challenging.  
5.3.8 Microbiota depletion differentially influences global and site-specific histone crotonylation  
We identified that antibiotic treatment produced global reductions in histone crotonylation and 
acetylation by western blot. However, by ChIP-seq we identified significant increases and decreases 
in crotonylation on antibiotics-treatment at specific sites relative to the rest of the genome, whilst no 
significant changes were observed for acetylation. This suggests that there are distinct differences 
between local and global crotonylation and acetylation. Whilst the global levels of histone 
crotonylation are reduced on antibiotics treatment, certain regions such as promoters may be 
protected from removal by chromatin and transcriptional machinery. As ChIP-seq measures the 
relative distribution of proteins across the genome, these protected regions would give a stronger 
signal in the antibiotics treated group relative to other regions and would be higher than in the control 




crotonylation (and acetylation) are distributed over the genome in an unfocused manner, hence why 
we detect these modifications in intergenic regions, reflecting background noise or a link to replication 
(Fellows et al., 2018). Certain regulatory elements, such as promoters, are consistently enriched as a 
result of specific targeting of histone modifications to these sites, enabling us to detect ‘peaks’ of 
enrichment. We do not yet understand the relationship between the local, site specific actions of 
hPTMs and their global changes. One interesting possibility is that global reduction of a hPTM may 
focus binding proteins to the remaining hPTM sites, coupling to downstream factors and enabling an 







6 General discussion 
6.1 Histone hydroxybutyrylation is influenced by different signals to that of acetylation 
or crotonylation 
In chapter 4, we saw no changes to histone acetylation or crotonylation when mouse diet was 
restricted but we did not test histone hydroxybutyrylation. After this experiment was conducted, Xie 
et al. (2016) found that starvation or ketoacidosis increases histone hydroxybutyrylation and that 
changes to this modification are associated with those genes that change in gene expression (Xie et 
al., 2016). In chapter 3, we found that histone crotonylation did not change when β-Hbu was added 
to HCT116 cells. Additionally, in chapter 5, hydroxybutyrylation did not change or increased when the 
microbiota was depleted with antibiotics whilst crotonylation and acetylation were strongly reduced. 
This implies that hydroxybutyrylation responds to different cues to that of acetylation or 
crotonylation. Hydroxybutyrate is derived from ketone bodies, a form of energy storage that is 
released upon starvation. Potentially, ketone bodies are the main source of hydroxybutyryl groups for 
histone transfer rather than metabolites released from the microbiota.  
6.2 Histone crotonylation and acetylation are influenced by the microbiota 
In this study we identified that the SCFAs crotonate, butyrate and propionate could promote histone 
crotonylation and acetylation in cell culture. We also showed that antibiotic induced depletion of the 
microbiota reduced SCFA concentrations, histone crotonylation and histone acetylation in mouse 
colon. Various different acetyl- and crotonyl-modifications were responsive to the microbiota 
including H4K8ac, H4K8cr and Kcr. Both H4K8ac and Kcr were associated with marks of regulatory 
elements such as H3K27ac and H3K4me3. But whilst the Kcr ChIP-seq revealed many genes which 
significantly changed in crotonylation on antibiotics treatment, there were no significant changes to 
H4K8ac in either ChIP-seq or ChIP-qPCR. However, we cannot rule out the possibility of acetylation 
not changing as a result of antibiotic treatment. In this study we compared H4K8ac to Kcr as ChIP 





are not equivalent modifications. Future studies could test H3K18ac or other acetylation marks using 
higher sample numbers to allow for the variability we have seen so far.  
We also found that a diet without fibre reduced some histone acetyl- and crotonyl- modifications 
along with colon luminal butyrate concentrations. Whilst we did not measure other microbial 
metabolites, the lack of changes to histone methylation suggests that it is not through metabolites 
such as folate or succinate. In support of this conclusion, a previous study found that colonization of 
germ-free mice promoted histone acetylation along with an increase in SCFA concentrations 
(Krautkramer et al., 2016). Together, this evidence demonstates that the microbiota is an important 
regulator of histone crotonylation and acetylation, and implicates SCFAs in this interaction. However, 
although we have shown that butyrate and propionate can promote histone crotonylation and 
butyrate can promote histone acetylation in cell culture, we have not directly shown that it is the 
SCFAs that are modulating histone acylations in vivo. Antibiotic treatment and depletion of the 
microbiota is likely to cause widespread changes to gut physiology. Changes to cell proliferation, 
activity of immune cells, the loss of other signals such as MAMPs and switching to other sources of 
energy due to the lack of microbial metabolites have the potential to influence histone modifications. 
Indeed, we observed changes to the expression of genes involving metabolism, energy generation, 
immune processes and cell adhesion by RNA-seq in the colon of antibiotic treated mice suggesting 
that multiple changes are occurring in colonocyte processes. As the gut environment is complex, with 
interactions between diet, microbiota, epithelium and immune cells, detangling the different 
possibilities will be a complex task. We observed some changes to histone acylations on antibiotics 
treatment of colon organoids, although these were not dose-dependent, therefore antibiotics 
treatment of germ-free mice would be a useful further experiment to determine the affect of 
antibiotics itself without the influence of the microbiota. To study whether butyrate or other SCFAs 
are the cause of the changes to histone acylations that we have observed, mice could be transplanted 
with butyrate producing bacteria. We observed no differences in crotonate supplementation to the 
drinking water of conventional mice or butyrate gavage of germ-free mice. However, these SCFAs are 
likely to be diluted by the stomach and mostly absorbed by the small intestine rather than the colon. 
Use of slower release molecules such as tributyrin could be used to increase colon butyrate 
concentrations. Additionally, 13C tracing experiments could be used to track specific molecules from 
the diet or SCFAs administered by gavage through to histone modifications in colonocytes. The timing 
of mouse collection is likely to be critical in these experiments as SCFA concentrations in the colon or 




6.3 By what mechanism do SCFAs change histone acetylation and crotonylation? 
The mode by which microbiota derived SCFAs influence histone acetylation and crotonylation is 
important because it will inform us in what circumstances this occurs and what functions this may 
relate to. This is because butyrate was found to either promote proliferation or apoptosis depending 
on whether it acted as a HDAC inhibitor or metabolite (Donohoe et al., 2012). We now know that it is 
possible for butyrate to promote crotonylation by HDAC inhibition as we and others have 
demonstrated that class I HDACs are histone decrotonylases (Madsen and Olsen, 2012; Wei, Liu, et 
al., 2017; Fellows et al., 2018; Kelly et al., 2018). Our kinetic studies show that HDAC1 is an effective 
decrotonylase enzyme with only a three-fold lower rate than that of its HDAC activity. Furthermore, 
Wei et al. (2017) demonstrated that class I HDACs could act as decrotonylases in cell culture. The 
identification of class I HDACs as decrotonylases does not define the mode of action of SCFAs, but 
merely increases the number of possible routes for these microbial metabolites to influence histone 
crotonylation. Butyrate was shown to mediate the degradation of HDAC2 (Kramer et al., 2003), 
therefore microbiota derived SCFAs could influence histone modifications by mediating HDAC 
abundance. In some experiments with antibiotic treated mice we saw a significant increase in HDAC2 
abundance. We also saw some statistically significant reductions in HDAC abundance on high fibre 
diets, but the effects we saw were not consistent across experiments. HDAC3 expression was also 
shown to be induced in the presence of commensal bacteria and HDAC expression in IECs mediates 
regulation of intestinal homeostasis by the commensal bacteria (Alenghat and Artis, 2014). Therefore, 
whilst SCFAs might affect HDAC levels, other cues from the intestinal microbiota may balance HDAC 
expression to maintain homeostatic functioning of the gut.  
SCFAs can also act as metabolites, providing acylated-CoAs for use by histone acyltransferases. We 
tested mice with a deficiency in ACAD, which converts butyryl-CoA to crotonyl-CoA, to determine how 
important the metabolism of butyrate by β-oxidation is for promoting crotonylation. ACAD deficient 
mice showed no difference in histone acylations to wild type mice, suggesting that this enzyme is not 
involved. Alternatively, histone acylations might have been upregulated by the action of ACSS2 which 
converts SCFAs to acyl-CoAs in the cytoplasm. Acetate, propionate and butyrate are provided by the 
microbiota and can be converted to their acyl-CoAs by ACSS2, but little is known about the presence 
of crotonate in the gut lumen. However, crotonate was identified in the faeces of Dachshunds at 
around three fold lower concentration than butyrate (Igarashi et al., 2017) and many bacteria have 
the metabolic capability to use crotonate (Guccione et al., 2010). Therefore, crotonate could be 
present in the mouse colon and provide crotonyl-CoA for the histone via ACSS2. Interestingly, we 
found in our mouse studies that the concentration of butyrate correlated better with histone 




influence histone acetylation or crotonylation, but butyrate did. This implies that histone acylations 
are upregulated in the gut by inhibition of HDACs, as butyrate is a HDAC inhibitor but acetate isn’t. 
However, further studies are required to determine the predominant mechanism of action of SCFAs, 
which is likely to vary depending on cell type. Testing the in vivo knock-down of enzymes such as 
HDAC1 and ACSS2, and heavy label tracing SCFAs in intestinal organoids will help us understand this 
complex interaction better.  
6.4 Conclusion 
Our study demonstrates a fascinating new link between the commensal gut microbiota and histone 
crotonylation. We have also shown that some of the changes to histone crotonylation on antibiotics 
treatment correlated with changes in gene expression. However, whether changes to histone 
crotonylation are the cause or a consequence of changes to gene expression remain unclear. This is a 
key issue in the field of histone modifications more generally, as these marks are often assumed to 
have a causative role in gene modulation without any direct evidence. In fact, loss of the strongly 
promoter-associated H3K4me3 had no effect on the levels of newly generated transcripts (Murray et 
al., 2019). Instead, SCFAs might change metabolism, leading to changes in gene expression that in turn 
change histone crotonylation. However, the fields of histone crotonylation and microbiota-epigenetic 
interactions remain exciting new topics with many avenues for further investigation. As the microbiota 
has been linked to a range of disorders including, cancer, inflammatory bowel disease and obesity; 
whilst epigenetic switches are involved in gene regulation, this interrelationship is likely to be a vital 
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[Abstract] Class I histone deacetylases (HDACs) are efficient histone decrotonylases, broadening the 
enzymatic spectrum of these important (epi-)genome regulators and drug targets. Here, we describe 
an in vitro approach to assaying class I HDACs with different acyl-histone substrates, including 
crotonylated histones and expand this to examine the effect of inhibitors and estimate kinetic 
constants. 
Keywords: Crotonylation, Acetylation, Butyrylation, Histone deacetylase, Enzyme, Kinetic, Chromatin 
[Background] Posttranslational modifications of histones are an important facet of genome 
regulation, including gene expression (for example see Pengelly et al., 2013; reviewed in Castillo et al., 
2017). Histone modifications alter chromatin structure and/or regulate the binding of proteins, such 
as nucleosome remodeling factors (reviewed in Bannister and Kouzarides, 2011). Most histone 
modifications are reversible and can be removed enzymatically. For example, histone acetylation is 
removed by histone deacetylases (HDACs), of which there exist several classes. In recent years new 
histone lysine acylations, including succinylation, propionylation, butyrylation, hydroxybutyrylation 
and crotonylation have emerged as new alternative acylations to the canonical histone acetylation 
and the functional relevance of many of these newly discovered histone modifications have been 
demonstrated (reviewed in Sabari et al., 2017). In particular, histone crotonylation is associated with 
active gene expression and is thought to be influenced by the metabolic state of the cell (Sabari et al,. 





decrotonylate histones (Wei et al,. 2017; Fellows et al., 2018).  
Histone deacetylation assays are often performed using fluorescent acetyl substrates, such as BOC-
lys(acetyl)-AMC, because this allows high-throughput in vitro approaches, suitable for drug discovery 
(Wegener et al., 2003a: 2003b and 2003c). However, we found that the analogous fluorescent crotonyl 
substrate BOC-lys(crotonyl)-AMC was inhibitory to histone deacetylases (Fellows et al., 2018). In this 
protocol, we describe a method for analysis of the activity of histone deacetylases with in vitro 
crotonylated histone H3, and we investigate the effect of an inhibitor and estimate kinetic parameters 
using an in vitro approach. This method does not require the use of radioisotopes. It also does not rely 
on fluorescent peptide mimics, and thus, the kinetic constants determined may be more 
representative of those found in vivo. The approach depends on the recognition of histone acylations, 
such as crotonylation, by specific antibodies. It is a versatile approach, which could be applied to study 
a variety of other histone modifications, enzymes, and inhibitors. 
Materials and Reagents 
1. 8-strip 0.2 ml non-flex flat cap PCR tubes with individual lids (STARLAB INTERNATIONAL, catalog 
number: I1402-3700) 
2. 250 ml and 1 L cylinders (Corning, catalog number: 3022P-250, 3022P-1L) 
3. Pre-cut extra thick blot paper, 7 x 8.4 cm (Bio-Rad Laboratories, catalog number: 1703966) 
4. Amersham Protran 0.45 µm nitrocellulose membrane, 300 mm x 4 m (GE Healthcare, catalog number: 
10600002) 
5. 5, 10 and 25 ml Costar® Stripette® serological pipettes (Corning, catalog numbers: 4487, 4488, 4489) 
6. 50 ml Falcon® tubes, polypropylene (Corning, catalog number: 352070) 
7. Eppendorf® tubes 5.0 ml, Eppendorf QualityTM (Eppendorf, catalog number: 0030119401) 
8. X-ray film 18 x 24 cm double sided (Scientific Laboratory Supplies, catalog number: MOL7016) 
9. Transparent acetate sheet, e.g., colour copier transparency film (Interaction-Connect, Q-CONNECT®, 
catalog number: KF00533) 
10. Milli-Q® water  
11. Recombinant human histone H3.1 protein, 1 mg/ml (New England Biolabs, catalog number: M2503S) 
Note: Prepare aliquots (e.g., 10 µl aliquots) and store at -80 °C. 
12. Recombinant catalytic domain of human p300 protein (Enzo Life Sciences, catalog number: BML-SE451-
0100), 100 µg, 15.18 µM (exact concentration may vary by batch, check the tube) 
Note: Prepare aliquots (e.g., 10 µl aliquots) and store at -80 °C. 
13. Crotonyl-coenzyme A trilithium salt ~90% pure as per HPLC (Sigma-Aldrich, catalog number: 28007) 
Note: For acetylation we used: Acetyl-coenzyme A (Sigma-Aldrich, catalog number: ACOA-RO ROCHE). 
Prepare 5 mM stock solution in water, aliquot and store at -80 °C. 




14. Trizma®-hydrochloride, ≥ 99.0% (Sigma-Aldrich, catalog number: T3253 ) 
15. Potassium chloride, 99.5-101.0% AnalaR NORMAPUR® (VWR, catalog number: 26764.298)  
16. UltraPureTM 0.5 M EDTA, pH 8.0 (Thermo Fisher Scientific, catalog number: 15575020) 
17. Tween 20 (Sigma-Aldrich, catalog number: P1379) 
18. Glycerol, ≥ 99% (Sigma-Aldrich, catalog number: G5516) 
19. Dithiothreitol (DTT) (Thermo Fisher Scientific, catalog number: R0861) 
20. Magnesium chloride hexahydrate, ≥ 99.0% (Sigma-Aldrich, catalog number: M2670) 
21. Zinc sulfate heptahydrate (Sigma-Aldrich, catalog number: Z0251) 
22. Recombinant human HDAC1 protein (Active Motif, catalog number: 31908) 50 µg, 0.1 mg/ml, 1.78 µM 
(exact concentration may vary by batch, check tube) 
Note: Prepare aliquots (e.g., 10 µl aliquots) and store at -80 °C. 
23. 2x Laemmli sample buffer (Bio-Rad Laboratories, catalog number: 1610737) 
Note: Add 2-mercaptoethanol to 5% v/v as described by supplier. 
24. 2-mercaptoethanol, ≥ 99.0% (Sigma-Aldrich, catalog number: M6250) 
25. Sodium Butyrate, 98% (Sigma-Aldrich, catalog number: 303410) 
Note: Prepare a 1 M solution in water, adjust to pH 7 and aliquot. 
26. Precast RunBlue 4-12% Bis-Tris (Expedeon, catalog number: NBT41227) 
27. 20x RunBlue MES run buffer (Expedeon, catalog number: NXB70500)  
28. PageRulerTM Prestained protein ladder, 10 to 180 kDa (Thermo Fisher Scientific, catalog number: 26616) 
29. 10x Tris/glycine/SDS electrophoresis buffer (Bio-Rad Laboratories, catalog number: 1610732EDU) 
30. UltraPureTM Tris buffer (Thermo Fisher Scientific, catalog number: 15504020) 
31. Glycine, ≥ 99.7% AnalaR NORMAPUR® (VWR, catalog number: 101196X) 
32. Methanol, ≥ 99.8% AnalaR NORMAPUR® (VWR, catalog number: 20847.307) 
33. Sodium chloride, 99.5-100.5% AnalaR NORMAPUR® (VWR, catalog number: 27810.295) 
34. Bovine serum albumin, heat shock fraction pH 7 ≥ 98% (Sigma-Aldrich, catalog number: A9647) 
35. Anti-crotonyl-histone H3 lys18 (H3K18cr) rabbit polyclonal antibody (PTM Biolabs, catalog number: 
PTM-517) 
36. Anti-rabbit IgG HRP linked whole antibody (GE Healthcare, catalog number: NA934-1ML) 
37. Enhanced chemiluminescence (ECL) Western blotting reagents (GE Healthcare, catalog number: 
RPN2106) 
38. Synthetic crotonylated H3K18cr peptide 95% pure, lyophilized (TGGKAPR-Lys(Crotonyl)-QLATKAA-EDA-
Biotin, BioGenes, Peptide 60556.1) (EDA is a spacer amino acid sequence) 
39. Histone acylation buffer (see Recipe 1) 
40. HDAC assay buffer (see Recipe 2) 
41. MES Run buffer (see Recipe 3) 
42. Tris glycine SDS (TGS) buffer (see Recipe 4) 




44. Tris-buffered saline, pH 7.5 (TBS) (see Recipe 6) 
45. TBS with tween 20 (TBS-T) (see Recipe 7) 
46. TBS-T with 3% (w/v) bovine serum albumin (TBS-T BSA) (see Recipe 8) 
 
Equipment 
1. Pipettes (Gilson, catalog numbers: F123602, F123601, F123600, F144801, model: P1000, P200, P20, P2) 
2. Pipette controller PIPETBOY acu2 (VWR, INTEGRA Biosciences, catalog number: 612-2964) 
3. Fume hood (e.g., Protector Xstream Laboratory Hood, Labconco) 
4. Milli-Q Water Purification System (Merck, catalog number: ZRXQ003WW) 
5. GE Healthcare AmershamTM HypercasetteTM Autoradiography Cassette (GE Healthcare, catalog number: 
RPN11643) 
6. Vortex-genie 2 (Scientific Industries, model: Vortex-Genie 2, catalog number: SI-0236) 
7. Microcentrifuge (STARLAB INTERNATIONAL, model: Mini Fuge, catalog number: N2631-0007) 
8. Two T100TM Thermal Cyclers (Bio-Rad Laboratories, catalog number: 1861096) 
9. Amersham electrophoresis power supply EPS 301 (GE Healthcare, catalog number: 18113001) 
10. XCell SureLockTM Mini-Cell Electrophoresis System (Thermo Fisher Scientific, catalog number: EI0001) 
11. Transblot® SD semi-dry electrophoretic transfer cell (Bio-Rad Laboratories, catalog number: 1703940) 
12. MI-5 x-ray film processor (Jet x-ray) 
13. Epson expression 1680 scanner (Seiko Epson, model: Epson Expression 1680) 
Note: Equivalent models of equipment specified here may also be used. 
 
Software 
1. ImageJ version 1.50 b 
2. Windows Excel 2016 
3. Adobe Illustrator CC 2015.3 
4. Graphpad Prism version 7.0 
5. Epson Scan Software in professional mode 
Note: Other versions of this software or similar software may be used but the instructions 
specified in the data analysis section may then differ. 
 
Procedure 
We found that decrotonylation by HDACs did not occur on synthetic, modified histone tail 




crotonylate histones in vitro using recombinant histone H3.1 and the catalytic domain of p300 
(‘p300’). We then follow decrotonylation by class I HDACs using specific antibodies, here against 
histone H3 crotonylated at lysine 18 (H3K18cr). H3K18cr is the dominant histone crotonylation 
mediated by p300 (Sabari et al., 2015) and appears to be the most abundant histone crotonylation 
in histones isolated from intestinal cells (Fellows et al., 2018). Importantly, highly specific 
antibodies have been generated that recognize H3K18cr (Sabari et al., 2015). We describe an assay 
for decrotonylation to address three questions: can HDAC1 remove the crotonyl group and how 
much of it is required, how effective is the HDAC inhibitor butyrate at preventing decrotonylation 
by HDAC1 and what are the kinetic parameters of HDAC1 regarding the decrotonylation of histone 
H3? The same steps can be performed for other acylations, such as acetylation, butyrylation or 
propionylation using the relevant acyl-CoA and antibody. This protocol can also be used to test 
other HDAC enzymes, using the relevant recombinant protein, and other HDAC inhibitors such as 
Trichostatin A (TSA) and Vorinostat (suberoyl anilide hydroxamic acid, SAHA). 
 
Part I: In vitro decrotonylation assay 
A. In vitro crotonylation of recombinant histone H3.1 using the catalytic domain of p300 
1. Defrost all reagents on ice. 
2. Dilute the 5 mM crotonyl-CoA stock solution 1:50 in histone acylation buffer. 
3. Prepare the reaction mix in a 0.2 ml PCR tube as described in Table 1. 
 
Table 1. Histone H3 crotonylation reaction set-up 
Component Volume (µl) Concentration in reaction (µM) 
Diluted Crotonyl-CoA 40 87.00 
Histone H3.1 4 5.65 
p300 Catalytic domain 
('p300') 2 0.66 
 
4. Mix well by pipetting or brief vortexing. 
5. Incubate for 2 h at 30 °C in a thermocycler. 
6. Transfer to a thermocycler at 65 °C and incubate for 5 min to stop the reaction. 
Note: Histone tails are unstructured. Therefore heat inactivation is unlikely to affect the modification. 





B. HDAC1 mediated histone decrotonylation assay 
1. Decrotonylation assay with different concentrations of HDAC1 
We verify the activity of the HDAC1 enzyme towards the substrate and demonstrate the minimum 
amount required to observe the decrotonylation reaction. 
a. Dilute the reaction from Part I Procedure A 1:3 in HDAC assay buffer, i.e., 46 μl of reaction mix and 
92 μl of HDAC assay buffer. 
b. Cut 3 tubes away from an 8-tube strip leaving a 5-tube strip. 
c. Label these PCR tubes as 1-5. 
d. On ice, add diluted reaction mix, HDAC assay buffer and HDAC1 as described below and shown in 
Table 2. 
Note: This sets up a two-fold serial dilution of HDAC1 in tubes 1-4 whilst keeping the other reagents 
constant. Tube 5 is the negative control without any HDAC1. As soon as HDAC1 has been added to 
tube 1, perform all steps as quickly as possible as the reaction will start from this point. Whilst it is 
impossible to capture the first few seconds of the reaction, as it takes a few seconds to set it up, it 
is important to be quick so that the initial phase of the reaction is recorded. 
i. To tube 1, add 28 μl of diluted reaction mix. 
ii. To tubes 2-5, add 14 μl of diluted reaction mix. 
iii. Add 1 μl HDAC assay buffer to tubes 2-5 to allow for the HDAC1 volume. 
iv. Add 2 μl of HDAC1 to tube 1 and mix well (0.1 mg/ml, 1.78 µM stock. 0.12 µM final 
concentration). 
v. Remove 15 μl from tube 1, add to tube 2 and mix well. 
vi. Remove 15 μl from tube 2, add to tube 3 and mix well. 
vii. Repeat with tubes 3 and 4 but not tube 5. 
 
Table 2. Reaction set-up with a serial dilution of HDAC1 
Tube Number 1 2 3 4 5 
Diluted reaction mix (µl) 28 14 14 14 14 
HDAC Assay Buffer (µl) - 1 1 1 1 
HDAC1 (µl) 





















f. Spin tubes briefly to bring all of the liquid to the bottom of the tube. 
g. Incubate in a thermocycler at 30 °C for 2 h. 
h. As soon as the time is up, remove from the thermocycler. 
i. If the sample is to be run on a gel, add 15 μl (an equal volume) of 2x Laemmli with 5% (v/v) 2-
mercaptoethanol and incubate at 95 °C for 1 min to stop the reaction. 
ii. If the sample is to be dot-blotted, just incubate at 95 °C for 1 min to stop the reaction. 
i. At this point the tubes can be frozen at -20 °C for at least a few days or continued with further 
analysis as explained in Part II. 
2. Exploring the effect of an HDAC inhibitor on histone decrotonylation 
Here, butyrate is introduced in serial dilution which allows testing of the ability of the compound to 
inhibit the decrotonylation. This can be used to estimate the concentration of inhibitor required to 
halve the amount of created product (IC50). 
a. Dilute the reaction mix from Part I A 1:3 in HDAC assay buffer i.e., 46 μl of reaction mix and 92 μl 
of HDAC assay buffer. 
b. Label an 8-strip of PCR tubes as 1-8. 
c. On ice, add diluted reaction mix, HDAC assay buffer, butyrate and HDAC1 as described below and 
shown in Table 3. 
Note: A double reaction is prepared in tube 1 and single reactions in tubes 2-6, allowing a two-fold 
serial dilution of butyrate to be performed in tubes 1-6 whilst keeping the other reagents constant. 
Tube 7 and 8 are negative controls, tube 7 is without butyrate and tube 8 is without butyrate and 
HDAC1. As soon as HDAC1 has been added to tube 1, perform all steps as quickly as possible as the 
reaction will start from this point. 
i. To tube 1, add 28 μl of diluted reaction mix. 
ii. To tubes 2-8, add 14 μl of diluted reaction mix. 
iii. Add 1 μl HDAC assay buffer to tubes 2-7 to allow for the volume of butyrate added to tube 1. 
iv. Add 2 μl HDAC assay buffer to tube 8 to allow for the volume of butyrate and HDAC1. 
v. Add 2 μl of 160 mM butyrate to tube 1 to give a final concentration of 10 mM once all reagents 
have been added. 
vi. Add 2 μl of HDAC1 to tube 1 and mix well (0.1 mg/ml, 1.78 µM stock. 0.11 µM final 
concentration). 
vii. Add 1 μl of HDAC1 to tubes 2-7. 
viii. Remove 16 μl from tube 1, add to tube 2 and mix well. 
ix. Remove 16 μl from tube 2, add to tube 3 and mix well. 





Table 3. Reaction set-up with a serial dilution of butyrate and constant HDAC1 
Tube Number 1 2 3 4 5 6 7 8 
Diluted reaction mix (µl) 28 14 14 14 14 14 14 14 
HDAC Assay Buffer (µl) - 1 1 1 1 1 1 2 


































d. Vortex all tubes by holding both sides of the strip. 
e. Incubate at 30 °C for 2 h. 
f. As soon as the time is up, remove from the thermocycler. 
i. If the sample is to be run on a gel, add 16 μl (an equal volume) of 2x Laemmli with 5% (v/v) 2-
mercaptoethanol and incubate at 95 °C for 1 min. 
ii. If the sample is to be dot-blotted, just incubate at 95 °C for 1 min. 
g. At this point the tubes can be frozen at -20 °C for at least a few days or continued with further 
analysis as explained in Part II. 
 
3. Determination of kinetic parameters of histone decrotonylation 
Determination of kinetic parameters such as the maximum initial rate allows assessment of whether 
the enzyme follows Michaelis-Menten kinetics and is a useful way to find out important kinetic 
parameters such as Kcat, Vmax and Km. It allows comparison of an enzyme’s activity with different 
substrates or comparison of the activity of different enzymes with the same substrate. This requires the 
change in substrate or product concentration to be plotted over time so that the initial rate can be 
determined (see Figure 1 for illustration). The concentration of the enzyme must be optimized so that 
the initial rate is within a measurable timeframe. Initial rates are then plotted against the substrate 
concentration at the start of the reaction, to determine the maximum rate (Vmax) and substrate 
concentration at half Vmax (Km) as shown in Figure 1. As the reactions performed here are analyzed by 




a reaction for each time point. Here, six identical reactions are set up and stopped at 0, 0.5, 1, 2, 4 and 
10 min. The shortest time point that is practical with the method we present is 30 sec. To reliably 
determine kinetic parameters, it is also necessary to perform the reaction three times for each 
substrate concentration, and five different substrate concentrations are recommended. This means 
that 90 reactions are required (5 substrate concentrations x 6 time points x 3 replicates). These have 
been grouped into three replicate sets named A, B, and C. In our hands, and as described below, the 
initial reaction occurs in the first minute. Reducing the amount of enzyme may allow longer reaction 
times and thus more time points during the initial phase. However, this must be balanced against 
keeping the change in substrate concentration for all reactions distinguishable from background noise. 
 
 
Figure 1. Enzyme kinetic graphs. The left graph shows the output of the assay, which gives 
the change in substrate concentration over time. The initial rate is determined from this by 
finding the gradient of the first part of the reaction which is linear. In the right graph, the initial 
rates of all the substrate concentrations tested are plotted to give the Michaelis-Menten curve 
which is hyperbolic. This allows determination of the kinetic parameters Vmax and Km. 
 
a. Crotonylate H3.1 as described in Part I Procedure A. 
i. To prepare enough crotonylated H3 for 90 assays, use more of each component to give a total 
volume of 230 µl as described in Table 4. 
 
Table 4. Histone H3 crotonylation reaction set-up with a larger volume 
Component Volume (µl) Concentration in reaction (µM) 
Diluted Crotonyl-CoA 200 87.00 




p300 Catalytic domain 
('p300') 10 0.66 
 
ii. Incubate in a thermocycler at 30 °C for 2 h. 
iii. Transfer the tube to another thermocycler at 65 °C and incubate for 5 min to stop the reaction. 
iv. Place tube on ice. 
b. On ice, dilute the reaction mix in HDAC assay buffer to give 1:4, 1:6, 1:8, 1:10 and 1:12 dilutions of 
the crotonylated histone H3. 
Note: Table 5 describes how to do this serially whilst using the minimal quantity of starting reaction 
mix. However, this can be done in a different way if required. At least 260 µl is needed for each 
dilution of the crotonylated histone H3 for the following steps. 
 
















630 275 180 110 50 
 
c. Prepare three 5-strip tubes numbered 0 min and labeled 1:4, 1:6, 1:8, 1:10 and 1:12 (first row of 
Figures 2A, 2B, or 2C in blue). 
d. Prepare 15 more 5-strip tubes numbered 0.5, 1, 2, 4 or 10 (minutes) and labeled 1:4, 1:6, 1:8, 1:10 
and 1:12 (the following five rows in Figure 2 in red). 
e. On ice, add 14 μl of the 1:4, 1:6, 1:8, 1:10 or 1:12 diluted reaction mix to each one. The tubes are 
kept on ice until HDAC1 is added. 
f. To one strip of reactions labeled 0 min (in Figure 2 in blue), add 1 μl HDAC assay buffer. 
g. Vortex briefly by holding both sides of the strip. 
Note: The tubes may be spun down or liquid carefully tapped to the bottom if there are bubbles or 
liquid on the sides or lid of the tube. 
h. Incubate immediately in a thermocycler at 30 °C for 1 min. 
Note: If HDAC1 is added to a reaction it would not be zero time, but would run for a few seconds 
until the reaction could be stopped. However, a negative control is needed to provide a baseline 
level. To make sure that no change in substrate concentration is seen without enzyme, we incubated 
a reaction without HDAC1 for 2 h and saw no reduction in crotonylated H3. Therefore, 1 min was 
chosen as this is easy to perform.  




j. Repeat Steps B3f to B3i with the two other strips of tubes labelled 0 min. 
k. Dilute the HDAC1 stock solution 1:4 in HDAC assay buffer, i.e., 20 µl HDAC1 and 60 µl HDAC assay 
buffer. 
l. To each tube in one strip of reactions labeled 0.5 min (in Figure 2 in red), add 1 μl of diluted HDAC1 
(for 0.03 µM final concentration). 
m. Vortex briefly by holding both sides of the strip and briefly spin or tap liquid down if required. 
n. Incubate immediately in a thermocycler set to 30 °C for 30 sec. 
Note: It will take about 20-30 sec to add the HDAC and vortex. If time points shorter than 30 sec are 
needed, reduce the amount of enzyme rather than doing shorter reaction times as these will be 
inaccurate. 
o. Transfer the strip to a thermocycler at 95 °C for 1 min to stop the reaction. 
p. Repeat Steps B3l-B3o with the other 0.5 min strips and then with the 1, 2, 4 and 10 min strips in 
stages, varying the incubation at 30 °C accordingly. 
Note: It is necessary to start the reactions in stages so that the time points can be exact. 
q. Organize the tubes so that you have replicate sets of reactions labeled A, B and C. The tubes can 
be frozen at this point or the experiment continued as described in Part II Procedure B. 
 
 
Figure 2. Setup of reactions 
The setup of all 90 reactions is shown, organized into replicate number, time and dilution of reaction 
mix.  
 





A. Western blot 
Western blot is suited to assays with a low number of individual reactions and provides clear bands of 
defined molecular weight, showing how the reaction progressed.  
1. Open a pre-cast SDS-PAGE gel and rinse the wells with Milli-Q water to rinse away the preserving 
solutions and bubbles in the wells. 
2. Assemble the gel in the electrophoresis tank with 200 ml of 1x MES buffer in the inner chamber and fill 
the outer chamber half full with 1x MES buffer. 
Note: Make sure that the inner tank is not leaking. Use a buffer dam if there is only one gel in the tank. 
MES buffer should be fresh each time in the inner chamber but can be used up to three times in the outer 
chamber. Placing the tank on ice may improve the quality of the run. 
3. Load 5 µl of pre-stained protein marker in the first well of the pre-cast SDS-PAGE gel. 
4. Load 8 µl of each sample in the subsequent wells. 
5. Run at 100-150 V, 250 mA for 1-1.5 h until the blue dye front reaches the bottom of the gel and/or the 
different sized bands of the marker have separated. 
6. Rinse gel in 1x TGS buffer briefly and cut off the wells from the top of the gel. 
7. Soak blotting paper in transfer buffer and place onto the semi-dry transfer machine. 
8. Soak a piece of nitrocellulose membrane that is the same size as the blotting paper in transfer buffer 
and layer on top of the blotting paper taking care not to introduce bubbles in between the layers. 
9. Layer the gel on top of the stack, positioning the marker so that it is parallel to the vertical side of the 
membrane and so that the blue line, showing how far the samples have reached, is above the 
membrane. 
Note: Again take care not to introduce bubbles in between the layers. 
10. Trim the gel so that it is the same size as the membrane. 
Note: When many gels are run, it is useful to cut a corner or corners of the membrane to distinguish 
them. Pen is not advised as it will run. 
11. Place another piece of blotting paper soaked in transfer buffer on top. 
12. Roll a round tube, such as a 10 ml pipette, firmly from one side to the other on top of the stack to 
remove any remaining bubbles.  
13. Transfer proteins onto the membrane for 45 min at 15 V, 270 mA. 
Note: One hour is recommended when two or three stacks are in the transfer machine. 
14. Place the membrane in a 50 ml Falcon tube and rinse membrane in TBS-T for a few seconds. 
15. Block by adding 15 ml TBS-T BSA and incubate with gentle agitation at room temperature for 1 h. 
16. In a 5 ml Eppendorf tube, prepare a 5 ml solution of anti-H3K18 crotonyl antibody at 1:2,000 to 1:5,000 
dilution (depending on lot number of antibody) in TBS-T BSA. 
17. Pour the used TBS-T BSA solution into another tube, which should be stored at 4 °C for later use and 
add the solution of primary antibody to the membrane containing tube. 
18. Incubate overnight at 4 °C with gentle agitation (rocking or rolling). 




20. Wash twice for 15 min with 15 ml TBS-T and gentle agitation. 
21. Wash once for 15 min with 15 ml TBS-T BSA. 
Note: The TBS-T BSA from the previous day can be re-used. 
22. In a 5 ml Eppendorf tube, prepare a 5 ml solution of anti-rabbit antibody coupled with horseradish 
peroxidase (HRP) at 1:10,000 dilution in TBS-T BSA. 
23. Discard the TBS-T BSA and incubate in anti-rabbit antibody for 1 h at room temperature. 
24. Wash three times briefly (5-10 sec) with 10 ml TBS-T and then wash three times for 15 min with 15 ml 
TBS-T. 
25. Remove the membrane from the falcon tube and place on a clean, flat surface e.g., on a large weigh 
boat. 
26. Pipette 1 ml of ECL chemiluminescent substrate (1:1 ratio of A and B), making sure that all of the 
membrane is covered and leave for 1 min. 
27. Dab off excess ECL by touching the edge of the membrane against a paper towel and place in on a sheet 
of transparent acetate (or some other transparent sheet) in a developing cassette. 
28. Layer another acetate sheet on top, taking care not to introduce bubbles. 
29. Seal edges with tape, close the lid and avoid exposing membrane to light. 
30. In a dark room, place x-ray film on membrane for 15 sec to 5 min depending on the signal. 
31. Pass the exposed film into the automatic developer and wait for it to come out at the other side. 
Notes: 
a. There may be lot-to-lot variation between antibodies, therefore it is good practice to validate the 
specificity of the anti-H3K18cr antibody (or whatever anti-acyl antibody used), e.g., using peptide dot 
blots. 
b. While we have not tested other image capturing systems as alternatives for the ECL/X-ray film setup, it 
is likely that such systems that can capture chemiluminescence are not only practical, but potentially 
even better suited than the use of x-ray films. 
 
B. Dot blot 
Dot blot is more appropriate than Western blot when multiple reactions (more than 15) need to be 
analyzed. It allows all the reactions to be put on a single membrane, so that their spot intensities can be 
directly compared. Reactions must be spotted in quadruplicate to allow for variation in pipetting or 
spreading of the solution on the membrane. This protocol is described as required for Part I Procedure B3. 
1. Cut one a piece of nitrocellulose membrane for each of the A, B and C sets of reactions. 
Note: Cut a slightly larger piece that you think you need and trim it later. A typical size for a 10 x 12 spot 
grid once trimmed is 5.5 x 7.5 cm. 
2. Pipette 2 μl of the reactions using a P2 micropipette in quadruplicate in grid format as shown in Figure 
3. 
Note: Hold the pipette steady and dispense liquid at an even rate to reduce variability in spots. Use a 




spotting may be improved by using a vacuum-based dot blot apparatus such as Bio-dot® from Bio-Rad. 
However, we have not tested such a device. 
 
 
Figure 3. Layout of reaction spots on a nitrocellulose membrane for dot blot assay. Placing 
the spots in this ordered way makes quantification easier later on. 
 
3. Allow spots to dry fully. This takes 5-10 min. 
4. Rinse briefly in transfer buffer and then with TBS-T. 
5. Continue with the Western blot protocol (Part II Procedure A) from Step A15, blocking the membrane. 
Note: It can be useful to use a larger volume of antibody as the pieces of membrane are bigger for this 
dot blot. Ten to fifteen milliliters is recommended for both primary and secondary antibody. The 




A. Quantify each spot or band 
1. Scan films to a computer using an Epson scanner and its software. Select the following parameters: 
positive film, 8-bit grayscale and 400 dpi. Scan it and save it as a TIFF file, including the date, experiment 
and exposure time in the file name. 
2. Choose an appropriate exposure time for each substrate concentration where the spots are not too 
faint or overexposed. 
Note: If the spot is too faint it will be hard to distinguish over background. If the spot is over-




between spots will not be observed. Different exposure times can be chosen for each substrate 
concentration so that the most suitable exposure is chosen for each. 
3. In a suitable program such as Adobe Illustrator or Photoshop, add a square of black and a square of 
white. Save it as a TIFF file. 
Note: When ImageJ gives the quantitative peaks for an image selection it shows the highest 
peak at the top of the window regardless of whether this peak is high in other selections. This 
makes comparison difficult between spots when they cannot be selected together (for example 
when there are too many spots). To avoid this problem, an area of black is included which gives 
the maximum possible value, and an area of white is included which gives the minimum 
possible value. This means that all values are relative to this and different selections can be 
compared.  
4. Open the image in ImageJ. 
5. Select an area of spots using the rectangle tool including the area of white and black. 




Figure 4. Determination of spot intensity using ImageJ software. Once the image is opened 
in ImageJ, a horizontal line of bands can be selected using the rectangle tool (blue box). Once 
this selection is plotted, the individual peaks corresponding to different spots can be selected 




selected peaks in the results tab. In the image above, the first two peaks have been selected, 
the third has been highlighted with the wand tool, and the sixth peak is being selected with 
the line tool (these are combined screenshots to show many operations at once). 
 
7. In the same section, choose ‘plot lanes’ (shortcut: Ctrl+3). 
8. Double-click the line tool and type a suitable value in the window to set it to the appropriate width, 
then select peaks corresponding to a spot or band. 
Note: The value only changes when you type the number, not when you press enter. Try out a few widths 
to find one that fits the peak well and then use this for all of the selected peaks. A value of 50 to 60 (no 
units given) usually fits the peaks from a spot and 70 to 100 for a band. Control/command-Z can be used 
to remove a selection if it is in the wrong place.  
9. With the same width setting, select an area without a peak which corresponds to the background. 
10. Using the wand tool, click on each peak area in turn and the values will come up in a results window. 
11. Select these, copy and paste the values into Excel. 
12. Attribute a reaction name to each value according to its position on the membrane. 
13. Repeat Steps 5 to 12 for the other rows. 
Note: Keep track of the order that you analyze spots and remember that there are four replicates for 
each reaction which are split into two rows. 
 
B. Calculate the initial reaction rate for each substrate concentration in Excel 
This is only applicable to Part I B3 where multiple time points and substrate concentrations were 
measured. 
1. Subtract values for each spot by the background value. 
2. Calculate the average of the values for the four spots for each reaction. 
3. Calculate the value of each time point relative to the zero time point. 
Note: For each dilution of substrate, divide each time point by the zero time point so that zero 
time is 1 and other values are relative to this. 
4. Convert dilutions of substrate to µM of crotonyl-H3. This assumes that the 5.65 µM of H3.1 was fully 
crotonylated at lysine 18 in the first reaction, which has been tested in Figure 5. 
Notes: 
a. Multiply each relative value by the concentration of modified histone in the reaction mix, as shown 
in Table 6, to convert spot intensity to substrate concentration. 
b. We assume this because we also spotted 0.45 to 45 µM of a synthetic crotonylated H3K18cr 
peptide (a short section of amino acids around the K18 position) and found that the preparation of 




in Figure 5. The peptide was diluted in HDAC assay buffer. 
 
 
Figure 5. Comparison of ECL intensity of crotonylated histone H3 and the H3K18cr crotonyl-
peptide by dot blotting. The H3K18cr peptide sequence was TGGKAPR-Lys(Crotonyl)-
QLATKAA-EDA-Btn, EDA is a spacer and Btn indicates C-terminal biotinylation. The intensity of 
spots for 5.65 µM crotonyl-H3 corresponds to an intensity of crotonyl-peptide between 4.5 
and 9 µM. 
Table 6. Converting dilutions of crotonyl-H3 reaction mix to concentration 
 
Concentration (µM) 














Figure 6. Determination of initial rate by plotting substrate concentration against time. Plotting the 
substrate concentration for each time point and replicate allows us to see how the reaction has 
progressed. In the first graph (upper panel), the reaction is fastest during the first minute, so only these 
time points are plotted in the second graph (lower panel) which now shows a linear relationship and 






6. Determine duration for the initial rate of the reaction before it starts to slow and fit a linear regression 
line for just these points. 
Note: In the set of reactions shown in Figure 6, the initial rate occurs in the first thirty seconds 
to first minute of the reaction. Choose whichever matches the data points closest.  
7. Take the gradient of the line for each of A, B and C replicates, this gives the rate. 
8. Repeat for the other substrate concentrations.  
9. Create a table of substrate concentration against rate and transfer to GraphPad Prism. 
 
C. Calculate kinetic constants using GraphPad Prism version 7 
1. Plot the initial rate of reaction against substrate concentration. 
2. In the analysis section, choose non-linear regression. 
3. Select enzyme kinetics-substrate versus velocity, choose Michaelis-Menten and click ‘OK’. 
4. This will give you Vmax, the maximum initial rate for that enzyme concentration when all active sites are 
occupied. It will also give you Km, the substrate concentration required to give half of the maximum 
rate. 
5. Select the enzyme kinetics-substrate versus velocity section again but this time choose Kcat. In the 
constrain tab by the parameter name ‘Et’, constrain ‘constant equal to’ and input the concentration of 
enzyme used into the value box, in our case this is 0.03, corresponding to the 0.03 µM of HDAC1 used. 
Note: An example of such an analysis is shown in Figure 7b of Fellows et al. (2018), depicting 
an analysis of the comparative kinetics of HDAC1 decrotonylation and deacetylation.  
 
Recipes 
1. Histone acylation buffer 
50 mM Tris-HCl pH 8 
50 mM KCl 
0.1 mM EDTA 
0.01% Tween 20 
10% Glycerol 
1 mM DTT 
Aliquot and store at -20 °C until use 




25 mM Tris-HCl pH 7.5 
50 mM KCl 
1 mM MgCl2 
1 µM ZnSO4 
Aliquot and store at -20 °C until use 
3. 1x MES buffer 
50 ml 20x RunBlue MES buffer 
950 ml distilled or Milli-Q water 
4. 1x TGS buffer 
100 ml 10x Tris/glycine/SDS electrophoresis buffer (Bio-Rad) 
900 ml distilled or Milli-Q water 
5. Transfer Buffer (recipe for 1 L buffer) 
5.8 g Tris 
2.9 g Glycine 
200 ml Methanol 
800 ml distilled or Milli-Q water 
6. Tris-buffered saline (TBS) 
302.5 g Tris 
438.0 g NaCl 
1 L distilled or Milli-Q water 
7. TBS with tween 20 (TBS-T) 
2.5 ml of 20% Tween 20 in 1 L of TBS 
8. TBS-T with 3% (w/v) bovine serum albumin (TBS-T BSA) 
Dissolve 6 g of BSA in 200 ml TBS-T and store at 4 °C 
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